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There is an urgent need to develop safe and effective treatments for psychotic symptoms in 
dementia and make better use of current treatments.  This will be aided by a better understanding 
of the mechanisms underlying both the symptoms and treatments.  Thus, two lines of research 
were followed: 1) analysis of the prevalence and course of psychotic symptoms in Alzheimer’s 
disease (AD) and dementia with Lewy bodies (DLB)/Parkinson’s disease dementia (PDD), and, 2) 
analysis of the response to treatments in AD.  To address the former, the COMT val158met and 
5HTTLPR polymorphisms were assessed with respect to the presence of persistent symptoms 
and the MAPT haplotype with respect to the course of symptoms.  The 5HTTLPR LL genotype 
was associated with a significantly increased risk of persistent delusions in DLB/PDD and the 
MAPT haplotype with a significantly increased risk of worsening delusions in AD.  Finally, the 
COMT val158met polymorphism was found to predict more rapid cognitive decline in mild AD 
patients. 
The examination of point 2) above chiefly concerned histamine H1 receptor antagonism and 
antipsychotic mortality.  Patients taking high affinity H1 antipsychotics had a significantly greater 
mortality risk compared with those taking no antipsychotics with evidence also suggesting effect 
modification by the HNMT gene polymorphism.  
Collectively, in what are among the best characterised cohorts to date, these findings bring 
greater clarity to the current understanding of the role of 5HTTLPR and COMT val158met in 
contributing to psychotic symptoms in dementia, supporting the prioritisation of serotonin-acting 
treatments in DLB/PDD and suggesting that dopamine levels may indirectly influence the 
presentation of psychosis via more rapid cognitive decline in AD.  New evidence was also found 
to support the hypotheses that tau pathology is associated with psychosis and histamine 






List of Figures ....................................................................................................................................9 
List of tables ................................................................................................................................... 11 
List of Abbreviations ....................................................................................................................... 13 
Acknowledgments .......................................................................................................................... 15 
Chapter 1 General Introduction ...................................................................................................... 16 
1.1 Clinical features, diagnoses and pathology of Alzheimer’s disease and dementia with Lewy 
bodies/Parkinson’s disease dementia ........................................................................................ 17 
1.1.1 Overview and clinical diagnoses of dementia ................................................................ 17 
1.1.2 Pathology and pathological diagnoses of dementia ...................................................... 21 
1.2 Psychotic symptoms in dementia ......................................................................................... 26 
1.2.1 Relationship between cognitive impairment and psychosis in dementia ...................... 29 
1.2.2 Heritability and familial aggregation of psychosis in Alzheimer’s disease ..................... 31 
1.2.3 Treatment of psychotic symptoms in dementia ............................................................. 32 
1.3 Section summary .................................................................................................................. 36 
1.4 Genetics of delusions and hallucinations in dementia and their treatment .......................... 38 
1.4.1 Serotonin transporter polymorphism and serotonergic correlates of psychosis in 
dementia ................................................................................................................................. 39 
1.4.2 Catechol-O-methyltransferase val158met polymorphism and dopaminergic correlates of 
psychosis in dementia ............................................................................................................ 46 
1.4.3 Tau, the MAPT haplotype and psychosis in AD ............................................................ 50 
1.4.4 Other polymorphisms associated with psychosis in dementia ...................................... 55 
1.4.5 Genome-wide association and linkage studies in Alzheimer’s disease psychosis ....... 55 
1.4.6 Pharmacogenetics of treatments for psychosis in AD ................................................... 56 
4 
1.4.7 Methodological Issues in Genetic Association Studies of Neuropsychiatric Symptoms in 
Dementia ................................................................................................................................. 61 
1.5 Summary .............................................................................................................................. 72 
1.6 Aims ...................................................................................................................................... 72 
Chapter 2 General Materials and Methods .................................................................................... 74 
2.1 Description of cohorts ........................................................................................................... 75 
2.1.1 Memantine for Long-Term Treatment of Neuropsychiatric Symptoms in Dementia 
(MAIN-AD) .............................................................................................................................. 76 
2.1.2 Memantine for Agitation in Dementia (MAGD) .............................................................. 79 
2.1.3 Oxford Project to Investigate Memory and Aging (OPTIMA) ......................................... 81 
2.1.4 The Course of Dementia, Neuropsychiatric Symptoms and Drug Use and its Impact on 
Health Service Resource Use (the Norway cohort) ................................................................ 82 
2.1.5 Improved Well-Being and Health for People with Dementia (WHELD) ......................... 82 
2.1.6 Dementia Studies in West Norway (DEMVEST) ........................................................... 83 
2.1.7 Greek Cohort ................................................................................................................. 83 
2.1.8 Alzheimer’s Research UK (ARUK) and Dementia Case Register (DCR)...................... 83 
2.1.9 Addneuromed (ANM) ..................................................................................................... 84 
2.1.10 Institute of Psychiatry and Newcastle brain banks ...................................................... 84 
2.2 Clinical assessments ............................................................................................................ 85 
2.2.1 Psychotic symptoms ...................................................................................................... 85 
2.2.2 Determining the presence of psychotic symptoms ........................................................ 87 
2.2.3 Cognitive impairment and disease severity ................................................................... 88 
2.3 Medication history................................................................................................................. 89 
2.4 DNA sources and preparation .............................................................................................. 89 
2.4.1 Buccal mucosa sample collection and DNA preparation ............................................... 89 
2.4.2 DNA from blood and brain samples ............................................................................... 90 
2.5 SNP selection ....................................................................................................................... 90 
5 
2.6 Genotyping ........................................................................................................................... 91 
2.6.1 Assay to Detect the val158met Polymorphism in COMT and the thr105ile Polymorphism 
in HNMT .................................................................................................................................. 91 
2.6.2 Assay to Detect the 5HTTLPR Polymorphism in SLC6A4 ............................................ 93 
2.6.3 Assay to detect the extended MAPT haplotype............................................................. 97 
2.7 Statistical analyses ............................................................................................................... 97 
Chapter 3 Determining the association of 5HTTLPR and COMT polymorphisms with delusions 
and hallucinations in AD and DLB/PDD ......................................................................................... 99 
3.1 Summary introduction ........................................................................................................ 100 
3.2 Hypotheses ......................................................................................................................... 102 
3.3 Methods .............................................................................................................................. 103 
3.3.1 Software ....................................................................................................................... 103 
3.3.2 Inclusion/exclusion criteria ........................................................................................... 103 
3.3.3 Design and cohort ........................................................................................................ 103 
3.3.4 Classification of symptoms .......................................................................................... 104 
3.3.5 Other data .................................................................................................................... 104 
3.3.6 Statistical analysis ....................................................................................................... 105 
3.4 Results: Lewy body dementias ........................................................................................... 107 
3.4.1 Descriptive statistics .................................................................................................... 107 
3.4.2 Primary analysis: 5HTTLPR ........................................................................................ 109 
3.4.3 Primary analysis: COMT val158met ............................................................................ 113 
3.4.4 Secondary analysis ...................................................................................................... 117 
3.4.5 Summary ...................................................................................................................... 118 
3.5 Results: Alzheimer’s disease ............................................................................................. 119 
3.5.1 Descriptive statistics .................................................................................................... 119 
3.5.2 Primary analysis .......................................................................................................... 121 
3.5.3 Secondary analysis ...................................................................................................... 126 
6 
3.5.4 Summary ...................................................................................................................... 128 
3.6 Discussion .......................................................................................................................... 129 
3.6.1 COMT val158met ......................................................................................................... 130 
3.6.2 5HTTLPR ..................................................................................................................... 131 
3.6.3 Strengths and limitations ............................................................................................. 133 
3.6.4 Conclusion ................................................................................................................... 136 
Chapter 4 COMT val158met is associated with rate of cognitive decline in Alzheimer’s disease137 
4.1 Summary introduction ........................................................................................................ 138 
4.1.1 Hypotheses .................................................................................................................. 139 
4.2 Methods .............................................................................................................................. 140 
4.2.1 Software ....................................................................................................................... 140 
4.2.2 Inclusion/exclusion criteria ........................................................................................... 140 
4.2.3 Design and cohort ........................................................................................................ 140 
4.2.4 Calculating cognitive decline ....................................................................................... 141 
4.2.5 Statistical Evaluation .................................................................................................... 141 
4.3 Results ................................................................................................................................ 143 
4.3.1 Descriptive statistics: COMT val158met and 5HTTLPR .............................................. 143 
4.3.2 COMT val158met and average annual MMSE decline ............................................... 145 
4.3.3 5HTTLPR and average annual MMSE decline ............................................................ 150 
4.4 Summary of findings ........................................................................................................... 155 
4.4.1 Summary of primary analyses ..................................................................................... 155 
4.4.2 Summary of secondary analyses ................................................................................ 155 
4.5 Discussion .......................................................................................................................... 156 
Chapter 5 The extended MAPT haplotype and worsening of psychotic symptoms in Alzheimer’s 
disease ......................................................................................................................................... 163 
5.1 Summary introduction ........................................................................................................ 164 
7 
5.1.1 Hypotheses .................................................................................................................. 165 
5.2 Methods .............................................................................................................................. 166 
5.2.1 Software ....................................................................................................................... 166 
5.2.2 Inclusion/exclusion criteria ........................................................................................... 166 
5.2.3 Design and cohort ........................................................................................................ 167 
5.2.4 Statistical Evaluation .................................................................................................... 167 
5.3 Results ................................................................................................................................ 170 
5.3.1 Descriptive statistics .................................................................................................... 170 
5.3.2 Primary analysis: MAPT haplotype and worsening psychotic symptoms ................... 172 
5.3.3 Secondary analysis: stratification by memantine treatment ........................................ 174 
5.4 Summary of findings ........................................................................................................... 177 
5.4.1 Summary of primary analysis ...................................................................................... 177 
5.4.2 Summary of secondary analysis .................................................................................. 177 
5.5 Discussion .......................................................................................................................... 178 
Chapter 6 Histamine H1 affinity of antipsychotics: relationship to mortality and a possible role of 
HNMT polymorphism ................................................................................................................... 183 
6.1 Summary introduction ........................................................................................................ 184 
6.1.1 Hypotheses .................................................................................................................. 185 
6.2 Methods .............................................................................................................................. 186 
6.2.1 Software ....................................................................................................................... 186 
6.2.2 Inclusion/exclusion criteria ........................................................................................... 186 
6.2.3 Design and cohort ........................................................................................................ 186 
6.2.4 Demographics and participant characteristics ............................................................. 190 
6.2.5 Statistical Evaluation .................................................................................................... 190 
6.3 Results ................................................................................................................................ 192 
6.3.1 Descriptive statistics .................................................................................................... 192 
8 
6.3.2 Primary analysis: antipsychotic mortality and HNMT genotype .................................. 195 
6.3.3 Secondary analyses .................................................................................................... 202 
6.4 Summary of findings ........................................................................................................... 204 
6.4.1 Summary of primary analysis ...................................................................................... 204 
6.4.2 Summary of secondary analysis .................................................................................. 204 
6.5 Discussion .......................................................................................................................... 205 
Chapter 7 General discussion ...................................................................................................... 210 
7.1 Key themes ......................................................................................................................... 211 
7.1.1 The 5HTTLPR polymorphism has different effects on persistent delusions in AD and 
DLB/PDD .............................................................................................................................. 211 
7.1.2 PFC dopamine levels may not underlie psychotic symptoms but may indirectly influence 
them via more rapid cognitive decline .................................................................................. 212 
7.1.3 Evidence of genetic models of psychotic symptoms in dementia ............................... 213 
7.1.4 Histaminergic neurotransmission is an important mechanism of mortality associated 
with antipsychotic treatment ................................................................................................. 215 
7.2 Strengths and limitations .................................................................................................... 216 
7.2.1 The cohorts .................................................................................................................. 216 
7.2.2 Genetics ....................................................................................................................... 217 
7.3 Future directions ................................................................................................................. 220 
7.3.1 GWAS and emerging technologies in genetic epidemiology: a focus on their impact on 
research into psychotic symptoms in dementia .................................................................... 221 
7.4 Concluding remarks............................................................................................................ 224 
Appendix ...................................................................................................................................... 225 




List of Figures 
Figure 1-1 MAPT isoforms ............................................................................................................. 23 
Figure 1-2 5HTTLPR polymorphism .............................................................................................. 40 
Figure 1-3 COMT val158met polymorphism .................................................................................. 47 
Figure 1-4 HNMT thr105ile polymorphism ..................................................................................... 59 
Figure 1-5 Flow diagram illustrating results of electronic and manual searches and study 
identification process ...................................................................................................................... 62 
Figure 1-6 5HTTLPR psychosis studies plotted by MMSE and whether or not a significant finding 
was reported .................................................................................................................................. 65 
Figure 2-1 ABI SDS example output for COMT val158met and HNMT polymorphisms ............... 92 
Figure 2-2 A 2% agarose gel image of the 5HTTLPR polymorphism ............................................ 94 
Figure 2-3 SDS output provided by Dr Jonathan Covault and Christine Abreu (University of 
Connecticut) ................................................................................................................................... 96 
Figure 2-4 SDS 7000HT output showing three genotype clusters of the 5HTTLPR polymorphism
 ....................................................................................................................................................... 96 
Figure 2-5 A 1% agarose gel image of the extended tau haplotype .............................................. 97 
Figure 4-1 Average annual MMSE decline by COMT val158met genotype (N=237) .................. 146 
Figure 4-2 Average annual MMSE decline by COMT genotype and AD severity (N=237: moderate 
n=112; mild n=125) ...................................................................................................................... 148 
Figure 4-3 Average annual MMSE decline by COMT genotype, including severe cases (N=266)
 ..................................................................................................................................................... 149 
Figure 4-4 Average annual MMSE decline by 5HTTLPR genotype (N=237) .............................. 151 
Figure 4-5 Average annual MMSE decline by 5HTTLPR genotype and dementia severity (N=237: 
moderate n=112; mild n=125) ...................................................................................................... 153 
Figure 4-6 Average annual MMSE decline by 5HTTLPR genotype including severe cases (N=266)
 ..................................................................................................................................................... 154 
Figure 5-1 Histogram of change in NPI delusions score from baseline to 12 weeks .................. 168 
Figure 5-2 Histogram of change in NPI delusions score from baseline to 12 weeks .................. 169 
Figure 6-1 Decision process for estimating antipsychotic start date ........................................... 189 
Figure 6-2 Kaplan-Meier curves for one year survival by level of antipsychotic exposure (Log-rank 
test: 
2
=20.1, df: 2, p<0.001) ........................................................................................................ 196 
10 
Figure 6-3 Kaplan-Meier curves for one year survival, comparing HNMT genotypes (Log-rank test: 

2




List of tables 
Table 1-1 5HTTLPR genetic association studies of psychosis ...................................................... 64 
Table 2-1 Overview of Sample Sources ........................................................................................ 75 
Table 2-2 Rules for the classification of delusions and hallucinations for each rating scale ......... 87 
Table 3-1 Participant demographics by 5HTTLPR genotype ...................................................... 109 
Table 3-2 Participant demographics by COMT val158met genotype .......................................... 109 
Table 3-3 Logistic regression: persistent delusions in DLB/PDD ................................................ 111 
Table 3-4 Logistic regression: persistent hallucinations in DLB/PDD .......................................... 111 
Table 3-5 Logistic regression: 5HTTLPR persistent delusions .................................................... 112 
Table 3-6 Logistic regression 5HTTLPR persistent hallucinations .............................................. 112 
Table 3-7 5HTTLPR genotype frequencies for DLB/PDD patients (by the presence/absence of 
symptoms) and controls ............................................................................................................... 113 
Table 3-8 Logistic regression: persistent delusions in DLB/PDD ................................................ 114 
Table 3-9 Logistic regression: persistent hallucinations in DLB/PDD .......................................... 115 
Table 3-10 Logistic regression: COMT val158met persistent delusions ..................................... 115 
Table 3-11 Logistic regression: COMT val158met persistent hallucinations ............................... 116 
Table 3-12 COMT val158met genotype frequencies for DLB/PDD cases (by the 
presence/absence of symptoms) and controls ............................................................................ 117 
Table 3-13 Participant demographics by COMT genotype .......................................................... 120 
Table 3-14 Participant demographics by 5HTTLPR genotype .................................................... 120 
Table 3-15 Logistic regression: persistent delusions in AD ......................................................... 122 
Table 3-16 Logistic regression: persistent hallucinations in AD .................................................. 123 
Table 3-17 Logistic regression: COMT val158met persistent delusions ..................................... 124 
Table 3-18 Logistic regression: 5HTTLPR persistent delusions .................................................. 124 
Table 3-19 Logistic regression: COMT persistent hallucinations ................................................ 125 
Table 3-20 Logistic regression 5HTTLPR persistent hallucinations ............................................ 125 
Table 3-21 5HTTLPR genotype frequencies for AD cases (by presence/absence of symptoms) 
and controls .................................................................................................................................. 126 
Table 3-22 COMT val158met genotype frequencies for AD cases (by presence/absence of 
symptoms) and controls ............................................................................................................... 126 
Table 4-1 Participant characteristics by study at baseline by COMT val158met genotype ......... 144 
Table 4-2 Participant characteristics by study at baseline by 5HTTLPR genotype ..................... 144 
12 
Table 4-3 Average annual MMSE decline by COMT val158met and persistent delusions ......... 145 
Table 4-4 Average annual MMSE decline by COMT val158met  and persistent hallucinations . 145 
Table 4-5 Average annual MMSE decline and baseline MMSE score by COMT genotype ........ 147 
Table 4-6 Average annual MMSE decline by 5HTTLPR and persistent delusions ..................... 150 
Table 4-7 Average annual MMSE decline by 5HTTLPR and persistent hallucinations ............... 151 
Table 4-8 Average annual MMSE decline and baseline MMSE score by 5HTTLPR genotype .. 152 
Table 5-1 Participants characteristics at baseline by treatment and MAPT haplotype ............... 171 
Table 5-2 Logistic regression: change in delusions ..................................................................... 173 
Table 5-3 Logistic regression: change in hallucinations .............................................................. 174 
Table 5-4 Logistic regression: change in hallucinations stratified by treatment arm ................... 176 
Table 5-5 Logistic regression: change in delusions stratified by treatment arm .......................... 176 
Table 6-1 Antipsychotic classification according to H1 affinity and typical/atypical ..................... 187 
Table 6-2 Frequency of prescribed antipsychotics ...................................................................... 192 
Table 6-3 Dementia diagnosis frequency .................................................................................... 193 
Table 6-4 Demographic characteristics of participants by HNMT genotypes .............................. 194 
Table 6-5 Demographic characteristics of participants by antipsychotic status .......................... 195 
Table 6-6 Univariate analysis of risk factors for one year mortality ............................................. 198 
Table 6-7 Multivariate analysis outcome of antipsychotic exposures for one year mortality  ...... 199 
Table 6-8 Multivariate analysis outcome of HNMT genotypes for one year mortality ................. 200 
Table 6-9 Multivariate analysis outcomes of antipsychotics exposure for one year mortality, 
stratified by HNMT genotypes ...................................................................................................... 201 
Table 6-10 Multivariate analysis outcomes of antipsychotics exposure for one year mortality, 



























Activities of Daily Living 
ANOVA 
 















Cambridge Mental Disorders of the Elderly Examination  
CDR 
 
Clinical Dementia Rating Scale 
CERAD 
 

























Dementia and Neurodegenerative Diseases Research Network 
DLB 
 
Dementia with Lewy bodies 
DLPFC 
 






Dorsal raphe nucleus 
DSM 
 















Genome wide association study 
H1AP- 
 
Low/no affinity H1 antipsychotic 
H1AP+ 
 















Minor allele frequency 
MAPT 
 






Mental Health Research Network 
MMSE 
 
Mini mental state examination 
MRN 
 










National Institute on Aging and the Ronald and Nancy Reagan Institute 
of the Alzheimer’s Association 
NINCDS-ADRDA 
Neurological and Communicative Disorders and Stroke and the 















Present Behavioural Examination 
PCR 
 






Parkinson's disease dementia 
PET 
 






Pro ne rata, as required 
PSP 
 
Progressive supranuclear palsy 
RCT 
 
Randomised controlled trial 
REC  
 












Single nucleotide polymorphism 
SSRI 
 


















Firstly, I would like to thank both of my supervisors, Professor Clive Ballard and Dr Emma Jones 
for giving the opportunity to undertake this project.  It was a pleasure to come back to science 
after nearly three years in the city and I cannot think of a subject and project I’d rather have 
worked on.  Thank you for your guidance and advice throughout and in particular the opportunity 
to be involved with such a diverse range of research activity.  It has become plainly obvious to me 
that these sorts of studies are not possible without large cross centre collaborations so I would 
like to thank all of the contributors of clinical data and samples.  Particular thanks to Dr John 
Powell for the lab space and Megan Pritchard for the desk space at the IOP.  And when speaking 
of contributors, it is only right to reserve the biggest thanks to the participants and patients, and 
their families, for supporting our work. 
 
I would like to thank everyone at the Wolfson CARD, past and present, for the company and 
entertainment: Emma (getting another mention!), Julie, Dave, Clare, Talisia, Jack, Liz, Matt, 
Chancie, Simone, and Natasha.  Thanks for the lunches, squash, the coffee (I probably should’ve 
made more) and all the rest of the fun we had. 
 
In my office: thanks to Zunera and Nicola for all the help and support with the clinical trial work 
and good luck with up and coming projects – looks like you’ll be busy!   
 
Finally, Sarah thanks for the proof read – must have been a nightmare for a non-scientist – and 
What’s App conversations which kept me going!  Family: Mum and Grandparents your lifetime of 
support enabled me actually undertake a PhD in the first place and Sergio for being there and 
maintaining your support throughout the whole thing (I know it’s not always been easy but I will be 
forever grateful).  Love you all. 
 
Declaration 
The work contained in this thesis is the work of the author and as such the copyright of this thesis 
rests with the author and no quotations from it or information derived from it may be published 




Chapter 1 General Introduction 
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1.1 Clinical features, diagnoses and pathology of Alzheimer’s disease 
and dementia with Lewy bodies/Parkinson’s disease dementia 
 
1.1.1 Overview and clinical diagnoses of dementia 
 
It is estimated that 34 million people have dementia worldwide.  Alzheimer’s disease (AD) is the 
most common form of dementia, accounting for around 62% of cases while Lewy body dementias 
(dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD)) account for around 
15% of patients.  Broadly, AD, DLB and PDD are insidious in their onset and characterised by the 
central clinical feature of progressive cognitive impairment.  PD on the other hand is characterised 
clinically by movement disorders such as rigidity and tremor and although it is not characterised 
by dementia per se, the majority of people with PD will go on to develop PDD (Aarsland, 
Andersen et al. 2003).  The vast majority of patients with AD, DLB and PDD have the sporadic 
form of the disease, with causes thought to arise from a variety of genetic and environmental 
sources (Lesage, Brice 2009, Chartier-Harlin, Crawford et al. 1991, Zarranz, Alegre et al. 2004, 
Zarranz, Alegre et al. 2004).  
 
The key differences between AD and DLB that confer the greatest reliability in making a 
differential diagnosis have been incorporated in operationalised diagnostic criteria (a diagnosis of 
PDD is made when dementia develops in the context of established PD, this will be returned to 
later in this section).  These criteria are the National Institute of Neurological and Communicative 
Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-
ADRDA) criteria for AD and the consensus criteria set out by McKeith et al. (2005) for DLB first 
established in 1984 and 1996 respectively (McKeith, Dickson et al. 2005, Dubois, Feldman et al. 
2007, McKhann, Drachman et al. 1984, McKeith, Galasko et al. 1996).  Both of these have 
undergone subsequent revisions (McKhann, Knopman et al. 2011, McKeith, Dickson et al. 2005) 
to incorporate advances in biomarker identification and to improve early differential diagnosis 
(Ballard, Halliday 2010).  In particular the revision to the NINCDS-ADRDA criteria places a good 
deal of emphasis on the pathophysiological and clinically observable characteristics of AD, 
focusing on defining AD in the pre-clinical, pre-dementia and full-blown disease stages (Jack, 
Albert et al. 2011, Sperling, Aisen et al. 2011, Albert, DeKosky et al. 2011).  Although any patients 
18 
with a diagnosis of probable AD from the 1984 criteria would fall under probable AD in the 2011 
criteria, possible AD patients under the 1984 criteria would not necessarily fall under the possible 
AD diagnosis of the 2011 criteria.  This is in part due to a greater recognition of DLB in the years 
following the 1984 criteria and the recognition that negative results of certain biomarker tests 
(positron emission tomography (PET) imaging of amyloid-β, cerebrospinal fluid (CSF) tau, 
structural magnetic resonance imaging) are not compatible with a diagnosis of AD regardless of 
clinical criteria being met.  The latest NINCDS-ADRDA criteria were introduced too late for use in 
the cohorts used with the present project therefore the 1984 criteria will be discussed henceforth, 
unless otherwise specified. 
 
In 2007 Dubois et al. developed research criteria for diagnosing AD, based on the NINCDS-
ADRDA criteria, which was followed by the updated AD lexicon in 2010. (Dubois, Feldman et al. 
2007, Dubois, Feldman et al. 2010).  Both of these place greater emphasis on the pre-dementia 
stages of early episodic memory impairment supported by biomarker confirmation, incorporating 
them into the diagnostic label of ‘AD’. The term ‘AD dementia’ is proposed and refers to stages of 
AD where cognitive symptoms are severe enough to interfere with daily functioning. 
 
Another widely used tool for the clinical diagnosis of dementia is the Diagnostic and Statistical 
Manual of Mental Disorders (DSM) criteria published by the American Psychiatric Association.  
The most recent edition (DSM-5) was published in May 2013 and contains revisions of 
terminology such that the former diagnostic codes relating to dementia have been replaced by 
codes referring to ‘major and mild neurocognitive disorders’.  It is important to note that this latest 
edition now includes specific criteria for dementia with Lewy bodies (‘Major or Mild Neurocognitive 
Disorder with Lewy Bodies’).     
 
The most recent DSM edition on which diagnoses were made in this project was the DSM-IV.  
Though there have been two more recent editions the criteria for dementia of any kind have not 
changed significantly (American Psychiatric Association. and American Psychiatric Association. 
Task Force on DSM-IV 1994).  At the time samples were collected for this project there were no 
DSM criteria for DLB and the criteria for PDD was classified under ‘dementia due to other medical 
conditions’.  Indeed, because of this the McKeith criteria for DLB have long been the principal 
criteria for the diagnosis of DLB.  The clinical diagnosis of PDD is a little less straightforward as 
19 
there has only been one set of criteria specifically proposed which have yet to be validated (Emre, 
Aarsland et al. 2007).  The diagnosis of PDD will be returned to later in this section.   
 
The DSM edition includes criteria for AD; those that form the DSM-IV (appendix A) are commonly 
used by clinicians to diagnose the disease.  However, the NINCDS-ADRDA criteria which offer 
greater validity and reliability, are more widely used for research purposes and so will be the 
focus of the remaining discussion concerning the clinical diagnosis of AD. 
 
The NINCDS-ADRDA and McKeith criteria themselves differ slightly in their categorisation but 
broadly speaking there are those items that are essential for a diagnosis of the dementia in 
question, those that are consistent or supportive with that diagnosis and those whose presence is 
not compatible with the diagnosis or make diagnosis less likely.  The combination of the different 
levels of criteria then determines whether the diagnosis is probable or possible.   
 
The NINCDS-ADRDA and McKeith criteria are listed in full in appendix B and appendix C 
respectively.  In both cases progressive cognitive impairment must be present for a diagnosis to 
be made.  However, the central cognitive criteria in both have been developed as a result of 
observations from research that deficits in specific cognitive domains, rather than global 
measures, offer the best differentiation between AD and DLB.  Typically, patients with DLB 
present with greater deficits in visuoperceptual ability, attention and executive function than AD 
patients, who are generally more impaired on tasks associated with hippocampal function, such 
as verbal and episodic memory (Tiraboschi 2006, Noe, Marder et al. 2004, Aarsland 2003, 
Collerton, Burn et al. 2003, Noe, Marder et al. 2004).  Longitudinal evaluation of symptoms is 
central to an accurate diagnosis in both dementias.  “Progressive worsening” is a prerequisite for 
AD according to the NINCDS-ADRDA criteria, and as would be expected there is much more of a 
focus on executive and attentional deficits among the central features of DLB, while memory 
impairment “is usually evident with progression” but does not have to be persistent or prominent 
in the early stages, unlike in AD (McKeith, Dickson et al. 2005). 
 
Neuropsychiatric symptoms, while common in the more moderate and advanced disease stages, 
do not form part of the diagnostic criteria for AD.  In keeping with the consistent evidence that 
visual hallucinations are present in the majority of patients with DLB (Aarsland, Ballard et al. 
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2001) this symptom forms one of the core features of the McKeith criteria for DLB, the others 
being fluctuating cognition and early Parkinsonism.  According to the McKeith criteria, a diagnosis 
of probable DLB can be made on the basis of the central cognitive features described in the 
above paragraph plus at least two of these core features.  Alternatively, the central features and 
one core feature coupled with one or more of the suggestive features (REM sleep disorder, 
neuroleptic sensitivity and low dopamine transporter uptake) can be used to diagnose probable 
DLB.  Central and suggestive features only (in the absence of any core features) can only lead to 
a diagnosis of possible DLB (see appendix C). 
 
Under the NINCDS-ADRDA criteria, a diagnosis of probable AD can be made when the criteria 
under section 1 (appendix B) are met, while a diagnosis of possible AD is generally reserved for 
otherwise unspecified dementia syndromes.  For research purposes this may be a “single 
gradually progressive severe cognitive deficit in the absence of other identifiable causes.”  A 
diagnosis of definite AD is only possible after neuropathological examination (see section 1.1.2 for 
neuropathology of AD). 
 
Concurrent cerebrovascular disease (which may cause a sudden onset of dementia or be evident 
from hemiparesis, visual field loss or brain imaging) is an important exclusion criterion for both 
DLB and AD.  Furthermore, as alluded to above, early Parkinsonism is not compatible with AD 
and in DLB the onset of Parkinsonism is important in the clinical differentiation between it and 
PDD. 
 
Clinically and pathologically, there is little that separates DLB from PDD.  A diagnosis of PDD is 
made when the symptoms of dementia occur in the context of established PD.  For research 
purposes the threshold is set at an arbitrary 1 year.  That is, if symptoms of dementia occur more 
than one year after the onset of Parkinsonism then a diagnosis of PDD is made (McKeith, 
Dickson et al. 2005).  PD is diagnosed according to the UK Brain Bank criteria, consisting of three 
steps (full details are included in appendix D) (Hughes, Daniel et al. 1992).  Step one involves 
diagnosing a Parkinsonian syndrome which must consist of bradykinesia as well as rigidity, 
resting tremor or postural instability not caused by dysfunction in other domains.  Step two 
requires the meeting of a series of exclusion criteria, along with three or more of the supportive 
features of step three in order for a diagnosis of definite PD to be made.  With regard to then 
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diagnosing dementia (i.e. PDD), a common procedure is to diagnose PD according to the Queen 
Square criteria. Then if dementia, according to the DSM-IV (appendix A) or other appropriate 
criteria, presents more than one year after the onset of PD a diagnosis of PDD is made.  
Diagnosing PDD by the Queen Square criteria and DSM-IV has been shown to have good 
positive predictive value in prospective validation studies.  Although more detailed criteria for PDD 
have been proposed (Emre, Aarsland et al. 2007) they have yet to be validated.  
 
The one year threshold is useful in the clinic but there is in fact little evidence that DLB and PDD 
are two separate entities.  Indeed, most research is supportive of a spectrum view where both 
DLB and PDD (collectively Lewy body (LB) dementias) and PD fall on a continuum of Lewy body 
disease. 
 
In keeping with the continuum view, there appears to be few differences in cognitive impairment in 
PDD and DLB.  Individuals with mild DLB have been shown to exhibit greater impairments in 
some, but not all, measures of executive function than PDD (Aarsland 2003).  However these 
differences do not appear to be present among patients with severe dementia while other studies 
have failed to find any difference at all between the two in a wide variety of cognitive domains 
(Noe, Marder et al. 2004).  Furthermore, although visual hallucinations are more common in DLB 
than PDD, the content and severity are identical (Aarsland, Ballard et al. 2001, Mosimann, Rowan 
et al. 2006).  There is also no way of distinguishing between the two diseases based on other 
neuropsychiatric symptoms. 
 
1.1.2 Pathology and pathological diagnoses of dementia 
 
DLB and PDD are also characterised by very similar underlying pathology.  In both cases cortical 
Lewy body (LB) pathology is the hallmark feature, particularly in the frontal, cingulate and 
entorhinal cortices.  Lewy bodies are abnormal protein aggregates with α-synuclein being the core 
component in both DLB/PDD and PD (Spillantini, Schmidt et al. 1997), but it is their presence in 
the cortex that is strongly associated with the development of dementia.  Specifically, Hurtig et al. 
(2000) used a LB staging system in a variety of brain areas including the (amygdala, 
hippocampus, subiculum, entorhinal cortex, midfrontal gyrus, postcentral gyrus, Wernicke’s area 
and cingulate gyrus) ranging from 0 to 3+, with 0 being no LBs and 3+ being >=5 per 100x field 
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(Hurtig, Trojanowski et al. 2000).  They found good sensitivity and specificity, with 91% of patients 
diagnosed with PDD clinically being found to have a cortical LB score of 2 or more and 90% of 
patients diagnosed with PD only having a cortical LB score of less than 2.  Consistent with this 
finding, cortical LB counts in PDD and also DLB brains were found to be significantly higher than 
in PD in a later study, whereas a greater proportion of brainstem LB pathology was associated 
with PD (Tsuboi, Dickson 2005).  Of note, the authors did not report any significant difference 
between the number and distribution of LB pathology in DLB and PDD, a finding which has also 
been observed in imaging analysis of grey matter atrophy (Burton 2004). 
 
The close clinical and pathological similarity between DLB and PDD has led most experts to 
support the LB disease continuum view, making the grouping together of these two syndromes 
acceptable for the study of underlying disease mechanisms (Aarsland, Ballard et al. 2004, 
McKeith, Dickson et al. 2005, McKeith 2007).  Besides Lewy body pathology, the brains of 
DLB/PDD patients frequently show the two hallmark pathological features of AD pathology: 
amyloid plaques and neurofibrillary tangles (NFT).  Tsuboi and Dickson (2005) examined the 
presence of AD pathology in the cortex and hippocampus of DLB patients and found NFTs to be 
completely absent in the former region while both amyloid plaques and NFTs were present in the 
latter (Tsuboi, Dickson 2005)(McKeith, Dickson et al. 2005)(McKeith, Dickson et al. 
2005)(McKeith, Dickson et al. 2005)(McKeith, Dickson et al. 2005)(McKeith, Dickson et al. 
2005)(McKeith, Dickson et al. 2005)(McKeith, Dickson et al. 2005)(McKeith, Dickson et al. 
2005)(McKeith, Dickson et al. 2005).  Similarly, in a later study significantly more amyloid plaques 
were found in the cortex and hippocampus, and significantly more NFTs found in the 
hippocampus, in DLB and PDD compared to PD, while the levels in DLB and PDD were not 
different (Tsuboi, Uchikado et al. 2007).  The McKeith diagnostic criteria take account of this and 
post-mortem cases are assigned a likelihood that the dementia of the patient was due to AD 
pathology.   
 
As stated above, the two hallmark pathological lesions associated with AD are amyloid plaques 
and NFTs.  NFTs are chiefly composed of abnormally phosphorylated and hyperphosphorylated 
tau protein while amyloid plaques are defined by the presence of amyloid β-peptide (Aβ) 
(Masters, Simms et al. 1985).   
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In addition to being the major component of NFTs in AD, there are pathological lesions 
characterised by abnormally phosphorylated and hyperphosphorylated tau protein present in 
other diseases, collectively known as tauopathies.  Alongside AD there are at least 25 such 
diseases, including Pick’s disease and other forms of frontotemporal dementia (FTD), progressive 
supranuclear palsy (PSP) and corticobasal degeneration (Spillantini, Goedert 2013).   The tau 
protein is encoded by a single gene composed of 16 exons, microtubule-associated protein tau 
(MAPT), on chromosome 17.  There are six isoforms in the adult human brain, generated by 
alternative splicing of exons 2, 3 and 10.  As shown in Figure 1-1, exons 2 and 3, just exon 2 or 
neither can be included (2N, 1N or 0N respectively).  Additionally, in each case a 31 amino acid 
repeat (exon 10) can either be omitted or included, generating three 3-repeat (3R) isoforms and 
three 4-repeat (4R) isoforms.  
 
Figure 1-1 MAPT isoforms 
In the MAPT gene exons 2, 3 and 10 are alternatively spliced to generate the six isoforms present 
in the human brain.  Figure from (Caffrey, Wade-Martins 2007) 
 
There are approximately equal amounts of 3R and 4R tau in the healthy adult human cortex but 
aggregation of either of the isoforms into filamentous inclusions is associated with various 
tauopathies.  For example, NFTs in AD contain all six isoforms, although some research suggests 
there is more 3R than 4R (Spillantini, Goedert 2013, Liu, Le et al. 2001) while tau filaments in 
PSP and corticobasal degeneration both contain only the 4R isoform and in Pick’s disease they 
are composed only of the 3R isoform (Spillantini, Goedert 2013).   
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Aβ is produced by cleavage of the amyloid precursor protein (APP gene on chromosome 21) and 
exists in varying lengths usually ranging from 38 to 43 amino acids (Ritchie, McLean et al. 2010).  
Aβ42 is the major component of amyloid plaques in AD (Iwatsubo, Odaka et al. 1994).     
 
The amyloid cascade hypothesis has provided the prevailing model of neurodegeneration in AD 
(Hardy, Allsop 1991, Hardy, Higgins 1992).  This hypothesis originally put amyloid deposition as 
the first pathological feature of AD, caused by increases in total Aβ, increases in the ratio of 
Aβ42:Aβ4o and decreased Aβ degradation and clearance.  The formation of plaques is followed by 
NFTs (although the mechanism linking the two is not clear), thus according to this hypothesis the 
cell death that follows in turn is either a direct result of amyloid deposition, caused indirectly via 
NFTs, or both.  Central to the formation and support of this hypothesis is genetic evidence that 
mutations in the APP gene cause early onset familial AD and are associated with increases in 
either total Aβ or the Aβ42:Aβ4o ratio.  Moreover, the APP gene is located on chromosome 21 and 
in people with Down syndrome it is therefore triplicated.  Both amyloid plaques and NFTs are 
present in the majority of people with Down syndrome by age 50.  They form in a pattern typically 
observed in the wider AD population (Mann, Esiri 1989), with NFTs developing later and being 
better correlated with the clinically observed severity of dementia (Margallo-Lana, Moore et al. 
2007), which is also true of AD patients without Down syndrome (Thind, Sabbagh 2007).  
Following on from the original hypothesis and from evidence indicating that amyloid plaques are 
not correlated with dementia severity, research focused on smaller soluble Aβ dimers, trimers and 
oligomers.  Specifically, a range of neurotoxic events may be associated with these smaller units 
of Aβ in people with AD, resulting from both their intra- and extracellular accumulation.  
Intracellular neurotoxic events may arise from the reuptake of Aβ at several different receptors, 
potentially interfering with the proteasome.  Moreover, extracellular neurotoxicity has been 
proposed to arise from Aβ binding at several receptors, including NMDA and frizzled receptors 
which may lead to cell death via mitochondrial dysfunction and wnt signalling respectively.  The 
latter providing one explanation for how Aβ may cause NFT formation (reviewed in (Kayed, 
Lasagna-Reeves 2013).   
 
It is important to highlight that although AD is characterised by both NFTs and amyloid plaques, 
they do not encompass the full extent of the neurological pathology associated with the disease.  
Mitochondrial dysfunction, oxidative stress and neuroinflammation are also implicated in the 
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pathogenesis of AD (Serrano-Pozo, Frosch et al. 2011).  Although the amyloid cascade 
hypothesis would put amyloid deposition as the starting point for all of these, it should also be 
noted that a mitochondrial cascade hypothesis has also been proposed, perhaps reflecting an 
increased recognition of other pathological processes (Swerdlow, Khan 2004).  
 
The progression and distribution of NFTs and amyloid plaques is predictable and for this reason 
various staging methods based on the severity of these lesions have been developed.  For 
research purposes they are used as an indication of disease severity rather than as a full 
characterisation of the pathology present in the brain.   
 
The NFT staging proposed by Braak and Braak (1991) is determined by the pattern and severity 
of burden and comprises of six stages.  NFTs are mainly localised to the transentorhinal region in 
stages I-II, becoming more severe and involving the entorhinal cortex and limbic regions in the 
middle stages, III-IV.  In the last stages (V-VI) NFT burden is still most severe in the 
aforementioned areas but overall there is significant involvement of most of the neocortex (Braak, 
Braak 1991).  Amyloid deposition was also staged by Braak and Braak in the same paper, 
although the staging does not refer specifically to amyloid plaques as it includes diffuse amyloid 
deposition as well.  First affected are basal areas of the frontal, temporal and occipital cortices.  
Amyloid deposition then spreads further to cover the rest of the neocortex (with the exception of 
the motor and sensory cortices) with the aforementioned basal areas still being the more severely 
affected.  There is also mild deposition in the hippocampus.  Finally, almost all areas of the 
neocortex become seriously affected and while there is a relative sparing of the hippocampus as 
a whole, there are areas of tightly packed amyloid deposits in CA1 and the fascia dentata.  These 
three stages correspond to stages A, B and C defined by the authors (Braak, Braak 1991). 
 
While the Braak and Braak staging focuses on the progression of NFT pathology the CERAD 
(Consortium to Establish a Registry for Alzheimer’s Disease) neuropathological criteria are based 
on the severity (semi-quantitatively graded as none, sparse, moderate or frequent) of amyloid 
plaque pathology from three areas of the neocortex: the middle frontal gyrus, inferior parietal 
lobule and the superior and middle temporal gyri (Mirra, Heyman et al. 1991).  The patient’s age 
is then used alongside the plaque grade, giving an age-related plaque score of 0 (no histologic 
evidence of AD), A (uncertain evidence of AD), B (suggestive evidence of AD) or C (histologic 
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evidence indicates AD).  This score is then integrated with the patient’s clinical history, forming 
the final diagnostic criteria for AD: normal (i.e. no evidence of dementia), possible, probable or 
definite.   These categories are based on the pathological criteria (the clinical history of dementia 
is not operationalised) and are not to be confused with the NINCDS-ADRDA criteria of the same 
names.   
 
The National Institute on Aging and the Ronald and Nancy Reagan Institute of the Alzheimer’s 
Association (NIA-REAGAN) staging considers all pathology in the brain to be abnormal, 
regardless of the clinical presentation of the patient during life.   Based on the observed pathology 
the likelihood that AD accounts for the dementia is rated as high (amyloid plaques and NFTs in 
the neocortex), intermediate (moderate amyloid plaques and NFTs in limbic regions) or low 
(amyloid plaques and NFTs in a limited distribution and/or severity).  These three stages 
correspond to Braak Stage V-IV/CERAD frequent score, Braak Stage III-IV/CERAD moderate and 
Braak Stage I-II/CERAD infrequent respectively. 
 
Currently the only treatments available for dementia target symptoms, rather than underlying 
pathology, and although the amyloid cascade hypothesis has allowed the identification of amyloid 
deposition as a potential treatment target for AD, clinical trials in this area have yet to be 
successful (Lobello, Ryan et al. 2012).  Effectively managing dementia and providing care for 
those with the disease is complicated by neuropsychiatric symptoms, particularly psychotic 
symptoms, which are common in all forms of dementia. 
 
1.2 Psychotic symptoms in dementia 
 
Besides visual hallucinations which characterise DLB/PDD clinically, a wide range of 
neuropsychiatric symptoms are present across all dementias, including AD.  These include 
hallucinations, delusions, delusional misidentification, agitation/aggression, depression and sleep 
disturbances.  Psychotic symptoms in all dementias are debilitating, persistent and are associated 
with a negative impact on disease course and often influence the decision to move patients into 
residential or nursing care (Lopez 2013, Stern, Albert et al. 1994).   
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Understanding psychosis in dementia is of central importance principally because there are 
currently no effective treatments (see section 1.2.3) but also because of its relationship with 
disease course which along with the nosology of the symptoms will be reviewed below. 
 
Broadly, psychosis refers to two particular symptoms: delusions and hallucinations.  Statistical 
data reduction techniques in a range of dementia disorders reliably identify a psychotic syndrome.  
In all instances this comprises delusions and hallucinations but along with these the psychosis 
syndrome is sometimes also composed of other symptoms such as anxiety and irritability (Proitsi, 
Hamilton et al. 2011, Levy, Cummings et al. 1996, Aalten, de Vugt et al. 2003, Aarsland, Larsen 
et al. 1999, Lange, Hopp et al. 2004, Lange, Hopp et al. 2004).  Only delusions and hallucinations 
are considered here as these are the principal symptoms of psychosis, thus henceforth the terms 
psychosis or psychotic symptoms will refer to only these two symptoms. 
 
In contrast to schizophrenia, hallucinations in dementia are mostly visual.  Auditory hallucinations 
have been estimated to occur in around 10% of people with AD, and around 20-40% of people 
with DLB and PDD (Ropacki, Jeste 2005, Noe, Marder et al. 2004, Aarsland, Ballard et al. 2001).  
Auditory hallucinations most frequently occur with visual hallucinations, there are not many 
estimates of their prevalence in isolation but two studies in PD put that figure at 0 and 2% 
respectively (Jeste, Finkel 2000, Ropacki, Jeste 2005, Inzelberg, Kipervasser et al. 1998, 
Fenelon, Mahieux et al. 2000, Noe, Marder et al. 2004).  It is not apparent from most of the 
genetic studies of psychosis in dementia what proportion of participants have auditory 
hallucinations, probably because most rating scales give a total hallucination score which will 
comprise all types. 
 
Again in contrast to schizophrenia, delusions of grandeur or other complex delusions are rare in 
all types of dementia.  The most common forms of delusion are paranoid types and 
misidentifications which are most frequently simple non-systematised beliefs concerning theft, 
harm and spousal infidelity (Jeste, Finkel 2000, Aarsland, Ballard et al. 2001).  There is also no 
distinction between these types of delusion in most genetic studies, for the same reasons as 
given above, therefore henceforth the terms delusions and hallucinations will refer to all types of 
each unless otherwise specified. 
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Long-term follow up studies put the frequency of psychotic symptoms in AD at 30-50%, with 
delusions being more common than hallucinations (Craig, Mirakhur et al. 2005, Levy, Cummings 
et al. 1996, Aalten, de Vugt et al. 2005).  In contrast, hallucinations are more common than 
delusions in DLB/PDD.  In DLB delusions and hallucinations are reliably found to be present in a 
majority of people, around 60% and 70% respectively, while the frequencies are less in PDD at 
around 30% and 50% respectively (Aarsland, Bronnick et al. 2007, Ballard, Holmes et al. 1999, 
Aarsland, Ballard et al. 2001). 
 
It is important to note that point prevalence estimates tend to underestimate the true frequency of 
psychotic symptoms.  In the Aalten et al. (2005) study of 199 mostly AD patients (two and 19 had 
DLB or mixed dementia respectively), point prevalence was 31% for delusions and 11% for 
hallucinations.  However, the two year cumulative prevalence was nearly double for hallucinations 
(20%) and rose considerably to 48% for delusions.  Similarly the 30-50% figure above from the 
Craig et al. (2005) study is a long-term retrospective estimate and considerably higher than the 
point prevalence estimate of 35% for delusions and 20% for hallucinations.  Similar patterns are 
observed in DLB; Ballard et al. (1999) report frequencies of delusions and hallucinations at first 
presentation to be 60% and 65% respectively, with those numbers rising to 70% and 73% for 
prevalence over the whole disease course. 
 
The fact that symptom estimates for delusions and hallucinations tend to increase with 
prospective evaluation suggests there is a reasonably large number of people who develop the 
symptom during follow up, that is to say psychotic symptoms have a high incidence.  Consistent 
with this, the one year incidence in AD reported by Levy et al. (1996) was 25% for psychosis.  
Aalten et al. (2005) calculated the 18 month incidence for delusions and hallucinations to be 34% 
and 20% respectively.  Once again, similar figures are reported in DLB: 30% for both delusions 
and hallucinations (Ballard, O'Brien et al. 2001). 
 
Psychotic symptoms are also persistent.  Estimates of persistence vary somewhat due to different 
lengths of follow up but most findings suggest that once a psychotic symptom emerges it tends to 
persist.  One year persistence of visual hallucinations and delusions in DLB has been reported to 
be 77% and 40% respectively (Ballard, O'Brien et al. 2001).  Lower estimates of persistence over 
one year exist in the AD literature with Ballard et al. (2001) putting the figure at 26% and 44% for 
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hallucinations and delusions respectively.  However, this is still a significant proportion of people 
and in other studies the estimates have been much higher, up to around 80% for one year down 
to 40-50% for both delusions and hallucinations in an eight year retrospective estimate (Craig, 
Mirakhur et al. 2005, Levy, Cummings et al. 1996). 
 
Along with incidence and prevalence estimates, knowledge of risk factors will also help to refine 
the psychotic symptom phenotypes.  Ropacki and Jeste (2005) conducted a large review of 55 
studies to examine risk factors for psychosis in AD.  The most notable risk factors (where over 
half the studies reported a significant association) were ethnicity, duration of illness and cognitive 
impairment.  Cognitive impairment is of particular relevance as it is necessarily present in all 
studies of psychosis in dementia and is therefore discussed in more detail in the next section.  
There has not been such a review in DLB/PDD, however most studies support a relationship 
between more severe cognitive impairment and psychotic symptoms (see next section).  The 
presence of early visuospatial deficits also has been identified as a predictor of hallucinations in 
DLB (Hamilton, Landy et al. 2011).  
 
1.2.1 Relationship between cognitive impairment and psychosis in dementia 
 
A key clinical feature associated with psychotic symptoms in AD is disease severity.  The wide 
body of evidence supporting an association with ante-mortem measurements is further 
strengthened by post-mortem studies showing a correlation with severity of tau pathology, a key 
marker of disease severity (see section 1.4.3).  Estimates of frequencies of hallucinations in mild, 
moderate and severe AD range from 0-21%, 10-23% and 22-56% respectively and there is a 
similar trend for delusions: 7-25%, 25-45% and 28-54% respectively (Lopez, Becker et al. 2003, 
Craig, Mirakhur et al. 2005, Piccininni, Di Carlo et al. 2005, Selbæk, Kirkevold et al. 2007).  A five 
year follow up study plotting cognitive impairment quantitatively against symptom frequency found 
that by year 1 (when Mini Mental State Examination (MMSE) score was approximately 16, 
indicating moderate dementia) hallucinations and delusions increased from 8 to 16% and from 40 
to 48% respectively (Holtzer, Tang et al. 2003).  By year 5 (when MMSE was approximately 10, 
indicating more severe disease) the frequency of hallucinations declined to 13% while delusions 
declined to 34%, suggesting a non-linear relationship.  Measures of quantitative symptom scores 
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rather than frequencies yield similar results, that is: hallucinations and delusions peaking in the 
moderate/moderate-severe stages (Suh, Kim 2004, Harwood, Barker et al. 2000). 
 
The relationship between cognitive impairment and psychosis in DLB/PDD is not so clear, 
although there have been a number of studies investigating this link.  In general most previous 
research supports a link with delusions or hallucinations in both PDD and DLB, with a slightly 
greater number supporting a link between hallucinations rather than delusions (Ballard, Holmes et 
al. 1999, Borroni, Agosti et al. 2008, Aarsland, Bronnick et al. 2007, Del Ser, McKeith et al. 2000, 
Aarsland, Cummings et al. 2001, Bronnick, Emre et al. 2011).  
 
In addition to cognitive impairment, psychotic symptoms are also associated with faster rate of 
cognitive decline.  McShane et al. (1997) found the severity of delusions (persecutory delusions 
specifically) to be associated with a 1.3-fold greater rate of cognitive decline (McShane, Keene et 
al. 1997).  Drevets et al. (1989) found that over five years the performance of psychotic 
participants declined 11 points on the Blessed Dementia Rating Scale while non-psychotic 
individuals declined only 5 (Drevets, Rubin 1989).  Interestingly, the rate of decline before the 
onset of psychotic symptoms has also been found to be a significant predictor of their 
appearance.  In one study, every 1 point decline in the Mattis Dementia Rating Scale between 
baseline and the year prior to the development of psychotic symptoms was associated with a 
nearly 2-fold increase in risk for developing psychosis.  Decline over the same period in verbal 
fluency was associated with a nearly 3-fold increase in risk for psychosis (Paulsen, Salmon et al. 
2000).  This latter finding may indicate that specific cognitive deficits such as executive function, 
or others that are implicated in frontal lobe function, may be of particular relevance to psychosis in 
dementia and some of the genes implicated in its aetiology (see section 1.4). 
 
The evidence so far indicates that while delusions and hallucinations are certainly present in all 
stages of DLB/PDD there is a less strong link with disease severity than in AD, where the 
evidence is more robust.  Here, there is a clear link between the increasing prevalence of 
psychotic symptoms and cognitive impairment.  This has clear implications for the genetic studies 
of psychosis, given the substantial variation in cognitive impairment both within and between 
previous samples, and the impact of this is discussed in detail in section 1.4.7.1. 
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1.2.2 Heritability and familial aggregation of psychosis in Alzheimer’s disease 
 
Psychosis has been found to aggregate in siblings with AD and this has been influential in the 
search for genetic correlates.  In the first study of its kind, Sweet et al. (2002) calculated that a 
sibling of an AD-psychosis proband had a 2.4-fold increased risk of psychosis.  This figure refers 
to individuals who experienced psychosis at any point during their assessment period.  Of 
significance, when the analysis was restricted to individuals who experienced only multiple 
symptoms (at one or more assessment) or recurrent symptoms (single or multiple) the risk 
increased to 3.8 (Sweet, Nimgaonkar et al. 2002).  It should be noted that an unusually high 
number of participants were classified as psychotic, 75%.  However two subsequent independent 
studies support these findings.  In the first, treating only individuals with multiple symptoms (at 
least two delusion symptoms and at least one hallucination symptom), psychosis prevalence was 
60% and the increased risk for psychosis in siblings of AD probands was nearly 4-fold 
(Hollingworth, Hamshere et al. 2007).  In the second, the psychosis prevalence was 50%, with 
36% experiencing multiple symptoms, and the risk associated with single and multiple/recurrent 
psychosis in the siblings of AD-psychosis probands was 2- and 3.8-fold respectively (Sweet, 
Bennett et al. 2010). 
 
There has been less of a focus on the heritability of psychotic symptoms in AD, although at least 
one study has reported an effect consistent with the results above. Here, there was a suggestion 
of a stronger genetic component in multiple or recurrent psychotic symptoms, the authors 
calculated 30% heritability for a single psychotic symptom and 61% for multiple or recurrent 
symptoms (Bacanu, Devlin et al. 2005).   
 
Heritability and familiality are not definitive proof of genetic causation.  Although it is somewhat 
unlikely that elderly siblings share similar environments the possibility that certain early life 
experiences shared between siblings contribute to psychosis risk in AD cannot be excluded.  
However, that persistent symptoms may have a stronger genetic basis than non-persistent 
symptoms is a logical assumption.  Psychotic-like phenomena, particularly hallucinatory 
symptoms, can arise out of acute episodes of delirium secondary to other medical conditions such 
as chest infections, stress and hospitalisation.  The prevalence of delirium in dementia patients 
varies but ranges from 7%-22% in nursing home and community based samples to 80% in 
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hospital samples, with most cases resolving in around six months from onset (Fick, Agostini et al. 
2002, Cole, McCusker et al. 2012).  Along with the apparent high heritability and familial 
aggregation of recurrent symptoms this serves to highlight the importance of prospective 
evaluation of symptoms, so that causes of psychotic-like symptoms other than dementia itself can 
be excluded.  This may even go some way to explain the lower heritability and familial 
aggregation in individuals with a single occurrence of symptoms in previous studies. 
 




Consistent with the importance of cholinergic deficits highlighted in autopsy studies (Ballard, 
Piggott et al. 2000), there is randomised controlled trial (RCT) evidence of a modest overall 
improvement of neuropsychiatric symptoms, particularly visual hallucinations, with the 
cholinesterase inhibitor rivastigmine in patients with DLB and PDD (McKeith, Del Ser et al. 2000, 
Emre, Aarsland et al. 2004, Edwards, Royall et al. 2007).  Although important, the overall level of 
improvement is modest and many individuals do not experience clinically significant 
improvements or they have significant residual psychotic symptoms.  Most other trials in DLB and 
PDD have focused on antipsychotics.   
 
Preliminary open trials of atypical antipsychotics in PD and DLB suggested some benefit in the 
treatment of neuropsychiatric symptoms (Onor, Saina et al. 2006, Fernandez, Trieschmann et al. 
2002, Takahashi, Yoshida et al. 2003).   There have been two RCTs of clozapine and one of 
olanzapine, all of which indicate a significant benefit (The French Clozapine Parkinson Study 
Group 1999, The Parkinson Study Group 1999) while RCTs of quetiapine and risperidone have 
shown no effect (Culo, Mulsant et al. 2010, Kurlan, Cummings et al. 2007).  The risk of severe 
neuroleptic sensitivity reactions is substantial in these individuals (McKeith, Fairbairn et al. 1992) 
and safety issues, an FDA black box warning and the need for regular blood monitoring have 
limited their use. 
 
1.2.3.2 Alzheimer’s disease 
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The data currently available from DLB and PDD patients are not large enough or well 
characterised enough to warrant investigation of genetic determinants of treatment response, 
therefore the rest of this section will focus on treatments for AD.  The lack of effective treatments 
in DLB and PDD does serve to highlight the importance of gaining a greater understanding of the 
aetiology of psychosis in these dementias, and genetic studies have an important role to play 
here.  
 
To return to treatment options in AD, there have been a number of investigations of 
antidepressant efficacy for neuropsychiatric symptoms in general (i.e. not specifically psychotic 
symptoms).  However, a recent meta-analysis only found evidence to support a modest benefit of 
selective serotonin reuptake inhibitor (SSRI) treatment when compared to placebo (Seitz, Adunuri 
et al. 2011).  Importantly, the only one of the studies reviewed that examined psychotic symptoms 
specifically failed to find any evidence that they were more effective than risperidone, the only 
current licensed antipsychotic for psychosis in dementia (Pollock, Mulsant et al. 2007). 
 
Two treatments for psychosis in AD deserve particular attention: antipsychotics and memantine.  
Antipsychotics are still widely used, despite the increased mortality rate associated with them, and 
it would be of benefit to understand the mechanisms underlying their harmful effects, particularly 
as alternatives are sought to replace their use.  Memantine is a safe and well tolerated drug in AD 
however evidence of its efficacy in treating psychotic symptoms is mixed.  Again, elucidating the 
genetic correlates of its efficacy may help identify poor responders or shed more light on how this 
drug exerts its effects; there has been no research in this area to date. 
 
1.2.3.2.1 Antipsychotics in AD 
 
Antipsychotics are a class of drug first developed for the treatment of schizophrenia but have long 
been the mainstay of pharmacological treatment of psychosis in AD.  As a result there is a large 
body of literature evaluating their efficacy in this regard.  Currently they are classified according to 
their affinity for blocking dopamine (DA) D2 receptors and the serotonin (5-hydroxytryptamine, 5-
HT) receptor 2A (5HT2A).  The older agents, typical antipsychotics, have no affinity for 5HT2A and 
the primary mechanism for their antipsychotic action is thought to be blockade of D2 receptors.  
Later hypotheses of psychosis incorporated the serotonergic system, particularly the 5HT2A 
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receptors, and as such a newer class of antipsychotic was developed targeting this receptor: the 
atypical antipsychotics.  Many of these still have some affinity for D2 blockade but what 
characterises them pharmacologically is their much higher relative affinity for 5HT2A (Meltzer, 
Matsubara et al. 1989).   
 
Current evidence suggests risperidone may be efficacious in the treatment of psychosis in AD, 
and the current guidance reflects this as it is the only licensed treatment available.  However, the 
results of a meta-analysis indicate that the benefit is likely to be only modest, with a weighted 
mean difference of -0.14 in favour of risperidone treatment over placebo (Ballard, Howard 2006).  
Despite risperidone being the only licensed treatment for psychosis in AD, other antipsychotics 
are still widely used, most notably among the atypical agents are quetiapine and olanzapine while 
haloperidol is the only typical agent still commonly used (Barnes, Banerjee et al. 2012).  Similar 
(i.e. modest) effect sizes are found for aripiprazole and olanzapine as for risperidone but these 
are based on fewer trials, while there is very little evidence that quetiapine is effective (Ballard, 
Howard 2006, De Deyn, Drenth et al. 2013).  There is also increased tolerability and mortality 
issues with haloperidol treatment (see below).  In spite of their continued use, there are significant 
safety concerns surrounding the use of antipsychotics in people with AD, including risperidone. 
 
Several studies have highlighted an increased mortality risk among patients with AD taking 
antipsychotics compared to those not.  In a large meta-analysis of 15 RCTs totalling over 5000 
participants Schneider et al. (2006) computed an overall 1.5-fold increased risk of death among 
individuals prescribed atypical antipsychotics.  Individual analysis by drug showed a trend towards 
increased mortality in three of the drugs investigated (risperidone, olanzapine and quetiapine) 
while the significant increased risk persisted with aripiprazole (Schneider, Dagerman et al. 2006).  
A secondary analysis comparing haloperidol to risperidone and quetiapine generated a relative 
risk of 2, indicating that it is more harmful.  Consistent with this evidence a large retrospective 
analysis by Wang et al. (2005) reported the use of typical antipsychotics to be associated with a 
1.4-fold increased risk compared to atypical antipsychotics (Wang, Schneeweiss et al. 2005). 
 
These two studies were followed by the DART-AD trial which followed up individuals five years 
after their participation in a clinical trial where their antipsychotic was either replaced with placebo 
or continued.  Overall, the antipsychotic group had a significantly higher mortality rate, the 
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difference becoming most notable after 12 months and particularly so at 36 months where there 
was 30% survival in the antipsychotic group, compared to 60% in the placebo group (Ballard, 
Hanney et al. 2009).   
 
There is not yet a mechanistic explanation for the harmful effects of antipsychotics, but one 
working hypothesis is that the sedating effects from histamine H1 antagonism cause secondary 
problems such as pneumonia and oedema (Ballard, Howard 2006).  This hypothesis will be 
explored in more detail in section 1.4.6.1. 
 
There is emerging evidence that pimavanserin, a newly developed 5HT2A inverse agonist 
(Meltzer, Mills et al. 2010), is efficacious in the treatment of psychosis in the context of PD.  The 
results of a subsequent six week trial in 199 patients released this year confirmed the preliminary 
2010 results and trials in AD and other dementias are awaited (Cummings, Isaacson et al. 2013). 
 
1.2.3.2.2 Memantine in AD 
 
Numerous RCTs have shown memantine to be a safe and well tolerated drug in people with AD 
(Gauthier, Loft et al. 2008, Wilcock, Ballard et al. 2008, Fox, Breitner et al. 2012).  It has also 
shown some efficacy in the treatment of psychotic symptoms. 
 
In a pooled analysis of six clinical trials, Gauthier et al. (2008) found a significant effect of 
memantine (compared to placebo) in the treatment of delusions and hallucinations, as measured 
on the individual Neuropsychiatric Inventory (NPI) item sub-scales, over 12 weeks.  Closer 
examination of this effect shows that symptoms actually remained more or less the same in the 
memantine group, while the placebo group worsened by 0.3 points on the NPI, against a baseline 
score of 3.9.  The results at 24 weeks were similar although the effect of memantine on 
hallucinations was lost.  Of patients symptomatic for delusions at baseline 62% improved after 24 
weeks of memantine while 52% improved in the placebo group.  No effect was found for 




A more recent 12 week RCT failed to find any major effect of memantine on psychotic symptoms, 
with the only significant finding being an effect at six weeks when analysing an NPI cluster 
consisting of the delusions, hallucinations and agitation/aggression subscales (Fox, Breitner et al. 
2012).  Given previous data showing quite a strong effect of memantine on agitation and 
aggression (Wilcock, Ballard et al. 2008), it is plausible that this result was driven at least in part 
by these symptoms. 
 
Memantine has two actions which are of potential interest in the treatment of psychosis in 
dementia; 5HT3A and NMDA receptor (NMDAR) blockade. 
 
In support of the hypothesis that 5HT3A may be a relevant target of memantine, there is RCT 
evidence that ondansetron, a 5HT3A antagonist, in combination with haloperidol is more effective 
than haloperidol alone for negative symptoms and psychopathology in schizophrenia (Zhang, 
Kang et al. 2006). Furthermore, in an early study ondansetron monotherapy was shown to be 
effective in the treatment of Parkinson’s disease psychosis (Zoldan, Friedberg et al. 1995).   
 
There has however been no research into 5HT3A receptor changes and psychosis in dementia 
and much more attention has been paid to memantine’s principal mechanism of action: NMDAR 
blockade.  Abnormal glutamatergic stimulation of NMDARs is hypothesised to be a major pathway 
of neurodegeneration, and so their blockade by memantine may be protective against glutamate 
excitotoxicity (Danysz, Parsons et al. 2000).  This is therefore thought to be central to a 
mechanistic explanation of its efficacy in treating AD itself.  There is preliminary evidence from 
animal studies that memantine may inhibit and even reverse tau phosphorylation via PP2A (a 
major phosphatase implicated in abnormal tau phosphorylation in AD), while studies in humans 
have reported a reduction in CSF phospho-tau after one year of memantine treatment (Degerman 
Gunnarsson, Kilander et al. 2007).  This is very early stage research and the exact relationship 
between NMDAR blockade and inhibition of tau phosphorylation is still not clear, however that tau 
is implicated in memantine’s mechanism of action is of particular relevance to psychosis in AD 
given the association between NFT burden and psychosis (see section 1.4.3). 
 
1.3 Section summary 
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AD, DLB and PDD together account for more than 70% of dementia cases.  They are 
characterised by different patterns of progression clinically.  Pathologically, the presence of NFTs 
and amyloid plaques distinguishes AD from DLB and PDD where Lewy bodies constitute the main 
hallmark pathological feature.  Distinguishing between DLB and PDD, either clinically or 
pathologically is difficult and most experts support their grouping together for research purposes. 
 
Psychotic symptoms (delusions and hallucinations) are common in DLB/PDD and AD.  They are 
of central importance to each type of dementia because of their negative impact on disease 
course and the paucity of effective treatments which currently exist. 
 
While well tolerated, cholinesterase inhibitors only appear to be of modest benefit in the treatment 
of visual hallucinations, and not effective at all in a large proportion of individuals with DLB and 
PDD.  With regard to antipsychotics, the best evidence base for the treatment of psychotic 
symptoms in DLB/PDD appears to be clozapine, but tolerability issues and an FDA black box 
warning limit its use. 
 
The picture is similar in AD.  There is some modest evidence from meta-analyses that memantine 
may, in addition to being effective in the treatment of cognitive and functional decline, confer 
some benefit to the treatment of psychotic symptoms.  However, more recent clinical trials have 
been disappointing.  Antipsychotics have repeatedly been associated with increased mortality and 
a number of other side effects including sedation, oedema and pneumonia, and as a 
consequence guidance on their use in AD is restricted to short-term risperidone prescription, 
which itself appears to be only modestly effective. 
 
There is an urgent need to identify safer and more effective therapies for psychosis in people with 
AD and DLB/PDD.   
 
The first step in addressing this need has to be a greater understanding of the mechanisms 
underlying psychosis in dementia and in the absence of animal models genetic studies have a 
pivotal role to play in elucidating these.  Moreover, genetic studies also have the potential to 
identify subgroups of likely poor responders, raising the possibility of more targeted therapeutic 
approaches using existing drugs. 
38 
 
1.4 Genetics of delusions and hallucinations in dementia and their 
treatment 
 
The high heritability of psychotic symptoms in AD has led to numerous genetic association 
studies examining the relationship between polymorphisms in key psychiatric-related genes and 
the prevalence and severity of psychotic symptoms.  The vast majority of these have been 
undertaken in AD (DeMichele-Sweet, Sweet 2010).  Although a small number have also been 
carried out in DLB/PDD psychosis, research in this area is severely lacking (Kiferle, Ceravolo et 
al. 2007, Borroni, Di Luca et al. 2006).  Genetic association studies have an important role to play 
in advancing current understanding of psychotic symptoms in dementia.  Assessment of psychotic 
symptoms almost exclusively relies on self-report and in the case of dementia, most often 
requires the input of a care giver in order to rate them.  They are therefore very difficult to model 
effectively in animals, with most models relying on appropriate observable correlates such as 
social withdrawal or cognitive dysfunction (Nestler, Hyman 2010).  The issue is further 
complicated by the presence of dementia, its interaction with psychosis and the different clinical 
characteristics of psychosis in dementia compared with other neuropsychiatric illnesses on which 
current animal models are focused. 
 
Post-mortem studies have undoubtedly played a key role in advancing understanding of 
psychosis in dementia, in particular because they allow researchers to localise neurobiological 
correlates.  However one key drawback is that conclusions about brain changes and their clinical 
correlates are limited to the stage of dementia in which the donor died.  Genetic association 
studies can provide important insights into the mechanisms underlying delusions and 
hallucinations, which are particularly difficult to investigate via the methods just described.  This 
last point notwithstanding it is important to use data from the aforementioned techniques in order 
to generate hypotheses and select candidate genes. 
 
A second potential benefit from the genetic association study method, which cannot be conferred 
from post-mortem studies, is in the prediction of treatment response, so called pharmacogenetics.  
This field is particularly attractive with respect to dementia given the current lack of effective 
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treatment strategies in this area and in particular the aforementioned adverse effects associated 
with antipsychotics.  Pharmacogenetic research into treatments for psychosis in dementia has 
only started relatively recently, with the focus entirely on AD. 
 
In the following sections four polymorphisms are discussed with respect to psychotic symptom 
prevalence and course in AD and DLB/PDD, antipsychotic mortality in AD and memantine 
efficacy in AD.   
 
1.4.1 Serotonin transporter polymorphism and serotonergic correlates of psychosis in 
dementia 
 
In the AD literature there have been a number of reported associations between polymorphisms 
in serotonergic genes and psychosis.  The two most widely studied serotonergic polymorphisms 
are the 5HT2A T102C single nucleotide polymorphism (SNP) and the serotonin transporter 
polymorphism, 5HTTLPR.  In fact, all of the 15 serotonergic polymorphism studies in AD 
psychosis have examined one or both of these.  Investigations of the 5HT2A SNP were initially 
born out of the key role of this receptor in the psychosis inducing actions of psychoactive drugs 
such as LSD and the antipsychotic properties of atypical antipsychotics which exhibit some 
efficacy in ameliorating psychosis in schizophrenia (Beasley, Tollefson et al. 1997, Holmes, 
Arranz et al. 1998).  It is a synonymous SNP and while this may mean it exerts its effects through 
influencing transcription or by being in linkage disequilibrium with the true causal variant, its 
functional consequences, if any, remain unknown.   
 
5HTTLPR is a 44 bp deletion polymorphism in the promoter region of the serotonin transporter 
(5HTT) gene, SLC6A4, with two alleles; one termed long (L) and one short (S).  In vitro studies 
have shown the S allele to be associated with a 3-fold lower rate of 5HTT transcription than the L 
allele as shown in Figure 1-2 (Lesch, Bengel et al. 1996, Collier, Stober et al. 1996, Heils, Teufel 




Figure 1-2 5HTTLPR polymorphism 
A 44 bp deletion in the promoter of the SLC6A4 gene termed the short (S) allele results in a 3-fold 
lower rate of transcription than the long (L) allele, producing less mRNA and protein allowing less 
serotonin to be taken up into the presynaptic cell.  Figure adapted from (De Neve 2011) 
 
The serotonin transporter is expressed mainly in the 5HT synthesising neurons of the midbrain, in 
particular the raphe nuclei, with lower concentrations also found in some areas containing 
ascending 5HT projections like the frontal cortex and hippocampus (Lesch, Aulakh et al. 1993).  
Therefore, one hypothesis for a mechanistic explanation for the role of 5HTTLPR in psychosis in 
dementia is that the reduced transcription of the S allele leads to reduced protein levels causing 
less 5HT reuptake capacity with consequences for 5HT neurotransmission.   
 
Post-mortem and PET studies, which have exclusively focused on healthy adults or adult 
neuropsychiatric syndromes other than dementia, have generated conflicting findings surrounding 
this hypothesis.  In healthy adults, there is no clear evidence of an association between 5HTT 
availability and 5HTTLPR genotype with several in vivo imaging studies failing to find an 
association (Willeit, Stastny et al. 2001, Shioe, Ichimiya et al. 2003, van Dyck 2004, Jacobsen 
2000, Murthy, Selvaraj et al. 2010).  However another study, larger than those aforementioned 
(N=96), did report greater 5HTT availability in SS and LL genotypes compared to heterozygotes 
SLC6A4 
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(although only the SS/LS comparison reached statistical significance) (van Dyck 2004).  This 
finding is difficult to interpret as one would not necessarily expect both homozygous groups to be 
similar.  This finding may be a false positive, reflect differences in the populations studied or 
reflect the complexity of this particular polymorphism.   
 
Evidence that the 5HTTLPR polymorphism may exert a different influence according to disease or 
disorder, and certainly evidence of the complexity of investigating these relationships, is provided 
by studies examining its effect in samples of adults with neuropsychiatric disorders other than 
dementia.  Heinz et al. (2000), examining a dominant inheritance model of 5HTTLPR (i.e. LL vs. 
LS/SS), found non-alcoholic LL homozygous controls to have a significantly higher number of 
5HTT sites in the dorsal raphe nucleus (DRN) than LL homozygous alcoholics (Heinz, Jones et al. 
2000).  Also examining a dominant inheritance model, Little et al. (1998) found that LS/SS carriers 
who were ethanol users had a significantly greater number of 5HTT sites than LS/SS carriers who 
were not ethanol users, again in the DRN, while binding potentials for LL carriers were similar 
(Little, McLaughlin et al. 1998).  Interestingly, in the study by Little et al., there was some 
evidence that 5HTT binding may differ by brain region and by disorder.  Specifically, cocaine 
users had higher 5HTT binding than ethanol users in the DRN but not in the median raphe (MRN) 
or substantia nigra (SN).   The S allele has also been associated with lower 5HTT binding in 
suicide studies (Bah, Lindström et al. 2008, Du, Faludi et al. 1999), in particular in the frontal 
cortex, though it is important to note that contradictory evidence has also been presented (Mann, 
Huang et al. 2000, Parsey, Hastings et al. 2006). 
 
The downstream effects of the 5HTTLPR polymorphism in terms of 5HTT binding density are 
clearly complex, but it is sensible to hypothesise that any effects in binding may be disease 
specific and brain region specific.  In addition, there is evidence that the influence of 5HTTLPR 
may also extend to affect 5HT receptors which are implicated in a variety of psychiatric disorders 
and thus may be important for psychosis in dementia, namely 5HT2A and 5HT1A. 
 
Alterations in density of both of these receptors have been observed in 5HTT knockout mice, 
highlighting a potentially important relationship in humans.  5HT1A receptor density is significantly 
reduced, particularly in the DRN, MRN, hypothalamus and amygdale of 5HTT -/- mice, while there 
were no changes in the frontal cortex or hippocampus (Li, Wichems et al. 2000).  5HT2A receptors 
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on the other hand are affected to a much lesser extent in 5HTT knockouts, with density increased 
in the hypothalamus and decreased in the striatum (Li, Wichems et al. 2003). 
 
The findings above regarding 5HT1A are supported by PET imaging in humans which has 
demonstrated the SS genotype to be associated with lower 5HT1A binding potential than the LL 
genotype (David, Murthy et al. 2005).  However, two later studies reported greater binding 
potential associated with the SS genotype and another found no association at all (Lothe, Boni et 
al. 2009, Borg, Henningsson et al. 2009, Lee, Bailer et al. 2005).  The reasons for these 
conflicting findings are not clear, however in common to all of these studies no impact has been 
found on 5HT1A autoreceptors in the brainstem nuclei from where 5HT neurons originate (DRN 
and MRN). 
 
It is well established that 5HTTLPR affects SLC6A4 transcription, with the SS genotype being 
associated with a significantly reduced rate of transcription compared with the LL genotype.  What 
is not so clear however is how this might translate into a mechanism for psychiatric symptoms in 
dementia.  It is possible that the 5HTT reuptake sites are affected, with there being some 
evidence for this in depression and substance abuse.  Evidence from 5HTT knockout mice, 
supported by preliminary PET imaging in man, points to a possible role for 5HTTLPR in altering 
5HT1A receptor density in many cortical areas of the brain.  Like the 5HTT binding studies, the 
direction of this relationship appears to be region specific and it is not yet known whether it too is 
disease/disorder specific. 
 
To date there have been no biochemical studies investigating the above links in dementia.  
However post-mortem studies, although there are not many focusing specifically on psychotic 
symptoms, have highlighted the serotonergic system more generally as an important correlate in 
AD and DLB/PDD. 
 
With regard to AD, a significant decrease in 5HT concentration and increase in 
acetylcholinesterase (AChE)/5HT ratio in the ventral temporal cortex (BA20), but not the anterior 
prefrontal cortex (BA10), has been shown to predict psychotic symptoms (Garcia-Alloza, Gil-Bea 
et al. 2005).  5HTTLPR may fit into this hypothesised mechanism by compounding 5HT levels 
reduced through neurodegeneration, in this instance it would be the LL genotype that would 
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increase susceptibility to psychotic symptoms relative to SS carriers.  The only other study 
specifically to address the relationship between serotonergic system changes and psychotic 
symptoms in AD focused on hippocampal regions and found no evidence to suggest that 5HT1A, 
5HT2A or 5HTT density is associated with these symptoms in this region (Lai, Tsang et al. 2010). 
 
Cheng et al. (1991) reported preserved 5HT2 receptor (though they did not discriminate between 
5HT2 subtypes) binding in the temporal cortex of DLB patients with hallucinations compared to 
those without (Cheng, Ferrier et al. 1991).   This evidence is supported by Perry et al. (1990) who 
cite a monoaminergic-cholinergic imbalance as an important neurochemical correlate (Perry, 
Marshall et al. 1990).  Specifically, the ratio of 5HTIAA (the main metabolite of 5HT) to choline 
acetyltransferase (ChAT) was 9.3 in DLB patients with hallucinations compared to 3.1 in those 
without hallucinations (which was comparable to control).  Again this analysis focused on the 
temporal cortex.   
 
It is noteworthy that the direction of the ratio associated with hallucinations in DLB (Perry, 
Marshall et al. 1990) is similar to that reported by Garcia-Alloza et al. (2005) in AD (although 
different markers were used).  Establishing common and distinguishing mechanisms underpinning 
the same symptoms across the AD/DLB/PDD spectrum will be important in advancing current 
understanding of these symptoms and implementing new treatment strategies. 
 
There is a lack of research addressing the relationship between serotonin dysfunction and 
psychotic symptoms in PDD but in PD with psychosis a recent PET study reported findings similar 
to Cheng et al. (1991) (Ballanger, Strafella et al. 2010).  The authors extended the analysis to 
examine frontal cortical areas as well as temporal cortical areas and reported increased 5HT2A 
binding in several regions in each to be associated with hallucinations.  Moreover, in a post-
mortem study of PD psychosis, Huot et al. (2010) have presented findings again supporting a role 
for the relative preservation of 5HT2A receptors in the temporal cortex (specifically BA21) in PD 
patients with hallucinations compared to those without hallucinations.  In contrast to Ballanger et 
al, Huot et al found no evidence of binding differences in the orbitofrontal cortex according to the 
presence of hallucinations (Huot, Johnston et al. 2010). 
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Although the patterns of association with changes in serotonergic neurochemistry and psychotic 
symptoms still require more research, there is evidence that this is an important correlate in AD 
and DLB.  There is even evidence to suggest that similar patterns of dysfunction underpin 
psychotic symptoms in these two dementias.  Although there have been no studies specifically 
focusing on PDD as it is very closely related to PD and DLB it might be expected that similar 
changes would be observed here. 
 
Taken together the above evidence strongly implicates brain region-specific serotonergic 
alterations in the aetiology of psychotic symptoms in dementia.  Although more post-mortem and 
PET research is needed, functionally significant polymorphisms such as 5HTTLPR provide a 
good opportunity to complement and enhance the findings from neurochemical research. 
 
There have been ten studies to date which have investigated the role of the 5HTTLPR 
polymorphism and psychotic symptoms in AD (Proitsi, Lupton et al. 2010, Borroni, Grassi et al. 
2006, Borroni, Grassi et al. 2006, Albani, Prato et al. 2009, Pritchard, Pritchard et al. 2007, 
Quaranta, Bizzarro et al. 2009, Sweet, Pollock et al. 2001, Rocchi, Micheli et al. 2003, Ueki, Ueno 
et al. 2007, Ha, Cho et al. 2005).  Of these, two were carried out in very similar cohorts but with a 
slightly different approach to classifying psychosis (Borroni, Grassi et al. 2006, Borroni, Grassi et 
al. 2006).  This section will review the results of these studies and their implications but section 
1.4.7 will discuss in detail how the methodological and analytical differences in these studies may 
have contributed to the differences in findings. 
 
Excluding Borroni et al. (2006b), the study which took the more different approach to analysis (i.e. 
factor analysis instead of examining symptom frequencies by genotype) and whose cohort was 
probably largely overlapping with Borroni et al. (2006a), four out of nine previous studies on 
5HTTLPR have reported an association with psychotic symptoms in AD.  However, the direction 
of the relationship is not consistent between these four studies.  Both Sweet et al. (2005) and 
Quaranta et al. (2009) reported a positive association between the L allele and LL genotype and 
psychotic symptoms with odds ratios (ORs) for the LL genotype of 2.6 and 7.25 for each study 
respectively.  Conversely the study by Borroni et al. (2006) reported the S allele (OR: 2.14) to be 
the risk factor, also interacting with the COMT high activity val allele to further increase the OR to 
9.6 (see section 1.4.2 for explanations of the COMT val158met polymorphism).  Lastly, no main 
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effect of 5HTTLPR genotype was found by Proitsi et al. (2010), there was just an interaction 
between the SS genotype and absence of the COMT high activity val allele. 
 
The findings in AD are suggestive of an association between 5HTTLPR and psychotic symptoms.  
Further investigation is warranted, in light of the methodological concerns outlined later but also 
because, as described previously, the functional consequences of both the S and L allele can 
plausibly fit mechanisms of psychosis.  It is also discussed in section 1.4.7 how this polymorphism 
may fit into more complex explanations of psychosis in dementia. 
 
There are few studies examining 5HTTLPR in neurodegenerative disease psychosis other than in 
the context of AD.  In one that is of particular relevance, Kiferle et al. (2007) examined the 
relationship between 5HTTLPR and visual hallucinations in PD and found no association (Kiferle, 
Ceravolo et al. 2007).  There have to date been no studies of the 5HTTLPR polymorphism in 
DLB/PDD so there is a need to expand genetic association studies to include this.  Given the 
paucity of studies in these two diseases it is at present only possible to begin to draw inferences 
from AD, and caution must still be exercised here. 
 
1.4.1.1 Section summary 
 
The 5HTTLPR polymorphism results in a 44 bp deletion in the promoter of the serotonin 
transporter gene, SLC6A4.  The allele with the deletion (S) is associated with an approximately 3-
fold lower rate of transcription than the long (L) allele, leading to less messenger RNA (mRNA) 
and functional consequences which are supported by animal studies and in vivo imaging in 
humans.  Given the good body of evidence from post-mortem studies in humans linking 
serotonergic dysfunction with psychotic symptoms in DLB/PDD and AD, 5HTTLPR is a good 
candidate polymorphism and has the potential to contribute to a mechanistic explanation of these 
symptoms. 
 
5HTTLPR is one of the most well studied polymorphisms in AD psychosis research.  Of the nine 
independent studies carried out to date, four have reported a significant association, two with the 
LL genotype, one with the SS genotype and one interaction with the COMT val158met 
polymorphism.  The inconsistent findings may be the result of a number of methodological 
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differences, which are discussed in more detail in section 1.4.7, however they do provide an 
indication that this polymorphism may be of potential importance to the pathogenesis of psychotic 
symptoms in AD.  There is also an urgent need to extend this research in DLB/PDD, with the goal 
of identifying common mechanisms which underpin the same symptoms in different types of 
dementia. 
 
1.4.2 Catechol-O-methyltransferase val158met polymorphism and dopaminergic correlates 
of psychosis in dementia 
 
The catechol-O-methyl transferase (COMT) val158met polymorphism is another relatively well 
studied polymorphism in AD psychosis research, and is the only polymorphism to also have been 
investigated in DLB.  Like the serotonergic gene research described above there has been a 
reasonable focus on other polymorphisms in dopaminergic genes, in particular those in DA 
receptors D1-4 (Sweet, Nimgaonkar et al. 1998, Holmes, Smith et al. 2001, Proitsi, Lupton et al. 
2010, Craig, Hart et al. 2004, Sato, Ueki et al. 2009, Pritchard, Ratcliffe et al. 2009) and the DA 
transporter (DAT) (Pritchard, Pritchard et al. 2008, Proitsi, Lupton et al. 2010).  Of all the 
dopaminergic polymorphisms examined in relation to psychosis in AD among the most convincing 
biochemical and molecular genetic evidence for functional impact on putative disease 
mechanisms comes from the COMT val158met polymorphism.  The same rationale for focusing 
on 5HTTLPR, as opposed to 5HT2A, can be applied to COMT val158met in this instance.  
Specifically although there is evidence that the DAT polymorphism alters transcriptional efficiency 
(Miller, Madras 2002) there is little evidence of its functional significance to psychosis in AD 
beyond this. 
 
On the other hand, COMT val158met has been extensively studied and there is solid evidence on 
which to base hypotheses concerning its role in the aetiology of psychotic symptoms in dementia.   
 
COMT is an enzyme responsible for terminating the action of dopamine and is encoded by a 
single gene on chromosome 22.  There are two COMT isoforms, the soluble 1.3kb transcript (S-
COMT) and the longer 1.5kb membrane bound transcript (MB-COMT).  MB-COMT (henceforth 
COMT) is the only one of the two that is expressed in the CNS (Hong, Shu-Leong et al. 1998).  
The COMT val158met polymorphism is a g/a SNP which leads to a valine (val)/methionine (met) 
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substitution in the amino acid sequence of the resulting protein (it is present in both isoforms), see 
Figure 1-3.  The met allele is significantly less heat stable at body temperature and is therefore 
associated with a 2-3 fold lower enzyme activity.  The presence of val, the so-called high activity 
allele, is associated with a downregulation of dopamine activity in the prefrontal cortex (PFC), 
which may in turn possibly increase expression of the DA precursor tyrosine hydroxylase in 
subcortical areas (Akil, Kolachana et al. 2003, Matsumoto, Weickert et al. 2003).   
 
 
Figure 1-3 COMT val158met polymorphism 
Contained in exon 4 of the COMT gene, the methionine coding allele is less thermostable than 
the valine allele, resulting in a lower activity enzyme associated with less efficient dopamine 
clearance and therefore higher dopamine levels.  This is particularly relevant for prefrontal areas 
where COMT is the major route of dopamine inactivation 
 
COMT is expressed widely in the human brain but it is its expression in the PFC that has 
garnered considerable attention in the field of psychiatry.  In the human brain dopamine 
transporters are another major route of dopamine inactivation, however they are not abundantly 
expressed in the PFC (Matsumoto, Weickert et al. 2003).  Furthermore COMT knockout mice 
show a 2- to 3-fold increase in dopamine levels in the dorsolateral prefrontal cortex (DLPFC) but 
not the striatum, providing further evidence that it is the major regulator of dopamine 
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The downstream effects of the changes in DA tone associated with COMT val158met have yet to 
be fully elucidated but a number of PET imaging and post-mortem studies have been carried out 
which provide some suggestions. 
 
In human PET studies, involving healthy adults, the COMT high activity val allele has been 
associated with an increase in the number of cortical (including DLPFC) and limbic dopamine D1 
receptors, consistent with a decrease in DA tone associated with this allele (Slifstein, Kolachana 
et al. 2008).  A similar PET study however found no association between the COMT val158met 
polymorphism and striatal or cortical D2 or D3 receptor availability (Hirvonen, Någren et al. 2010).  
There are few studies of this kind (that is, examining changes in dopamine receptor availability) 
so it would be premature to draw concrete conclusions, however this pattern of receptor change, 
involving the DLPFC, is worth noting. 
 
There is evidence implicating D2 receptor changes in the pathogenesis of psychotic symptoms in 
disorders other than dementia such as schizophrenia and bipolar disorder.  Specifically, increased 
striatal D2/D3 receptors have been observed in bipolar patients with psychosis compared to those 
without (Pearlson 1995).  In AD, a more recent PET study noted a similar pattern: a significant 
correlation between the delusion score on the NPI and dopamine D2 binding potential (Reeves, 
Brown et al. 2009), while a post-mortem study of AD cases found a selective increase of D3 
receptors, but not D2 or D1 receptors, among those with psychosis (Sweet 2001).  These studies 
in AD provide support for a hypothesis implicating dopaminergic neurotransmission in the 
aetiology of psychotic symptoms.  However, to return to the COMT val158met polymorphism, 
although limited, PET evidence links the val allele to D1 receptor changes, not D2 or D3.  
 
There is a much larger body of evidence implicating D1 receptors in cognition rather than 
psychosis in the wider literature, consistent with the dopamine hypothesis of schizophrenia which 
states that hypostimulation of PFC D1 receptors is responsible for negative and cognitive 
symptoms while hyperstimulation in subcortical areas is responsible for positive symptoms (Abi-
Dargham 2004).  Therefore an arguably more likely hypothesis with respect to psychosis in AD, 
and certainly one for which there is more evidence, is that the psychological phenotype 
associated with COMT val158met would be cognitive in nature, perhaps meditated via D1 
receptors.  In healthy individuals tested before and after cognitive training, larger decreases in D1 
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binding potential have been associated with greater improvements on working memory tasks 
(McNab, Varrone et al. 2009) while in schizophrenics higher D1 binding potential is associated 
with worse performance in cognitive tests (Abi-Dargham, Mawlawi et al. 2002).  This relationship 
will be discussed in detail in section 1.4.7.2 however it is important to note at this stage that the 
influence of COMT val158met, and indeed 5HTTLPR, on psychotic symptoms may not be a direct 
one. 
 
The relationship with D1 receptors notwithstanding, the above studies highlight the importance of 
dopaminergic neurotransmission in the aetiology of psychosis and also draw attention to the 
possibility that psychotic symptoms may share common neurobiological correlates regardless of 
the principal psychiatric diagnosis of the patient (Reeves, Brown et al. 2009, Pearlson 1995). 
 
Taken together, the evidence surrounding DA receptor changes in psychotic symptoms in AD and 
the known physiological consequences of the COMT polymorphism presented above provides 
evidence that the COMT val158met polymorphism might be implicated in psychosis in dementia.  
However, the previous research in this area has yielded mixed results.  
 
There have been seven previous investigations of the COMT val158met polymorphism and 
psychotic symptoms in AD.  Four of these have been conducted by the same group in Italy 
(Borroni, Grassi et al. 2007, Borroni, Di Luca et al. 2006, Borroni, Grassi et al. 2006, Borroni, 
Grassi et al. 2006).  All four of these studies found the high activity val allele to increase risk for 
psychosis.  However, it would be prudent not to attribute any more weight to these findings than 
would be attributed to any one study, given that there is likely to be significant or complete overlap 
in patients included in each of the four studies (the authors were contacted to confirm this but no 
response was received).  In Borroni et al. (2006b) a 2.4- and 2.7-fold increased risk of psychosis 
was associated with COMT val allele and val/val genotype respectively and as noted in section 
1.4.1 an interaction was also found between COMT val and the 5HTTLPR S allele.  In further 
support of the val allele carrying the risk, Sweet et al. (2005) found the risk of psychosis to be 
increased in individuals with each copy of the val allele carried (Sweet, Devlin et al. 2005).  
However, in the third independent study in AD, again as noted in section 1.4.1, Proitsi et al. 
(2010) did not find a main effect of the COMT polymorphism but they did find a significant 
interaction between the 5HTTLPR SS genotype and absence of the COMT val allele (Proitsi, 
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Lupton et al. 2010).  Finally, in a small DLB study the val/val genotype was again found to raise 
risk for psychosis (Borroni, Di Luca et al. 2006), while in the only study to be carried out in PD 
psychosis, no association was found (Camicioli, Rajput et al. 2005). 
 
1.4.2.1 Section summary 
 
Compared to serotonin, there is less research surrounding dopaminergic neurotransmission and 
psychotic symptoms in AD.  However the evidence that does exist, along with the previous 
positive associations of COMT val158met in AD psychosis studies suggests this polymorphism 
and by extension dopaminergic neurotransmission may be important in the aetiology of psychotic 
symptoms. 
 
Although only two out of three previous studies have reported the val allele as a risk for psychosis 
this is indicative of lower dopaminergic neurotransmission, probably in the frontal cortical areas, 
being associated with psychosis in AD.  With the same finding being reported in a preliminary 
DLB study, there is an indication that psychotic mechanisms are perhaps shared in the two 
disorders.  Given what is known about COMT expression in the brain, it could be speculated that 
frontal cortical regions are important in this mechanism.  However, it is important to note that 
these regions are also implicated in cognition which is itself a correlate of psychotic symptoms, 
providing a further reason to clarify the role of this polymorphism in well characterised cohorts. 
 
1.4.3 Tau, the MAPT haplotype and psychosis in AD 
 
In AD and other tauopathies the ratio of 4R to 3R tau is disrupted and this is thought to play a role 
in the neurodegenerative process, though the exact mechanism is not known.  To focus on AD, 
post-mortem studies have shown that relatively less 3R tau is expressed in AD when compared to 
controls.  In the nucleus basalis tau 4R expression was 1.4-fold greater than 3R expression in AD 
cases, a significant difference to the control ratio of 1:1 and a shift attributed to less expression of 
3R as opposed to greater expression of 4R (Ginsberg, Che et al. 2006).  An earlier study with 
more extensive brain region coverage reported similar findings, but notably the 4R:3R ratio was 
only significantly higher in AD compared to controls in those regions that are typically heavily 
burdened with NFTs in AD (namely, the hippocampus, medial frontal cortex and medial temporal 
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cortex, but not in the entorhinal cortex).  The occipital and motor cortices, the caudate and 
cerebellum all showed a similar ratio to control brains (Yasojima, McGeer et al. 1999).  Absolute 
levels of 4R tau were also significantly higher in AD compared to control in the heavy tau burden 
areas, while 3R tau expression was significantly lower.  It is therefore important to note the 
complexity of tau isoform expression; not only does it depend on disease but it is also brain-
region specific.   
 
The above only accounts for tau isoform expression, rather than abnormal phosphorylation and 
aggregation into NFTs, but suggests that alterations in tau transcription may precipitate the 
formation of NFTs in AD.  A comparison between NFT composition in AD and progressive 
supranuclear palsy (PSP) found that in the basal ganglia, another region heavily affected by tau 
pathology in AD, detergent insoluble tau fragments were composed of less 4R tau than 3R tau by 
a factor of around 0.75, while the reverse was found for patients with PSP (Liu, Le et al. 2001).  
This was examined in only one brain area but is consistent with NFTs in AD being composed of 
all MAPT isoforms. 
 
The significance of tau in AD psychosis will be discussed in further detail below, but at this stage 
it is important to note that tau pathology is complex.  It appears that disruption of the 4R:3R ratio, 
either in favour of relatively more of either isoform is associated with different tauopathies and 
that, in addition, in certain brain regions the 4R:3R ratio is more susceptible to being perturbed.    
 
There is a body of literature linking tau pathology to psychosis in AD.   Early post-mortem studies 
reported higher levels of NFT pathology to be associated with psychotic symptoms, although the 
exact patterns of association differ slightly.  Zubenko et al. (1991) examined a psychosis 
syndrome (delusions and/or hallucinations) and tangle pathology in four brain regions: the medial 
frontal and superior temporal cortices, the entorhinal cortex (which connects the hippocampus 
with many other regions, notably the amygdala, cingulate and frontal cortex) and the 
presubiculum (an area with close connections to the hippocampus) (Zubenko, Moossy et al. 
1991).  The authors found that patients with psychosis had significantly higher densities of tangle 
pathology in the middle frontal cortex and presubiculum than those without.  Subsequently, Forstl 
et al. (1994) examined separate psychotic symptoms, namely persecutory delusions, 
misidentifications, visual hallucinations and auditory hallucinations (Forstl, Burns et al. 1994).  The 
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authors failed to replicate the earlier association found by Zubenko et al. of tangle density in the 
medial frontal cortex and psychosis.  They did however, again unlike the earlier finding, report a 
2-fold higher number of NFTs in the parahippocampus gyrus (which includes the entorhinal 
cortex) in patients with any type of delusion compared to those without.  No association was 
found with any other type of psychotic symptom.  Forstl et al.’s failure to replicate the previous 
findings of Zubenko et al. may well be a result of them beginning with the assumption that 
individual psychotic symptoms may differ in their aetiology, therefore highlighting the importance 
of treating individual symptoms separately, particularly when evaluating their role in disease 
mechanisms. 
 
Two later studies again examined NFT pathology in some of the areas studied previously (namely 
CA1 and the entorhinal cortex of the hippocampus, the medial frontal cortex and the superior 
temporal gyrus) (Sweet, Hamilton et al. 2000, Farber, Rubin et al. 2000).  Farber et al. found a 2- 
to 3-fold greater density of tangles in patients with psychosis (delusions and/or hallucinations) 
than those without in the medial frontal and superior temporal cortices but not the hippocampus or 
entorhinal cortex.  That is, they found similar findings to Zubenko et al., but not Forstl et al., 
perhaps due to the similar measure of psychosis employed.  Conversely, Sweet et al. failed to 
find any association between severity of tangle pathology and psychosis in the hippocampus, 
medial frontal or superior temporal cortices.  There is however more emerging preliminary 
evidence that phospho-tau in the DLPFC is higher in AD patients with psychosis (Murray, 
Kirkwood et al. 2013) and other recent evidence suggesting that levels are also raised in agitation 
and aggression (Guadagna, Esiri et al. 2012).  The exploration of the relationship between tau 
pathology and psychosis is made more complicated by the relationship between disease severity 
and both tau pathology and psychosis.  Genetic association studies offer the valuable opportunity 
to explore this relationship over the disease course, having the potential to bring greater clarity to 
current understanding of this relationship. 
 
One source of MAPT genetic variation that appears to affect the transcription of different tau 
isoforms is the extended MAPT haplotype.  The extended MAPT haplotype exists in two forms, 
termed H1 and H2.  The H2 allele exists exclusively in Caucasians: from a practical point of view 
H2 frequencies are 0% in Native American, East Asian and African populations (Evans, Fung et 
al. 2004).  Moreover, a variant of the H1 clade, H1c, has been identified as important in itself, 
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possibly driving the associations previously attributed to H1 (Myers, Kaleem et al. 2005, Myers, 
Pittman et al. 2007). 
 
The MAPT haplotype has been shown to have functional consequences.  In control brains with no 
evident neuropathology the H1 haplotype is associated with a 1.3- to 1.4-fold increase in 4R tau 
expression relative to the H2 haplotype in the globus pallidus while the figure in the frontal cortex 
is slightly lower at 1.2- to 1.3-fold higher (Caffrey, Joachim et al. 2006).  Subsequently the same 
group showed that the H2 haplotype is associated with a 2-fold increase in 2N tau expression 
relative to the H1 haplotype (see Figure 1-1 for a depiction of tau isoforms) (Caffrey, Joachim et 
al. 2008).  These results do not allow any conclusions to be drawn about the propensity of 
isoforms resulting from either haplotype to be abnormally phosphorylated, but they are important 
in illustrating possible mechanistic effects of the haplotype.  In AD, the tau H1 and the H1c 
haplotype have been implicated as a risk for the disease, but this has not been universally 
replicated (Myers, Pittman et al. 2007, Baker, Graff-Radford et al. 2000, Russ, Powell et al. 2001, 
Myers, Kaleem et al. 2005). Moreover, in a mixed AD and control cohort (analysed this way 
because no expression differences were found between cases and controls) the H1c haplotype 
has been associated with increased total tau expression and a relatively higher increase in 4R tau 
expression (25%) compared to other haplotypes (Myers, Pittman et al. 2007).  The implication 
here is that the tau H1c haplotype is responsible for causing a greater proportion of 4R tau to be 
expressed and that this is in turn implicated in tangle formation.  It is noteworthy that overall tau 
expression was not associated with the haplotype in the studies by Caffrey et al. (2006, 2008), in 
contrast to that of Myers et al. (2007).  This perhaps reflects that the H1c hapolotype is the true 
driver of higher expression and that analysing the H1 haplotype only masks important differences.  
However, a more recent study in healthy adults suggests a more complex picture in which the H1 
haplotype may have a distinct role.  Hayesmoor et al. (2009) found no effect of H1c haplotype on 
total tau expression but they did report a strong negative correlation between H1 expression as a 
proportion of total tau expression (i.e. from H1 and H2 haplotypes) and age at death 
(Hayesmoore, Bray et al. 2009). 
 
The complexity of this haplotype is further illustrated by evidence from the wider literature 
highlighting that the H2 haplotype may negatively impact disease, despite being generally found 
to be protective in most tauopathies.  Specifically, the H2 haplotype has been associated with a 
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lower age of onset in both FTD and dementia associated with Down’s syndrome (Jones, 
Margallo-Lana et al. 2008, Borroni, Yancopoulou et al. 2005, Laws, Perneczky et al. 2007).  In 
this latter study by Laws et al. (2007) the H2 haplotype was also associated with more severe 
decline of glucose metabolism in the frontal cortex of FTD patients.  This may be of relevance in 
AD psychosis because there is evidence suggesting the dysfunction of glucose utilisation in 
prefrontal brain regions is correlated with the presence of delusions (Sultzer, Brown et al. 2003, 
Mentis, Weinstein et al. 1995).  This is not a universal finding however as the only other cohort 
study examining this relationship failed to find any difference in metabolism in frontal brain areas 
but did report hypometabolism and hypermetabolism in the medial occipital and inferior temporal 
cortices respectively (Hirono, Mori et al. 1998).  Whether this effect is present and mediated by 
the tau H2 haplotype in AD remains to be established, but the current evidence could implicate it 
as a putative psychotic symptom risk factor. 
 
There has been one genetic association study of the extended MAPT haplotype in AD psychosis 
research.  DeMichele-Sweet et al. (2011) in one of the largest and most well characterised 
studies of its kind tagged the entire MAPT gene but did not find an association with psychosis 
(DeMichele-Sweet, Klei et al. 2011).  Although this is evidence against MAPT genetic variation 
playing a role in psychosis, and in view of the study design and cohort can be considered 
reasonably robust, there are two important points to highlight.  Firstly, the authors examined 
delusions and hallucinations together and as has been highlighted in several sections previously 
there is a good body of evidence that these symptoms do not completely share the same 
aetiology.  Secondly, tau may not be associated with the presence or absence of psychosis; 
however it could act as a modifier once psychosis has set in causing it to become more severe.  
This would be analogous to a disease modifying hypothesis, for example the aforementioned 
study by Laws et al. (2007) found no association between the tau haplotype and FTD but did find 
it modified age at onset, suggesting that it could represent a risk for FTD with a different clinical 
presentation, once neurodegeneration as set in. 
 
1.4.3.1 Section summary 
 
In post mortem studies, a greater burden of NFT pathology has been associated with psychotic 
symptoms in AD with a good degree of consistency, suggesting AD with psychotic symptoms may 
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represent a form of the disease with a more severe pathology.  Further exploration of this 
hypothesis is possible through a genetic association approach because of the advantage of being 
able to serially evaluate participants and correlate ‘real time’ clinical data with genetic variation 
which has known functional significance.  One such source of variation is the extended MAPT 
haplotype which has been shown to affect total tau transcription and 4R isoform expression in a 
brain region specific manner with possible implications for NFT pathology and thus psychosis. 
 
1.4.4 Other polymorphisms associated with psychosis in dementia 
 
Besides the polymorphisms outlined above, there is a reasonable body of literature pertaining to 
genetic associations of other putative psychosis risk genes, comprising at least 34 studies in total.  
Of these, 22 examined the role of APOE, the single biggest genetic risk factor for sporadic AD, 
which have been identified in a review by DeMichele-Sweet et al (2010).  Of these 22, eight found 
a significant association (DeMichele-Sweet, Sweet 2010).  Two much larger subsequent studies 
(N~800) examined APOE again, one failed to find an association (Demichele-Sweet, Lopez et al. 
2011), but the other did report an association (Christie, Shofer et al. 2012).  What is particularly 
important about this latter finding is the phenotype that was examined.  The authors examined 
two phenotypes, one with people who suffered both delusions and hallucinations, and one with 
delusions only.   Hallucinations alone could not be examined as 94% of those with hallucinations 
also had delusions.  Under the delusions and hallucinations phenotype the APOE*4 allele 
emerged as protective against hallucinations (OR: 0.7 for one allele and 0.3 for two), while there 
was no effect observed when examining people with delusions but not hallucinations.  Given the 
size of the study this represents strong evidence that the previous psychosis phenotype of 
delusions and/or hallucinations is not appropriate for genetic studies. 
 
1.4.5 Genome-wide association and linkage studies in Alzheimer’s disease psychosis 
 
Genome-wide association studies (GWAS) are becoming increasingly common in AD as a whole 
and have yielded some influential findings (Hollingworth, Harold et al. 2011, Harold, Abraham et 
al. 2013).  Such studies require large numbers of cases to generate sufficient power and this has 
been the biggest barrier to their use in AD psychosis research.  One GWAS paper has been 
published, but no hits reached genome-wide significance.  This study was probably 
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underpowered, however some sub-threshold loci were identified namely in the visinin like protein 
1 (VSNL1) and solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9) genes.  
Although not implicated in psychosis in AD previously, the associated proteins have been 
implicated in schizophrenia and AD. 
 
Linkage studies are another method that is useful in establishing whether psychotic symptoms 
have a genetic basis.  This method has been employed in three studies investigating AD 
psychosis (Avramopoulos, Fallin et al. 2005, Bacanu, Devlin et al. 2002, Hollingworth, Hamshere 
et al. 2007).  Genome-wide significant linkage was found at loci on chromosome 14, 15 and 2 
respectively and in two cases this indicated allele sharing among relatives without psychotic 
symptoms (Hollingworth, Hamshere et al. 2007, Avramopoulos, Fallin et al. 2005).  The genetic 
linkage studies in this area have therefore not provided consistent evidence, although arguably 
the most plausible candidates to arise from this method are the nicotinic acetylcholine receptors 
located in the region identified on chromosome 15 by Hollingworth et al (2007). 
 
1.4.6 Pharmacogenetics of treatments for psychosis in AD 
 
Antipsychotic agents target a diverse range of receptor systems, including cholinergic, 
serotonergic, dopaminergic, noradrenergic and histaminergic receptors.  Actions at many of these 
systems are key mediating pathways in the common adverse events associated with this class of 
drugs, and could potentially be influenced by genetic polymorphisms affecting these receptor 
systems.  In addition, there is known genetic variability in the pathways responsible for the 
metabolism and breakdown of antipsychotic drugs, which could also impact on the severity of 
adverse events.  Pharmacogenetics therefore offers an exciting opportunity to contribute towards 
effective individualised medicine, where genetic polymorphisms could inform our understanding of 
the severity of potential risks and likelihood of benefit of specific individuals to antipsychotic and 
other therapies, and possibly inform the optimal starting dose.   
 
Despite the potential opportunities, this area has not been well studied in dementia. Of note 
however, one well-controlled proof of concept study (Dombrovski, Mulsant et al. 2010) highlighted 
that the 5HTTLPR SS genotype was associated with reduced treatment response and an 
increased propensity of adverse events during risperidone treatment.  There have been two other 
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much smaller cohort studies examining antipsychotic treatment response in AD.  Both focused on 
the 5HT2A T102C polymorphism and examined antipsychotic efficacy, rather than modification of 
side effects or adverse reactions (Angelucci, Bernardini et al. 2009, Engelborghs, Holmes et al. 
2004). 
 
The study by (Dombrovski, Mulsant et al. 2010) is therefore the first indication that genetic 
variants in pathways targeted by commonly used psychotropic drugs may be useful in predicting 
response (with respect to adverse events) in individuals with dementia. An earlier study also 
provides a good indication that pharmacogenetics may inform the likelihood of adverse events in 
response to antipsychotic drugs in people with dementia (Pollock, Mulsant et al. 1995).  In this 
study the authors determined the activity of CYP2D6 (the enzyme responsible for the metabolism 
of most antipsychotics), identifying a 5-fold increase in adverse events (predominantly sedation 
and extrapyramidal symptoms (EPS) in poor metabolisers.  This is of particular importance as 
sedation is a common side effect in people with dementia prescribed antipsychotic drugs and may 
be an important mediating factor of more serious secondary consequences such as oedema, 
pneumonia, stroke and increased risk of mortality in people with dementia (Ballard, Howard 
2006).   
 
1.4.6.1 Histamine, its relationship to antipsychotic mortality and the Histamine-N-
methyltransferase polymorphism  
 
Histamine in the CNS plays a vital role in sleep and wake, cardiovascular regulation and the 
maintenance of fluid balance (Haas, Sergeeva et al. 2008).  Blockade of the histamine H1 
receptor is a well established cause of sedation and an action of many antipsychotic drugs.  
Sedation in dementia is associated with prolonged antipsychotic prescription and would carry a 
risk of dehydration and peripheral oedema which in turn may impact mortality (Corbett, Ballard 
2012).  It is therefore not surprising that the H1 blocking effect of many antipsychotics has been 
implicated in the adverse effects associated with their use.  
 
Histamine H1 receptor agonists disrupt sleep/wake cycles and the first antihistamines such as 
chlorpheniramine are strong sedatives (Nicholson, Pascoe et al. 1991).  Specifically, PET imaging 
has demonstrated that cortical H1 antagonism is likely to underpin the sedative effect of H1 
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blockers (Tashiro, Mochizuki et al. 2002).  H1 mRNA levels are reduced in olanzapine treated rats 
(Han, Deng et al. 2008) but not in those treated with the low affinity H1 antagonist antipsychotics 
aripiprazole and haloperidol, suggesting that histamine signalling may be affected in chronic 
antipsychotic treatment. 
 
The importance of histamine blockade in people with AD is however not limited to sedation.  
Numerous studies in animals have demonstrated a clear link between the histamine H1 and H2 
receptors and the physiological states (e.g. fluid balance) highlighted above.  Histamine and the 
H1 and H2 agonists 2-thiazolylethylamine and 4-methylHA stimulate vasopressin and oxytocin 
release, which would act to increase water retention (Knigge 1999). Furthermore, 24h of 
dehydration increases histamine synthesis in the hypothalamus by 40% and antagonism of 
histamine H1 receptors decreases dehydration induced vasopressin release by 50-70% (Kjaer, 
Knigge et al. 1994).  With respect to AD, an early study showed impaired vasopressin secretion 
and self-reported ratings of thirst in response to dehydration compared to age-matched controls 
(Albert, Nakra et al. 1989).  This potentially important effect has not been studied since, nor has 
any interaction with histamine.  This notwithstanding, alongside the research in animals linking 
histamine to fluid balance, it is reasonable to hypothesise that chronic blockade of brain H1 
receptors would suppress vasopressin release in response to dehydration, which may be 
significant in a condition like AD where vasopressin is already compromised.   
 
The first and most obvious candidate gene for modification of antipsychotic effect is clearly the H1 
receptor, HRH1.  However, there are no non-synonymous HRH1 SNPs common enough in 
European samples to warrant investigation in the present cohorts (Garcia-Martin, Ayuso et al. 
2009).  There are a number of non-synonymous SNPs, however in a hypothesis driven approach 
there is not sufficient evidence, either from previous association studies or from molecular genetic 
approaches, to include them in the analysis. 
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Figure 1-4 HNMT thr105ile polymorphism 
Located in exon 4 of the HNMT gene located on chromosome 2.  The T allele changes the amino 
acid at position 105 from theonine to isoleucine resulting in a less thermostable protein with a 
lower affinity for histamine 
 
A second plausible candidate for genetic modification of antipsychotic associated mortality is the 
histamine-N-methyltransferase (HNMT) gene.  HNMT is one of two enzymes (the other being 
diamine oxidase) responsible for termination of the actions of histamine and represents the only 
route to doing so in the human CNS, it is encoded by a single gene on chromosome 2 (Figure 
1-4).  A common c/t SNP in exon 4 of the gene has been identified which results in a 
threonine/isoleucine substitution at position 105 (thr105ile).  This polymorphism is associated with 
an approximately 2-fold decrease in enzyme activity (Preuss, Wood et al. 1998, Horton, Sawada 
et al. 2001).   
 
The hypothesis here is similar to that described for COMT, namely, a decrease in enzyme activity 
resulting from the rarer T allele would be associated with an increase in histamine levels and thus 
affect histaminergic neurotransmission, impacting key physiological process such as fluid balance 
and sleep.  Consistent with this, HNMT is expressed in the prefrontal cortex and hypothalamus, 
two areas in which histaminergic neurotransmission is associated with wake and fluid balance 
respectively (Panula, Nuutinen 2013). 
 
HNMT has been shown to significantly affect histamine neurotransmission in animal studies.  In 
rats, inhibition of HNMT by SKF 91488, dyaminopyrimidine or metoprine has been shown to 
cause increases in endogenous histamine levels, a dose dependent increase in mean arterial 
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blood pressure and a decrease in heart rate (Duch, Bowers et al. 1978, Jochem 2002, Klein, 
Gertner 1981, Jochem 2004).  Moreover, other animal studies have shown that SKF 91488 also 
induces wakefulness to a greater extent than direct injections of histamine, consistent with the 
hypothesis that histamine neurotransmission, mediated by HNMT is implicated in sedation (Lin, 
Sakai et al. 1988).  
 
1.4.6.1.1 Section summary 
 
Although the presence of the low activity T allele could lead to higher levels of histamine resulting 
in raised blood pressure due to greater activation of H3 autoreceptors, an arguably more likely 
hypothesis is that the more common C allele would carry the risk.  In this case, higher enzyme 
activity would lead to reduced levels of histamine relative to T carriers, which would in turn lead to 
less competition with antipsychotics for H1 receptors causing more sedation.  Less endogenous 
histamine alongside chronic blockade of H1 receptors may also affect the ability to respond to 
dehydration by inhibiting vasopressin release.  It will be important to identify possible harmful 
mechanisms such as this in the prescription of antipsychotics to help inform future prescribing 
practice.  
 
1.4.6.2 The extended MAPT haplotype and memantine treatment response 
 
There is some suggestive evidence that memantine may inhibit and reverse the abnormal tau 
phosphorylation, which may contribute to its mechanism of action (see section 1.2.3.2.2). 
 
It is not yet known whether the composition of NFTs in AD with and without psychosis differs.  
This gap in the literature notwithstanding, that hyperphosphorylated tau may be an important 
correlate of psychosis is potentially very interesting, particularly given the lack of effective 
treatments at present.  Although the results surrounding memantine as a treatment for psychotic 
symptoms have been disappointing, in light of memantine’s safety and tolerability profile in AD it 
is argued here that steps should be taken to identify the reasons why this may be.  There has 
however been no such research to date.  With evidence implicating tau in psychotic symptoms in 
AD and inhibition/reversal of phosphorylated tau by memantine it is proposed here that exploring 
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the extended tau haplotype may help explain the inconsistent findings that have arisen from the 
memantine literature. 
 
There has been no research to date examining the pharmacogenetics of memantine treatment 
response.  Tau is implicated in psychosis in AD and part of the mechanism of action of 
memantine may be inhibition and reversal of tau phosphorylation, thus although there are still 
many unknowns in this relationship, the tau haplotype may, alongside clinical trial data, help 
identify a subset of non-responders. 
 
1.4.7 Methodological Issues in Genetic Association Studies of Neuropsychiatric Symptoms 
in Dementia  
 
1.4.7.1 Cognitive impairment has confounded previous research on the 5HTTLPR 
polymorphism and psychosis 
 
As discussed in section 1.2 there are several clinical correlates of psychosis in dementia.  The 
most important of these is cognitive impairment, not least because it is by definition present in all 
participants in dementia studies.   
 
Psychotic symptoms are more prevalent in the moderate-severe stages of dementia than the mild 
stages.  It follows that focussing on patients with mild dementia who have not yet gone through 
the main risk period for the development of psychotic symptoms may be an important bias in 
previous research.  While this has been noted as important going forward in previous reports 
(Proitsi, Powell 2012, DeMichele-Sweet, Sweet 2010), its impact on past research has yet to be 
quantified, but is essential to inform a correct interpretation. 
 
The literature surrounding the COMT val158met polymorphism is simply not extensive enough to 
conduct an analysis of this point.  Therefore a systematic review and semi-quantitative analysis 
was carried out on the 5HTTLPR literature to evaluate the impact of cognitive impairment on 
whether a significant association was identified.   
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1.4.7.1.1 Study Identification and Selection 
 
Where relevant to the present review the criteria set out in the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses checklist were followed (Moher, Liberati et al. 2009).   
 
 
Figure 1-5 Flow diagram illustrating results of electronic and manual searches and study 
identification process 
From (Creese, Ballard et al. 2013) 
 
The results of the following identification process and study selection are illustrated in Figure 1-5.  
A search of PubMed/MEDLINE and Scopus was conducted using the search term “(dementia or 
alzheimer*) AND (serotonin or 5ht*) AND (polymorphism or gene*)”.  The only limit on the search 
was that articles had to be written in English.  The resulting 649 records over the two lists were 
screened for candidate gene association studies of the 5HTTLPR polymorphism in relation to 
psychotic, delusional or hallucination symptoms in Alzheimer’s disease.  References contained in 
review articles and meta-analyses (DeMichele-Sweet, Sweet 2010, Borroni, Costanzi et al. 2010, 
Ramanathan, Glatt 2009, Flirski, Sobow et al. 2011) were also manually searched for any 
additional studies not picked up by the above search.  Any duplicate articles were excluded.   
 
Ten articles were found using the aforementioned method and these were screened in detail to 
meet the following inclusion criteria: 1) standardised diagnosis of Alzheimer’s disease; 2) 






Excluded (see text): 
(n=2) 
Included in analysis: 
(n=8) 
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psychotic symptoms (delusions, hallucinations or psychosis) assessed using standardised 
assessment tool; 3) level of cognitive impairment measured using MMSE and reported.   
 
One study (Rocchi, Micheli et al. 2003) did not report MMSE, leaving nine in total.  However, two 
were carried out by Borroni et al. in 2006 (Borroni, Grassi et al. 2006, Borroni, Grassi et al. 2006), 
using very similar cohorts, both reporting significant findings.  In order to exclude any bias 
resulting from including non-independent cohorts, the Borroni et al. study with the analysis most 
similar to the other studies was included, that is the one that examined symptom frequencies 
using logistic regression rather than factor analysis (Borroni, Grassi et al. 2006), leaving eight 




In total, there have been eight published 5HTTLPR studies meeting the stipulated inclusion 
criteria (Table 1-1).  Gender proportion was similar across the eight studies.  Similarly, 
participants in all studies came from similar sources; that is, hospital outpatient clinics.  Five 
studies employed a cross sectional design while three were carried out in prospectively studied 
cohorts.  Other potential confounds such as age of onset and disease duration were not 
consistently reported across the studies so it is not possible to discuss these factors in the 
present review.  
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Table 1-1 5HTTLPR genetic association studies of psychosis 
From (Creese, Ballard et al. 2013) 
 
As shown in Table 1-1, four out of eight studies reported a significant association between the 
5HTTLPR polymorphism and psychotic symptoms in dementia (Borroni, Grassi et al. 2006, 
Quaranta, Bizzarro et al. 2009, Proitsi, Lupton et al. 2010, Sweet, Pollock et al. 2001); two found 
the LL genotype/L allele to be associated while one found the SS genotype/S allele associated 
and the last reported only an interaction between SS and the absence of COMT val to be 
associated.  Six of the eight investigated a psychotic phenotype of some kind; definitions are 
listed by study in Table 1-1.  Of the remaining two studies not using a psychosis phenotype, one 
investigated delusions only while another investigated delusions and hallucinations separately, in 
each case no significant association was found (Albani, Prato et al. 2009, Ueki, Ueno et al. 2007). 
 
Allele frequencies were distributed as expected according to ethnicity (Gelernter, Kranzler et al. 
1997, Kunugi, Hattori et al. 1997).  Among the six European ancestry cohorts (Sweet 2001, 
Borroni, Grassi et al. 2006, Albani, Prato et al. 2009, Quaranta, Bizzarro et al. 2009, Pritchard, 
Pritchard et al. 2007, Proitsi, Lupton et al. 2010) the S allele was carried by 42-57% of individuals 
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while this figure was much higher at 75 and 89% in the two Asian cohorts (Ha, Cho et al. 2005, 
Ueki, Ueno et al. 2007).  Neither of the Asian studies reported a significant association, leaving 
the four previously mentioned significant studies among the six European cohorts. 
 
The median MMSE score of the eight studies included was 16.75.  On examination of mean 
sample MMSEs plotted according to whether or not the result was significant (Figure 1-6 below), it 
can be seen that those studies that have reported a significant finding have on the whole lower 
MMSE scores than those which report no association.  Specifically, three out of four studies with 
a mean MMSE of below 16.75 reported a significant finding, while one out of four above 16.75 
reported a significant association. 
 
Figure 1-6 5HTTLPR psychosis studies plotted by MMSE and whether or not a significant finding 
was reported  
Dotted line represents median MMSE of the 8 studies included (16.75).  From (Creese, Ballard et 
al. 2013) 
 
Four of the eight studies incorporated disease severity into their statistical analyses (Quaranta, 
Bizzarro et al. 2009, Borroni, Grassi et al. 2006, Proitsi, Lupton et al. 2012, Pritchard, Pritchard et 
al. 2007), and three of these reported a significant finding, two for the SS genotype (Proitsi, 
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Lupton et al. 2010, Borroni, Grassi et al. 2006) and one for the LL genotype (Quaranta, Bizzarro 
et al. 2009).  The one study not reporting an association (Pritchard, Pritchard et al. 2007) had a 
sample with a relatively high MMSE (18.6 ±4.2).  Of the remaining four which did not incorporate 
MMSE into their analysis (Albani, Prato et al. 2009, Ha, Cho et al. 2005, Sweet, Pollock et al. 
2001, Ueki, Ueno et al. 2007), one reported a significant finding (Sweet, Pollock et al. 2001) and 
this study was one of two which had a sample MMSE of lower than 16.75 (the other being (Ha, 
Cho et al. 2005)). 
 
If the two Asian studies are excluded, all three of the remaining lower MMSE studies and one of 
the three remaining higher MMSE studies report significant associations (the median remains the 




This review quantifies the extent to which cognitive impairment (measured by MMSE) may have 
acted as a confounding variable in the literature surrounding genetic association studies of the 
5HTTLPR polymorphism in AD psychosis.  Three out of four studies with a sample MMSE below 
the median of 16.75 reported a significant finding compared with one out of four among those 
above.  This brings greater clarity to the current understanding of the role of the 5HTTLPR 
polymorphism and suggests that it is a risk factor for psychosis in people with AD.  This 
conclusion is strengthened by the fact that three of the four studies which factored MMSE into 
their analyses reported a significant association. 
 
The exploration of other potential clinical and demographic confounding variables was limited by 
the inconsistent reporting among previous studies.  However, it is useful to discuss these as they 
are relevant to the studies examining the role of COMT val158met as well.   
 
Those variables that were able to be reviewed were gender, the source of participants and 
ethnicity.  The former two appeared to be broadly similar among all the 5HTTLPR studies 
reviewed.  Conversely, both of the Asian studies failed to report a significant association and this 
may have been driven by the substantially higher frequency of the S allele among these 
populations.  When excluded from the review, although two studies were lost in doing so, the 
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relationship between cognitive impairment and significant association did strengthen: all three 
lower MMSE studies were positive, while only one out of three higher MMSE studies was positive.  
Ethnicity has been highlighted as important in previous, more general reviews, but as the first 
review specifically of this polymorphism it is possible to refine the initial conclusion and propose 
that a relationship between 5HTTLPR and psychosis may not exist in the Asian population and 
that among Europeans the relationship may only be present among those with greater cognitive 
impairment. 
 
What has been highlighted here is the importance of consistency in phenotypic definition and 
perhaps that psychotic symptom phenotypes in AD should be described with reference to 
cognitive impairment.  With these considerations, more work is needed to fully determine the role 
of 5HTTLPR in psychosis in AD   
 
There is evidence that individual psychotic symptoms differ in their underlying neurobiological 
associations (Forstl, Burns et al. 1994) as well as their clinical presentation (Ballard, Bannister et 
al. 1995) and it is therefore vital that in future suitable phenotypes are identified and used 
consistently.  The evidence presented here suggests cognitive impairment should be considered 
as part of this phenotype but there is less scope to draw firm conclusions about the definitions of 
the psychotic symptoms themselves.  Although all studies were selected on the basis of their 
investigation of delusions, hallucinations or psychosis, the phenotype definitions did vary 
somewhat.  The two Asian cohorts were the only two that did not investigate a psychosis 
phenotype it is therefore not possible to say whether it is specifically a combined phenotype that 
is related to 5HTTLPR, and if so susceptible to moderation by cognitive impairment, rather than 
individual symptoms as ethnicity that may have been driving the results here.  A further constraint 
to this interpretation is that only two of the six European studies reporting on a psychosis 
phenotype also reported on delusions and hallucinations separately.  Although in each case this 
did not change the results (they both remained negative), the fact that it is two studies alone 
makes it impossible to draw conclusions about the relationship between 5HTTLPR, individual 
psychotic symptoms and cognitive impairment. 
 
Prospectively assessed cohorts offer the best opportunities for accurate symptom classification.  
They offer far more accurate differentiation between transient psychotic-like phenomena such as 
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delirium and persistent psychosis; however their use in AD psychosis genetic research, 
presumably largely due to practical constraints, is limited.  There is evidence that multiple or 
recurrent psychotic symptoms are more heritable than single symptoms occurring at any 
assessment (61% and 30% respectively) (Bacanu, Devlin et al. 2005).  However, even among 
those studies reviewed here which employed prospective designs the multiple and/or recurrent 
definition was not adopted, potentially leaving non genetic factors to play a much greater role in 
the phenotype, a clear issue when aiming to establish the role of genetic variability in a symptom. 
 
What cannot be disentangled based on this review is why half of the significant studies reported 
the L allele as associated with psychosis, one reported the association to be with the S allele and 
one reported only a significant interaction with the COMT val158met polymorphism.  There are 
two possible sources of this variation.  The first is differences in the sample characteristics, with 
the most obvious source being phenotype definition.  Unlike Sweet et al. (2001) and Quaranta et 
al. (2009) (who both report the LL genotype as the risk), Proitsi et al. do not stipulate any 
exclusion criteria which would mitigate the impact of transient episodes of delirium on NPI 
symptom score in their study.  Delirium is common in dementia and unless participants are 
assessed serially or measures are taken to account for delirium there is a risk that participants 
could wrongly score highly on ratings of psychotic symptoms, particularly hallucinations.  This is 
further complicated by research showing that delirium accelerates cognitive decline in dementia 
(Fong, Jones et al. 2009).  Therefore there may be different biological mechanisms underlying 
delirium and psychosis which may give rise to the different results here.  The second source of 
variation is at the genetic level and this will be discussed in greater detail in section 7.2.2 of the 
General Discussion. 
 
It should be acknowledged that this review has only been conducted on eight studies and due to 
the substantial differences between them with regard to methodology and analysis it was not 
possible to conduct a meta-analysis, therefore the conclusions should be tempered by this.  
Although it was not possible to statistically test this relationship, what is described extends the 
findings from a substantial number of studies highlighting more severe cognitive impairment as a 
risk for psychosis in AD and demonstrates that this is likely to have influenced the results of 
previous genetic association studies of 5HTTLPR. 
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The aim of this analysis was to quantify the issue of cognitive impairment in genetic studies of the 
5HTTLPR polymorphism and psychotic symptoms in AD, which has been the subject of much 
discussion previously.  In summary, this review highlights that most of the significant findings of 
studies of 5HTTLPR and psychosis in AD have been carried out in cohorts with more severe 
cognitive impairment.  All of the arguments presented above relating to phenotypic definition are 
applicable to the studies examining the COMT val158met as well. 
 
In order to accurately describe the relationship between 5HTTLPR, and other polymorphisms, and 
psychosis, future studies should consider the cognitive impairment of their sample, select non-
psychotic controls accordingly and interpret their findings with reference to the level of cognitive 
impairment of the sample. 
 
1.4.7.2 COMT val158met, 5HTTLPR and cognitive decline in Alzheimer’s disease 
 
As stated in section 1.4.2 the role of COMT val158met and 5HTTLPR in psychotic symptoms in 
dementia may not be direct.  Dopamine and serotonin are involved in a wide variety of 
physiological functions including reward, depression, sleep, eating and, importantly, cognition.  
Cognitive decline is a well-established correlate of psychosis in AD and it will be important to 
elucidate whether and to what extent COMT val158met and 5HTTLPR are involved in cognitive 
decline.  Not only will this bring a more complete understanding of the genetic correlates of 
psychotic symptoms it may also explain why faster cognitive decline is a correlate, that is to say 
genetic polymorphisms in AD patients with psychotic symptoms may be responsible. 
 
Both the COMT val158met and 5HTTLPR polymorphisms have been implicated in cognitive 
processes and performance.  In the case of COMT val158met, there is a much larger body of 
literature implicating it in cognitive performance than psychosis.  It is surprising then that it has 
been the focus of so little research in dementia, particularly in light of the relationship between 
cognitive impairment and psychotic symptoms.  However, there has been some focus on COMT 
val158met in PD.  
 
In a relatively large study of 288 PD patients, Foltynie et al. (2004) reported a dose dependent 
decrease in executive function, specifically planning ability, with each met allele carried (Foltynie, 
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Goldberg et al. 2004).  Interestingly the direction of this relationship is opposite to what has been 
found in healthy adults and those with adult psychotic disorders, where the met allele has been 
associated with better cognitive performance than the val allele (Basterra, Sanchez-Torresa et al. 
2011, Malhotra, Kestler et al. 2002), although not consistently (Wardle, de Wit et al. 2013).  
However, in a follow up study by the same group, there was no effect of genotype on MMSE 
decline over 5.2 years (averaging 0.3 points per year), but they did replicate their previous finding 
of impaired executive function being associated with the met allele in an independent cohort of 
individuals (N=138) (Williams-Gray, Hampshire et al. 2008). 
 
The COMT val/val genotype has been associated with decline in both executive functioning and 
declarative memory in cognitively normal adults over a five year period (de Frias, Annerbrink et al. 
2004, de Frias, Annerbrink et al. 2005).  However, two other studies examining decline over two 
and ten year periods failed to find a effect on decline although one did report an average overall 
worsening of performance average across the five years among val/val genotypes, particularly on 
a measure of working memory (Starr, Fox et al. 2007, Erickson 2008).  
 
Findings from individuals with 22q11.2 deletion syndrome add further strength to the hypothesis 
that dopamine levels mediated by COMT genotype impact cognitive performance.  Individuals 
with 22q11.2 deletion syndrome only carry one copy of the COMT due to a micro-deletion on 
chromosome 22 which includes the entire gene.  Gothelf et al. (2005) measured cognition during 
late childhood and early adolescence and evaluated the impact of the COMT val158met 
polymorphism in a group of 22q11.2 deletion syndrome individuals alongside others with other 
developmental disabilities (Gothelf, Eliez et al. 2005).  They found that the COMT met genotype 
predicted a greater decline in cognitive ability in 22q11.2 deletion syndrome participants, but not 
in the control group.  These individuals would probably have had a lifelong increase in 
dopaminergic tone, resulting from reduced expression of COMT, which appears to have been 
exacerbated the low activity met allele.  Taken with the results from healthy adults, the suggestion 
here is that too much or not enough dopamine signalling in the PFC can negatively impact 
cognition, consistent with an inverted U shaped curve and may have implications in 
neurodegenerative diseases where dopaminergic neurotransmission is affected. 
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There has only been one study of the relationship between 5HTTLPR and cognitive decline.  In 
this study of 411 older adults, without dementia, no effect was reported.  There was however an 
association between a variable number tandem repeat (VNTR) polymorphism in SLC6A4 which is 
also known to affect transcription.  The 12 repeat homozygous genotype (also associated with 
higher transcription) was associated with a decrease in fluid intelligence, memory and aggregated 
general cognition score over a 15 year period (Payton, Gibbons et al. 2005). 
 
Unlike dopamine, serotonergic deficits have received some attention in the AD literature 
surrounding post-mortem correlates of cognitive decline.  Density of 5HT2A receptors in the 
temporal cortex (BA21) is negatively correlated with rate of cognitive decline in AD (Lai, Tsang et 
al. 2005).  An earlier study also found density of 5HT1A receptors in the frontal cortex (BA11) to be 
positively correlated with cognitive decline (Lai, Tsang et al. 2002).  Lai et al. (2002) also 
demonstrated that serotonin levels in the frontal cortex were negatively correlated with cognitive 
decline.  The 5HTTLPR L allele may fit into this picture by exacerbating the already depleted 
levels of serotonin associated with cognitive decline, due to the increased in 5HT reuptake sites 
associated with this allele.  One must be careful not to imply causation, the Lai et al. (2005) study 
only reported a correlation, but if an association with 5HTTLPR was found it would bring greater 
clarity to this hypothesis as it would provide a functional serotonergic association with cognitive 
decline.  
 
1.4.7.2.1 Section summary 
 
In summary, there have been no post-mortem investigations into the role of dopaminergic 
neurotransmission and cognitive decline in AD.  However, there is evidence from a wider body of 
genetic association studies that the COMT val158met polymorphism is associated with cognitive 
decline in healthy adults, those with neuropsychiatric syndromes and more broadly cognitive 
performance in PD.  Conversely, the literature surrounding 5HTTLPR and cognitive decline is 
sparse; the only study conducted to date failed to find an association but there evidence from 
post-mortem studies in AD implicating 5HT in cognitive decline.  Frontal cortical serotonin 
concentration and 5HT1A receptor density and 5HT2A receptor density in the temporal cortex are 
associated with rate of cognitive decline in AD.  Given that cognitive impairment may have 
confounded previous research into 5HTTLPR and psychosis it would be prudent to consider the 
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role of both polymorphisms in cognitive decline in AD.  Indeed this would be essential in order to 




 Delusions and hallucinations are common in AD and DLB/PDD but their aetiology is not 
well understood. 
 Candidate gene association studies are a useful tool in advancing understanding in this 
area.  Three widely studied polymorphisms, 5HTTLPR, COMT val158met and the 
extended MAPT haplotype, will form the basis of the work presented here. 
 Both 5HTTLPR and COMT val158met are implicated in cognition, which is a close 
correlate of psychosis in dementia, although this relationship has yet to be investigated in 
AD. 
 Treatment options of psychotic symptoms are currently very limited.  Two that are in use 
in AD, antipsychotics and memantine, have mixed efficacy and in the case of 
antipsychotics there are serious safety concerns. 
 The mechanisms underlying the safety concerns associated with antipsychotic use in AD 
are not well understood but it is hypothesised that sedation via antagonism of histamine 




 To examine the relationship between the 5HTTLPR and COMT val158met 
polymorphisms and delusions and hallucinations in AD and DLB/PDD in cohorts.  Patient 
data will be well characterised for these symptoms in order to provide a more complete 
understanding of the common mechanisms that may underlie psychosis across the AD, 
DLB/PDD spectrum. 
 
 To establish whether either of the above polymorphisms are associated with rate of 
cognitive decline in AD in order to bring greater clarity to current understanding of their 
role in the aetiology of psychotic symptoms. 
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 To examine the course of delusions and hallucinations in AD and their relationship to the 
extended MAPT haplotype in order to evaluate whether tau is associated with a more 
severe course of AD, specifically with respect to psychotic symptoms. 
 
 Establish the extent to which the histamine acting antipsychotics and the HNMT 
polymorphism affect mortality in AD.   
 
 Conduct a preliminary exploration of the mechanisms that underpin efficacy in memantine 




Chapter 2 General Materials and Methods     
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2.1 Description of cohorts 
 
Clinical data and samples from dementia patients were obtained from eleven different sources, 
these are summarised in Table 2-1 and described in detail from 2.1.1 onwards. 
 
Table 2-1 Overview of Sample Sources 
Source Source Type DNA Sample Type N
1
 
MAIN-AD RCT Buccal swab 77 
MAGD RCT Buccal swab 34 
OPTIMA Prospective cohort study Brain 148 
Norway Prospective cohort study Buccal swab 63 
WHELD RCT Buccal swab 70 
DEMVEST Prospective cohort study Blood 151 
Greek Outpatients Buccal swab 121 
ARUK Prospective cohort study Buccal swab/Brain 305 
DCR Prospective cohort study Buccal swab 158 
ANM Prospective cohort study Buccal swab/blood 260 
Brain banks Prospectively followed individuals Brain 21 
TOTAL   1408 
1
Reflects the total number of patients available for screening for use in studies presented in the 
results chapters 
Abbreviations: MAIN-AD (Memantine for Long-Term Treatment of Neuropsychiatric Symptoms in 
Dementia); MAGD (Memantine for Agitation in Dementia); OPTIMA (Oxford Project to Investigate 
Memory and Aging); Norway (The Course of Dementia, Neuropsychiatric Symptoms and Drug 
Use and its Impact on Health Service Resource Use); WHELD (Improved Well-Being and Health 
for People with Dementia); DEM EST (Dementia Studies in West Norway); ARUK (Alzheimer’s 
Research UK); DCR (Dementia Case Register); ANM (Addneuromed) 
 
In addition there were a total of 113 cognitively and neurologically normal controls, screened for 
absence of dementia drawn from the ANM and DCR cohorts and a study of post operative 




2.1.1 Memantine for Long-Term Treatment of Neuropsychiatric Symptoms in Dementia 
(MAIN-AD) 
 
A 24 week randomised, placebo controlled clinical trial evaluating whether memantine is safer 
and more effective than neuroleptics for the treatment of neuropsychiatric symptoms in 
Alzheimer’s disease. 
 
Written informed consent was obtained for two hundred participants recruited from four sites in 
the UK (London, Essex, Oxford and Newcastle) and one in Norway.   
 




 Living in a nursing or social care facility.  
 Fulfill the NINCDS/ADRDA criteria for possible or probable Alzheimer's disease (AD).  
 Taking at least 0.5mg daily of haloperidol, 0.5mg daily of risperidone, 5mg daily of 
olanzapine or 25mg daily of quetiapine or another neuroleptic, which in the opinion of the 
responsible clinician could be safely converted to one of these neuroleptics, for a 
minimum of 3 months prior to entry into the study.  
 If taking a cholinesterase inhibitor, it has been prescribed for at least 6 months before the 
date of assessment, with a stable dose for at least 3 months.  
 Not taking anticonvulsants other than carbamazepine or sodium valproate. The use of 
either of these 2 agents is permissible if the dose has been stable for at least 4 weeks.  
 If taking any other psychotropic drugs (e.g. antidepressants, benzodiazepines, 
chlormethiazole), that the dose has been stable for at least 4 weeks prior to 
randomization.  
 Not currently or in the past 6 weeks receiving treatment with memantine and a 
responsible clinician not considering treatment with memantine.  
 Not taking any medications that are contra-indicated or not recommended in combination 
with memantine, as defined in the British National Formulary, including ketamine, 
dextromethorphan, amantidine.  
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 Clinician responsible for care, or study clinician considers that the patient suffers from any 
physical condition (including marked extra-pyramidal disorder), which would make 
participation in the trial distressing or likely to increase suffering.  
 Patients with a systolic blood pressure whilst sitting greater than 180 mm/Hg or less than 
90 mm/Hg, or a diastolic blood pressure whilst sitting greater than 100 mm/Hg or less 
than 50 mm/Hg at the screening visits or baseline.  
 Patients with a recent history (within 3 months of screening) or currently untreated B12 or 
folate deficiency.  
 Patients with a recent history (within 3 months) or untreated clinically significant 
hypothyroidism or hyperthyroidism (patients with thyroid disease may be included 
provided they are euthyroid and stable).  
 Severe aggression (≥8) on item 3 of the NPI subscale, with aggression as the 
predominant symptom.  
 Patients with psychotic DSM IV TR Axis 1 disorder other than in the context of 
Alzheimer’s disease, including schizophrenia, schizoaffective disorder and bipolar 
disorder.  
 Participants known to have sensitivity to memantine, amantadine, rimantidine or lactose.  
 A current diagnosis of primary neurodegenerative disorders other than Alzheimer’s 
disease for example  untington’s disease, Parkinson’s disease, etc.  
 Uncontrolled epilepsy.  
 Current evidence of delirium.  
 Severe renal impairment, as measured by or equivalent to an estimated creatinine 
clearance of < 5 mL/min/1.73m
2
  
 Severe hepatic impairment.  
 Unable to swallow tablets or capsules.  
 Low probability of treatment compliance.  
 Currently taking memantine.  
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 Memantine during the 6 weeks prior to randomization.  
 Previous evidence of lack of efficacy or tolerability to memantine.  
 Taking any of the following substances:  
 An investigational drug during the 4 weeks prior to randomization.  
 A drug known to cause major organ system toxicity during the 4 weeks prior to 
randomization.  
 Started any new psychotropic medication during the 4 weeks prior to randomization. 
Participants who have been on a stable dose of psychotropic during the 4 weeks prior 
to randomization are still eligible.  
 Other N-methyl-D-aspartate (NMDA) antagonists: amantadine, ketamine, and 
dextromethorphan.  
 Barbiturates and primidone.  
 Baclofen and dantrolen.  
 Antimuscarinics.  
 Anticonvulsants other than sodium valproate or carbamazepine. These 2 agents were 
permissible if doses had been stable for at least 4 weeks.  
 
Following medical screening, individuals eligible for the study were randomised to either continue 
their current dose of neuroleptic medication (or similar) or stop their current dose of neuroleptic 
and commence memantine (10 mg twice daily, or 10 mg once daily for individuals with impaired 
renal function). 
 
Assessments were carried out at four time points during the 24 week period; 0 (baseline), 6 
weeks, 12 weeks and 24 weeks (end of study).  Medication history was also recorded at baseline 
from GP records and during the study from nursing home medication administration records.  
Similarly, relevant medical history was recorded from GP notes and records were kept during the 
study of any newly developed co-morbidity.  A proportion of London participant visits and general 
trial administration (submitting amendments, information for the reporting of serious adverse 
events) was carried out by Byron Creese. 
 
In November 2010, approximately one year after the start of recruitment to the clinical trial itself, I 
submitted a substantial amendment to the MAIN-AD Research Ethics Committee (REC) to allow 
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collection of buccal mucosa cells from participants enrolled at the UK study sites.  This study is 
therefore covered under the original MAIN-AD REC approval.  This sub-study was adopted into 
the UKCRN portfolio and support was obtained from the Thames Valley and North East branches 
of the Dementias & Neurodegenerative Diseases Research Network (DeNDRoN).  In total, 
samples were obtained from 77 individuals from the London, Oxford, Essex and Newcastle sites.  
Training in the collection of samples was provided to all additional research staff.  DeNDRon staff 
at the Oxford and Newcastle site were responsible for consenting and collecting samples.  At the 
Essex site, North Essex Partnership Foundation Trust carried out consenting and some sample 
collection.  Some sample collection at the Essex site, and all consenting and sample collection at 
the London site was carried out by me. 
 
2.1.2  Memantine for Agitation in Dementia (MAGD) 
Collaboration with Dr Chris Fox, University of East Anglia 
 
This cohort is described in detail in Fox et al. (2012).  In summary, this was a 12 week 
randomised, placebo controlled clinical trial into whether memantine is a safe and effective 
treatment for agitation in dementia.  Participants were recruited according to the below 




 Residential/Inpatients at recruitment to the study with a history of at least 2 weeks 
behavioural disturbance. 
 Alzheimer’s disease only as per NINCDS-ADRDA criteria and Haschinski Score<=4. 
 Moderately severe to severe Alzheimer’s disease (baseline MMSE>=4)  
 Clinically significant agitation that requires treatment. 
 Severity of agitation defined by Cohen Mansfield agitation inventory (CMAI) > =45. 




 Memantine usage in the 4 weeks prior to the start of the study. 
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 Cholinesterase inhibitor for less than 3 months and not on a stable dose. 
 Antipsychotic, anti-epileptic, antidepressant, benzodiazepine, lithium or hypnotic dosage 
alteration in the 2 weeks prior to the start of the study. 
 Anti-parkinson medication. 
 Hypersensitivity to memantine or any of the excipients in the formulation. 
 Severe renal impairment 
 Epilepsy, history of convulsions or seizure, or receiving any anti-epileptic treatment. 
 Concomitant usage of N-methyl-D-aspartate (NMDA) antagonists such as amantadine, 
ketamine or dextromethorphan. 
 Recent myocardial infarction, uncompensated congestive heart failure and uncontrolled 
hypertension. 
 Severe, unstable or poorly controlled medical illness. 
 Any disability that may interfere with the patient completing the study procedure. 
Active malignancy. 
 Delirium, pain or any medical illness as a clear cause of agitation. 
 Any important drug interactions: Prohibited during study and in the 14 days preceding 
enrolment/inclusion are: Analgesic dextromethorpan mentioned above Dopaminergics- 
amantadine mentioned above warfarin due to theoretical International Normalised Ratio 
prolongation. 
 
One hundred and fifty three participants who met the inclusion/exclusion criteria above and 
passed medical screening were recruited from five UK centres (Oxford, Plymouth, South East 
London, Kent and East Anglia) and randomised to either memantine 10 mg twice daily or placebo 
for 12 weeks.  Assessments were carried out at baseline, 4, 6 and 12 weeks. 
 
Dr Chris Fox (MAGD Chief Investigator) gave his support for a substantial amendment to be 
submitted (by me) to the MAGD REC to allow collection of buccal mucosa cells from participants 
in the study.  The amendment was approved in November 2010, several years after recruitment 
first started into the trial.  This study is therefore covered under the original MAGD REC approval.  
The sub-study was adopted into the UKCRN portfolio and support was obtained from the Kent 
and South East London/South East Mental Health Research Network (MHRN) hubs and South 
West, Thames Valley and East Anglia DeNDRoN.  Training was provided to all staff.  DeNDRoN 
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staff at these five research sites took consent and samples from participants.  In total samples 
were obtained from 34 individuals. 
 
2.1.3  Oxford Project to Investigate Memory and Aging (OPTIMA) 
 
Samples from this source are covered by REC project reference 10/H0703/30.  On enrolment, 
participants in OPTIMA consented for their tissue to be used in research.  As part of OPTIMA 
participants underwent detailed clinical evaluations approximately every six months until death.  
Information on medication was also collected at most visits. 
 




For pathologically confirmed samples: 
 Meet the Consortium to Establish a Registry for Alzheimer's disease (CERAD) criteria for 
probable or definite Alzheimer’s disease (Mirra, 1991) or the National Institute of Aging 
(NIA-REAGAN) criteria for high likelihood of Alzheimer's disease (Hyman et al., 1997); 
Or for clinically diagnosed samples: 
 Operationalised clinical diagnosis of AD at death made using National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's disease and 
Related Disorders Association (NINCDS-ADRDA) criteria for probable Alzheimer's 




 Any patients not meeting the criteria listed for each disease set out under inclusion 
criteria. 
 
The criteria were kept deliberately wide due to the different experiments planned, thus allowing 
the exclusion of certain cases as and when dictated by each experiment. 
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The project was approved and DNA and accompanying clinical data was supplied for 148 patients 
in total. 
 
2.1.4 The Course of Dementia, Neuropsychiatric Symptoms and Drug Use and its Impact 
on Health Service Resource Use (the Norway cohort) 
Collaboration with Dr Geir Sælbeck and Dr Sverre Bergh, Innlandet University Hospital Trust 
 




 Nursing home patients with a planned stay of more than four weeks. 




 Not able to obtain buccal swab samples for DNA extraction. 
 
Buccal swab kits were provided to the research team in Norway who collected the samples and 
returned them to KCL for DNA extraction and storage see section 2.4.  
 
Assessments are carried out at baseline and at 3, 6, 12, 18, 24 and 36 months.  At the time of this 
project a maximum of six months of data was available.   
 
2.1.5 Improved Well-Being and Health for People with Dementia (WHELD) 
 
This study was an RCT evaluation of a variety of non-pharmacological interventions on quality of 
life and psychotropic drug use in dementia.  Individuals were eligible for this study provided that 
they were residing in participating care homes and scored ≥1 on the Clinical Dementia Rating 
Scale (CDR) and ≥4 on the Functional Assessment Staging Tool (indicating mild dementia, see 
section 2.2.3.2) and met NINCDS-ADRDA criteria for probable or possible AD.  This was a three 
centre study with sites at Oxford, South East London and North East London. 
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Participants were assessed on a variety of measures at baseline and 9-12 months after.  
 
Buccal swab samples were covered under REC approval 10/H0703/30.  That is, unlike MAIN-AD 
and MAGD, sample collection was not a sub-study of WHELD.  Ethical approval was obtained in 
early 2012.  Although it was a separate study to the WHELD RCT, ethical permission was 
obtained to access the WHELD participant database to identify participants.  I carried out the 
consenting and sample collection for all participants, at all three sites and some patient 
assessments at the South East London site. 
 
2.1.6 Dementia Studies in West Norway (DEMVEST) 
Collaboration with Prof. Dag Åarsland, University of Oslo and Karolinska Institute 
 
The DEMVEST cohort is an existing collection of DNA samples from patients in Norway stored at 
KCL and extracted from blood collected from individuals with dementia who were assessed at 
baseline and at 12 months.  The cohort contains AD, DLB and PDD patients.   
 
2.1.7 Greek Cohort 
Collaboration with Prof. Magda Tsolaki, Aristotle University of Thessaloniki and Dr John Powell, 
KCL 
 
Individuals were AD patients and attendees at hospital outpatients’ clinics.  They received regular 
assessments but because it was not part of a particular project the frequency of assessments 
varied somewhat as did the length of follow up for each patient.  However the entire database 
was requested and the specific inclusion/exclusion criteria for each study in the results chapters 
was applied as required.  Medication history was available for most patients.  Dates of death were 
not originally available but were obtained on request from Dr Mariana Siapera in Greece. 
 
2.1.8 Alzheimer’s Research UK (ARUK) and Dementia  ase Register (D R) 
Collaborations with Prof. Simon Lovestone, Dr Rob Stewart and Dr John Powell, KCL 
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Individuals recruited into these cohort studies were assessed at yearly intervals on a wide range 
of measures.  In general individuals were followed up for a maximum of 4-5 years.  Dates of death 
and medication were recorded for most individuals however they were not entered onto the 
electronic data base.  Therefore, paper files for every case were screened and this information 
recorded. 
 
2.1.9 Addneuromed (ANM) 
Collaboration with Prof. Simon Lovestone and Dr John Powell, KCL 
 
The wider aims of this project are to identify AD biomarkers and improve experimental models for 
AD biomarker discovery.  DNA samples were collected from six sites in Europe (University of 
Kuopio, Finland; University of Perugia, Italy; Aristotle University of Thessaloniki,  reece; King’s 
College London, UK; University Hospital Toulouse, France and University of Lodz, Poland) and 
are stored at KCL.  Individuals were followed up every three months for one year at all sites, while 
some of those at the London site continued to be followed up at yearly intervals thereafter up to a 
maximum of 8 years. 
 
Dates of death were not routinely collected as part of the study however the PIs for each site were 
contacted and asked for the reasons for withdrawal and dates of death for everyone who did not 
complete one year of assessments. 
 
2.1.10 Institute of Psychiatry and Newcastle brain banks 
 
Samples from this source are covered by REC approval 08/H1010/4.  Requests were made to 
each brain bank for donors meeting the following criteria: 
 
 Diagnosis of DLB or PDD according to McKeith et al. (2005) criteria (DLB) or UK 
Parkinson’s Disease Society Queen Square Criteria for PD and DSM-IV criteria for 
dementia (PDD). 
 Serial assessments for at least six months of psychotic symptoms using a standardised 
validated tool. 
 MMSE at last assessment available. 
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2.2 Clinical assessments 
 
2.2.1 Psychotic symptoms 
 
2.2.1.1 Neuropsychiatric Inventory (NPI) 
 
The NPI (Cummings 1997) is a questionnaire which assesses the following 12 behavioural 
symptoms in dementia: delusions (persecutory or misidentifications), hallucinations (visual, 
auditory or tactile), agitation/aggression, anxiety, depression, apathy, disinhibition, euphoria, 
irritability/lability, aberrant motor disturbances, sleep disturbances and appetite/eating disorders. 
 
It is administered by a researcher in an interview style with a care giver who has an appropriate 
level of contact with the participant.  The interviewer asks whether the participant has experienced 
each symptom at all over the past four weeks.  If the symptom is not present the interviewer 
moves on to the next symptom.  If the response is positive the interviewer uses probing questions 
to clarify the nature of the symptom and then determines if indeed it should be coded as present.  
For example, a carer may report that the participant has experienced hallucinations over the past 
4 weeks; however on further questioning it may become apparent that they were discreet 
hypnagogic hallucinations, which should not be counted as it is unlikely that these are associated 
with any pathological processes. 
 
If the interviewer decides it should still be coded as present the carer is then asked how often the 
symptom occurs on a scale of 1 (occasionally) to 4 (every day) and how severe it is, when it does 
occur on, from 1 (mild) to 3 (severe).  These frequency and severity scores are then multiplied to 
give a composite NPI score for that symptom, the highest possible score being 12 (with scores of 
9, 8, 6, 4, 2, 1 and 0 falling below).   
 
The questionnaire also contains a distress score for each symptom where the carer is asked how 
distressing the symptom is on a scale of 0 (not at all) to 5 (extremely/severely). 
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This scale was used in the following cohorts: MAIN-AD, MAGD, Norway, DEMVEST, Greek, 
ARUK, ANM, DCR, and WHELD. 
 
2.2.1.2 Cambridge Mental Disorders of the Elderly Examination (CAMDEX) 
 
CAMDEX (Roth, Tym et al. 1986) is an interview schedule which, alongside measuring cognitive 
impairment, assesses the extent of behavioural and psychological morbidity according to 
interviewer observations (10 items) as well as in interviews with both the participant (37 items) 
and their main carer (18 items).   The items on the scale rate the presence of delirium/confusion, 
depression, sleep disturbances, anxiety, and delusions and hallucinations.  For psychotic 
symptoms specifically, ratings from the informant section of the scale were used, in keeping with 
the other assessment scales used in this project.  Psychotic symptoms are covered by one item 
for hallucinations and one item for persecutory delusions, rated in a binary fashion.   Although the 
questions only refer to the patient’s present state, longitudinal assessment with this scale allows 
persistence to be rated.  It also has sections which allow the interviewer to collect information on 
co-morbidities, past medical history and current medication. 
 
This scale was used in the OPTIMA cohort. 
 
2.2.1.3 Present Behavioural Examination (PBE) 
 
The PBE is a detailed examination, administered by an investigator, of the presence of 
neuropsychiatric symptoms over the four weeks prior to the assessment (Hope, Fairburn 1992).  
Questions relating to psychotic symptoms specifically are covered by one question for 
hallucinations (covering auditory or visual), one question for grandiose delusions and one 
question for persecutory delusions.  One mandatory question for each symptom is asked which is 
followed up with further questioning to ascertain qualitative information and the frequency of the 
symptom, on an ordinal scale ranging from 0 (not at all) to 6 (every day) 
 
This scale was used in the brain bank samples obtained from London. 
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2.2.1.4  olumbia University Scale to Assess Psychopathology in Alzheimer’s disease 
(CUSPAD) 
 
The CUSPAD tool is a brief assessment of symptoms of psychosis, behavioural disturbance and 
depression in AD (Devanand, Miller et al. 1992).  Assessment is administered by an investigator 
and considers the symptoms over the four weeks preceding the interview.  For psychotic 
symptoms a general question about the presence of delusions or hallucinations is followed up by 
more specific questions designed to ascertain their exact nature (e.g. auditory or visual 
hallucinations/paranoia or misidentifications) in a decision tree format.  Symptoms are categorised 
as present or absent. 
 
2.2.2 Determining the presence of psychotic symptoms 
 
Several different rating scales were used in both AD and DLB/PDD cohorts.  As such, symptom 
scores at each visit were converted into a binary present/absent rating according to the rules set 
out in Table 2-2. 
 
Table 2-2 Rules for the classification of delusions and hallucinations for each rating scale 
Rating Scale Score used Symptom present Symptom absent 
NPI Delusions, hallucinations: 
frequency x severity 
Score  >0 Score = 0 
    
CAMDEX Hallucinations, persecutory 
ideas 
Symptom score = 1 Symptom score = 0 
    
PBE Hallucinations, delusions 
defined as positive rating on 
grandiose ideas or persecutory 
ideas items. Frequency scores 
used for both 
Symptom frequency 
score >0 (for 
delusions either of 
the items can be 
rated >0) 
Symptom frequency 
score = 0 (for 
delusions all of the 
items must be rated 0) 
CUSPAD First general question relating 
to the presence/absence of 
symptoms 




2.2.3 Cognitive impairment and disease severity 
 
2.2.3.1 Mini Mental State Examination (MMSE) 
 
The MMSE (Folstein, Folstein et al. 1975) is a 30 point questionnaire designed to assess 
cognitive impairment in dementia.  It is widely used both clinically and in research.  The question 
assesses six cognitive domains: 1) orientation (to time and place); 2) registration (repeating the 
names of three objects until remembered); 3) attention/calculation (either subtracting 7 from 100 
then from 93 and so on or spelling “world” backwards); 4) recall (of the words in the registration 
section); 5) language (naming objects, repetition of a phrase, following an instruction, writing a 
sentence) and, 6) the copying of a complex shape. 
 
The MMSE is not used as the sole means of clinically diagnosing dementia but a total score of 
27-30 would be consistent with a cognitively normal individual while a score below that may 
indicate dementia.  In research, the MMSE is frequently used as an indicator for dementia 
severity, with a score of 20 and above, 10-19 and 0-9 indicating mild, moderate and severe 
dementia respectively. 
 
2.2.3.2 Functional Assessment Staging Tool (FAST) 
 
The MMSE is based purely on cognition, another way of staging an individual’s dementia severity 
is through the assessment of functional/activities of daily living (ADL) impairment.  The FAST 
(Reisberg, Ferris et al. 1985) is designed to assess just this.  It is an ordinal scale ranging from 1 
(normal aging) through 7 (late stage dementia) and to be scored deficits must be related to the 
dementia and not another medical condition, such as stroke or physical disability.  Stage 4 
represents mild dementia and is given when an individual’s ADL becomes affected (e.g. cooking, 
cleaning, finances).  In stage 5 individuals would have problems selecting the correct clothing.  
Stage 6 is split into five sub-sections (6a to 6e): in 6a an individual would need help putting on 
clothes while b, c, d and e represent further more serious impairments (bathing, toileting and 
urinary and faecal incontinence).  Similarly stage 7 is split into 7a through 7f.  These are the last 
stages of dementia where an individual’s speech is limited to a few or a single word(s) per day (7a 
89 
and b) and subsequently they can no longer walk, sit up, smile or hold their head up (7c, d, e and 
f).   
 
2.3 Medication history 
 
The protocols for each study included the recording of current medication at each visit, although 
dose was not consistently recorded either between or sometimes within studies.  Medication 
history for the ARUK cohort was manually recorded for each visit from the paper notes of all 
patients and transferred to Excel.  For datasets which already included medication history, this 
was not universally coded and often existed in list format rather than each drug occupying its own 
cell in Excel.  A list of psychotropic drugs was created and broadly categorised into antipsychotics 
(each drug had its own code), antidepressants, sedatives, anti-dementia drugs and histamine H1 
antagonists.  Medication doses were not consistently available from all cohorts therefore this 
information was not collected.  I wrote Excel formulae to search lists for the names of relevant 
drugs and recode into numbers. 
 
2.4 DNA sources and preparation 
 
2.4.1 Buccal mucosa sample collection and DNA preparation 
 
Buccal mucosa cells were collected from individuals enrolled in the following cohorts: MAIN-AD, 
MAGD, Norway and WHELD.  Collection kits (10 cotton wool buds and a 15ml plastic tube 
(Sarstedt Ltd.) containing 2.5ml collection buffer (see below) were provided by the Social, Genetic 
and Developmental Psychiatry (S DP) Centre at the Institute of Psychiatry, King’s College 
London, as part of a service they operate which also involves DNA extraction, quality testing, 
determination of concentration and storage (Freeman, Smith et al. 2003). 
 
Buccal mucosa cells were removed by rubbing cotton wool buds on the inside of the mouth (i.e. 
cheeks and lips).  Normally a person can do this themselves, however for people with dementia it 
was much more effective for the research team to conduct the procedure, due to the impaired 
comprehension and language abilities in many of these individuals.  Where possible the research 
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teams of the various studies had face to face training provided by Byron Creese, however in most 
cases training was provided over the phone with an accompanying video and step-by-step 
instruction sheet. 
 
Up to ten buds are used per participant, with a greater number of buds yielding a greater amount 
of DNA.  Each bud is rubbed on a different part of the participant’s mouth for approximately 20 
seconds.  After use, each bud is placed in the plastic tube so that one plastic tube is used for all 
the buds collected from a participant.  The buffer consists of the following: 100 mM NaCl, 10 mM 
Tris-HCl pH 8.0, 10 mM ethylene diaminetetraacetic acid (EDTA) pH 8.0 with 0.2 mg/ml 
proteinease potassium and 0.5% w/v sodium dodecyl sulphate.   
 
Samples were then sent to the SGDP for DNA extraction (according to an established protocol: 
Freeman et al., 2003) and storage until requested for use.   
 
2.4.2 DNA from blood and brain samples 
 
DNA from blood and brain was obtained from participants in the following cohorts: ARUK, ANM, 
DCR, DEMVEST, OPTIMA, Greek, brain banks and non dementia controls.  The DNA for all was 
extracted and stored by the research teams at the respective institutions responsible for each 
cohort and samples were requested for use for this project, with the exception of DEMVEST.  
Here, blood was extracted locally and sent to KCL (Wolfson Centre for Age-Related Diseases) for 
extraction (by Dr Emma Jones) and storage since 2008. 
 
2.5 SNP selection 
 
The experiments that follow used a candidate gene approach.  Resources and time dictated that 
only a small number of SNPs could be investigated in this thesis.  There are around 20,000 genes 
in the human genome and many millions of SNPs therefore picking a SNP at random will have 
such a small likelihood of being associated with a given phenotype as to make investigation 
worthless.  Before detailing genotyping methods the process for selecting which SNPs to examine 
will be discussed.  In selecting SNPs we used the following criteria: 
 
91 
 Biological plausibility: SNPs had to be in psychosis-relevant pathways. 
 Support from in vivo or in vitro models: SNPs had to have known functional 
consequences (e.g. they lead to an amino acid change or are transcription altering). 
 Prior evidence of genetic association. 
 Common enough in European samples to warrant investigation in cohorts of the size 
used in these experiments. 
 
On the basis of the above criteria the following four polymorphisms were investigated: 5HTTLPR, 
COMT val158met, extended MAPT haplotype and HNMT.  A full review of the functional 
significance and supporting evidence for the selection of these polymorphisms is can be found in 
sections 1.4.1 (5HTTLPR), 1.4.2 (COMT val158met), 1.4.3 (extended MAPT haplotype) and 
1.4.6.1 (HNMT). 
 
It is acknowledged that there are a number of other commonly studied polymorphisms.  Most 
notably among the serotonin acting polymorphisms is 5HT2A.  Although this is a well studied 
polymorphism in AD psychosis and in a biological plausible pathway it is synonymous and it is not 
clear how it would exert its effect on psychotic symptoms if such an effect was found.  Therefore 
5HTTLPR was prioritised in this study; it is as well studied as 5HT2A but there is a far greater body 




I carried out the genotyping blind to symptom status.  Taqman SNP genotyping assays were used 
to analyse the COMT val158met and HNMT polymorphism while electrophoresis or a custom 
Taqman assay was used to analyse the 5HTTLPR polymorphism.  The MAPT haplotype was also 
analysed by electrophoresis.  Each procedure is described in detail below. 
 
2.6.1 Assay to Detect the val158met Polymorphism in COMT and the thr105ile 
Polymorphism in HNMT 
 
2.5 ng DNA from each sample was pipetted onto a 96- or 384-well reaction plate (Applied 
Biosystems) to be included in a reaction mixture with a total volume of 25 µl (for 96-well plates) 
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also containing 1x TaqMan SNP Genotyping assay (Applied Biosystems, containing forward and 
reverse primers and two allele specific probes, see below) and 1x TaqMan Universal PCR Master 
Mix (AmpliTaq Gold DNA polymerase, AmpErase UNG, dNTPs with dUTP, passive reference, 
and buffer).  In the case of 384-well plates the total reaction volume was 5 µl, with the volumes of 
assay and mastermix adjusted proportionally. One non-template control (NTC) was included one 
each plate. 
 
Each TaqMan SNP Genotyping assay contains two allele specific probes 5’-labelled with VIC or 
FAM reporter dyes and 3’-labelled with a non-fluorescent quencher, which when in close proximity 
to the reporter dyes inhibits their fluorescence.  During PCR the probes bind to the site of their 
respective allele.  During the DNA synthesis stage, AmpliTaq Gold DNA polymerase cleaves the 
dye from the probe, allowing it to fluoresce.  End point fluorescence was read using an ABI Prism 
7000 or 7900 Sequence Detection System.  In individuals homozygous for allele-1 or allele-2 only 
VIC or FAM fluorescence respectively is detected, whilst in heterozygotes both VIC and FAM 
dyes is detected (see Figure 2-1). 
 
Genotyping of the COMT val158met polymorphism in the ARUK and Greek cohorts was carried 
out by the lab of Dr John Powell, King’s College London and data were made available for this 
study.  I carried out the COMT val158met genotyping for all the remaining samples. 
 
Figure 2-1 ABI SDS example output for COMT val158met and HNMT polymorphisms 
Three fluorescence clusters are shown which correspond to the three possible genotypes: blue 
and red=homozygous, green=heterozygous (specific calls would depend on the polymorphism but 
the principal is exactly the same).  Grey square=NTC 
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2.6.2 Assay to Detect the 5HTTLPR Polymorphism in SLC6A4 
 
I used two methods to detect the 5HTTLPR polymorphism, the first was PCR followed by 
electrophoresis and the second was a custom Taqman SNP genotyping assay (Applied 
Biosystems) used because of the need for a high throughput method. 
 
Genotyping of the 5HTTLPR polymorphism in the ARUK and Greek cohorts was carried out by 
the lab of Dr John Powell, King’s College London and data were made available for this study.  I 




2.6.2.1.1 5HTTLPR deletion 
 
25 ng DNA, 4   nM of primers 5’-GAGGGACTGAGCTGGACAACCAC-3’ and 5’-
GGCGTTGCCGCTCTGAATGC-3’ (Sigma-Aldrich), 1x Q solution, 1x PCR buffer, 2 units of Taq 
DNA polymerase and 200 µM dNTPs (all from Qiagen) were included in a total reaction volume of 
50 µl.  The following cycling conditions were used: 95
°
C for 1 minute, 40 cycles of (95
°
C for 30 
seconds, 61
°
C for 30 seconds, 72
°
C for 1 minute), 72
o
C for 10 minutes.  PCR products were 
analysed by electrophoresis on a 2% agarose gel.  The S allele is represented as a band of 




Figure 2-2 A 2% agarose gel image of the 5HTTLPR polymorphism 
Far left lane: 100 bp DNA ladder.  A 528 bp band represents LL genotype while a smaller 484 bp 
(i.e. samples with the 44 bp deletion) band represents the SS genotype.  Heterozygotes are 
therefore represented by two bands, one of each size 
 
I used this method on the DLB/PDD cases and on the POCD controls.  Genotyping of the 
DLB/PDD cases was carried out by Dr Emma Jones. 
 
2.6.2.1.2 5HTT rs25531 SNP 
 
Genotyping of the rs25531 SNP, the G allele of which is almost always inherited with the L allele 
and reduces transcriptional activity to that of the S allele, was also attempted.  The protocol 
proposed by Wendland et al. (2006) was followed.  Broadly it specifies a method similar to the 
above but with an additional digest step before electrophoresis (Wendland, Martin et al. 2006).   
200nM of forward (5'-TCCTCCGCTTTGGCGCCTCTTCC-3') and reverse (5'-
TGGGGGTTGCAGGGGAGATCCTG-3') primers were included along with the reagents specified 
in the section above at the same concentrations and 5 ng of DNA in a total reaction volume of 20 
µl.  Following PCR cycling (95ºC for 15 minutes, followed by 35 cycles of (94ºC for 30 seconds, 
65.5 ºC for 90 seconds, 72 ºC for 60 seconds), 72ºC for 10 minutes) 7 µl of product was digested 
with 1x buffer and HpaII (New England Biolabs) in a total volume of 20 µl for 3 hours.  The G 
allele of rs25531 creates a restriction site recognised by HpaII which cuts the DNA fragment 
creating two bands, whereas fragments carrying the more common A allele are not digested.  











This assay was first tested on DNA from several different sources but the bands after digestion 
were too faint to make a reliable genotype call.  In order to address this problem the assay was 
optimised by first removing Q solution and then by adding 0, 1, 2 and 3 µl of MgCl2, as suggested 
by the manufacturers (Qiagen).  However in no instance did this improve the quality of the DNA 
bands visualised by electrophoresis.  Due to time constraints at this stage of the project and the 
need to process a large number of samples a high throughput method of genotyping 5HTTLPR 
was opted for and the genotyping of rs25531 was postponed.  
 
2.6.2.2 Custom Taqman SNP genotyping assay to detect the 5HTTLPR polymorphism  
 
This assay was adapted from Covault et al. (Covault, Tennen et al. 2007).  25 ng of DNA was 
pipetted into a 96-well reaction plate (Applied Biosystems) for inclusion in a total reaction volume 
of 30 µl.  The remaining 25 µl volume of reaction mixture consisted of 200nM of each forward and 
reverse primer (5’-GCAACCTCCCAGCAACTCCCTGTA-3’ and 5’-
GAGGTGCAGGGGGATGCTGGAA-3’ respectively) and 6 nM and 12 nM of  IC and one FAM 
labelled probes respectively (all obtained from Applied Biosystems constructed as described in 
section 2.6.1), 1x Universal PCR Master mix and 1x Q solution.  The FAM labelled probe 
(TGCAGCCCCCCCAGCATCTCCC) is specific to the L allele as it binds to a section of DNA 
within the 44 bp deletion.  The target sequence of the VIC probe 
(TCCCCCCCTTCACCCCTCGCGGCATCC) is present in both the L and S alleles and serves as 
a positive internal control.  One NTC was included on each plate along with three samples (one of 
each genotype) for which genotype had been verified by electrophoresis. 
 
The following cycling conditions were used: 50°C for 2 minutes, 95°C for 10 minutes then 50 
cycles of (98°C for 15 seconds, 62.5°C for 90 seconds). 
 
The three genotypes (LL, LS and SS) are differentiated by the level of FAM fluorescence 
detectable.  The authors (Covault et al., University of Connecticut) were contacted and agreed to 
provide their raw ABI SDS output, shown Figure 2-3 with the raw data from this study in shown in 
Figure 2-4.    
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Figure 2-3 SDS output provided by Dr Jonathan Covault and Christine Abreu (University of 
Connecticut) 
Coloured clusters as per A; black dot=undetermined; turquoise dot=NTC; yellow dot=non 
amplifiers 
Figure 2-4 SDS 7000HT output showing three genotype clusters of the 5HTTLPR polymorphism 
The VIC labelled probe (x axis) fluoresces at the same wavelength for all cases because its target 
sequence is in the amplicon of both alleles.   The FAM fluorescence (y axis) detected is 
dependent on the number of L allele present as the probe’s target sequence is contained in the 
deleted 44 bp sequence: red=0 (SS genotype), green=1 (LS genotype), blue=2 (LL genotype); 
grey square=NTC; black cross=undetermined.  
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2.6.3 Assay to detect the extended MAPT haplotype 
 
25 ng DNA along with 100 nM of primers 5’ -GGAAGACGTTCTCACTGATCTG-3’ and 5 ‘-
AGGAGTCTGGCTTCAGTCTCTCTC-3’, 200 µM dNTPs, 1.25 units Taq DNA polymerase and 1x 
PCR buffer were included in a total reaction volume of 50 µl.  A touchdown PCR method was 
used to optimise target sequence amplification.  The starting temperature of 58°C was decreased 
by 0.2 each of the 35 cycles using the following conditions: (94°C for 30 seconds, touchdown 
annealing for 30 seconds, 72°C for 30 seconds).  Amplified DNA fragments were analysed by 
electrophoresis and visualised on a 1% agarose gel.   
 
H1/H2 haplotype discrimination is based on the presence/absence of a 238bp deletion in intron 9 
which is found only in the H2 haplotype (Baker, Litvan et al. 1999).  H1 homozygotes are 





Figure 2-5 A 1% agarose gel image of the extended tau haplotype 
Far left lane: 100 bp DNA ladder.  A 484 bp band represents H1/H1 haplotype while a smaller 246 
bp (i.e. samples with the 238 bp deletion) band represents the H2/H2 haplotype.  Heterozygotes 
are represented by a band of each size 
 
2.7 Statistical analyses 
 
Analysis plans for each study are described in detail in their respective results chapters.  Briefly, 
outcomes were either categorical or continuous level and in the case of the latter datasets were 
examined for deviations from parametric data assumptions and appropriate methods were 
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Chapter 3 Determining the association of 5HTTLPR and COMT 
polymorphisms with delusions and hallucinations in AD and 
DLB/PDD 
 
Related papers:  
 
 Creese, B., Ballard, C., Aarsland, D., Londos, E., Sharp, S., Jones, E. (In Press) 
Determining the Association of the 5HTTLPR Polymorphism with Delusions and 
Hallucinations in Lewy Body Dementias.  Am J Geriatr Psych. 
 Creese, B., Ballard, C., Aarsland, D., Londos, E., Sharp, S., Jones, E. (2013) No 





3.1 Summary introduction  
 
Neuropsychiatric symptoms are common in all forms of dementia and psychosis is of particular 
importance in people with DLB/PDD and AD, with more than 70% of patients experiencing visual 
hallucinations and more than 60% of patients experiencing delusions in the former.  While the 
frequency is less in AD (at around 30-50%) both symptoms are highly persistent and distressing 
in a significant proportion of individuals (Ballard, O'Brien et al. 2001).   
  
Clinical correlates of psychotic symptoms include sensory deprivation, diminished consciousness, 
early visuospatial deficits and cognitive impairment (McKeith, Galasko et al. 1996, Hamilton, 
Landy et al. 2011), all of which highlight the importance of longitudinal evaluations in accurately 
distinguishing transient and persistent psychotic symptoms and to inform clinical treatment 
decisions.  The association of the severity of cognitive impairment and psychosis is less 
consistent in DLB/PDD than in AD (Ballard, Holmes et al. 1999, Del Ser, McKeith et al. 2000, 
Aarsland, Cummings et al. 2001), but remains an important potential confounder which needs to 
be considered in the design and analysis of studies examining the biological associations of 
psychosis in these individuals.    
 
Despite the prevalence, persistence and distress caused by psychotic symptoms, safe and 
effective treatment options are limited.  There is RCT evidence of a modest improvement of visual 
hallucinations with the cholinesterase inhibitor rivastigmine in patients with DLB and PDD 
(Wesnes, McKeith et al. 2002, Emre, Aarsland et al. 2004) and although open trials of 
antipsychotics have suggested some benefit (The Parkinson Study Group 1999), the risk of 
severe neuroleptic sensitivity reactions is substantial in these individuals (McKeith, Fairbairn et al. 
1992).  In AD there is evidence of a modest effect of risperidone, olanzapine and aripiprazole 
however there are safety concerns surrounding these drugs and other antipsychotics which are 
still commonly used (Ballard, Howard 2006).  There is therefore an urgent need to identify safer 
and more effective therapies for psychosis in people with all three types of dementia, which has to 
be based upon a better understanding of the underlying distinct pathological mechanisms as well 
as those which may be shared with the same symptoms across different dementias.  In the 
absence of effective animal models of psychosis in dementia, post-mortem, imaging and genetic 
studies will be vital in achieving this mechanistic understanding. 
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Post-mortem studies have highlighted the serotonergic system as an important correlate of 
psychotic symptoms and other neuropsychiatric symptoms in AD, DLB and PDD   (Lanctot, 
Herrmann et al. 2001).  Cheng et al. (1991) reported preserved 5HT2A binding in DLB patients 
with hallucinations compared to those without, while Perry et al. (1990) cite a monoaminergic-
cholinergic imbalance as an important neurochemical correlate (Cheng, Ferrier et al. 1991, Perry, 
Marshall et al. 1990).  There is limited evidence specifically focusing on serotonergic associations 
of hallucinations in PDD, however in PD psychosis two recent binding studies have reported 
greater 5HT2A binding in patients with hallucinations than those without (Huot et al., 2010 and 
Ballanger et al, 2010), paralleling previous reports in people with DLB.  There is also evidence of 
neurochemical changes associated specifically with delusions in DLB patients (Ballard, Piggott et 
al. 2000).  Here the authors found elevated muscarinic M1 receptor binding to be associated with 
delusions but not hallucinations thus indicating there may be distinct mechanisms underlying 
these two symptoms of psychosis.   
 
Genetic studies in DLB and PDD are lacking but in the wider AD literature there have been a 
number of reported associations between polymorphisms in serotonergic pathway genes and 
psychosis (DeMichele-Sweet, Sweet 2010, Ballard, Howard 2006).  Although there are 
inconsistencies, the strongest evidence is for the 5HTTLPR polymorphism.  Studies by Sweet et 
al. (2001) and Quaranta et al. (2009) in AD have both reported a positive association between the 
L allele and LL genotype and psychotic symptoms (Quaranta, Bizzarro et al. 2009, Sweet, Pollock 
et al. 2001), although this is not a consistent finding (Proitsi, Lupton et al. 2010, Borroni, Grassi et 
al. 2006).  Conversely, the only study in PD psychosis failed to find a significant association with 
the 5HT2A T102C receptor polymorphism or 5HTTLPR and visual hallucinations (Kiferle, Ceravolo 
et al. 2007).   In PDD and DLB there have been no such studies to date. 
 
Similarly, there is evidence from in vivo PET imaging of dopaminergic correlates of psychotic 
symptoms in AD (Reeves, Brown et al. 2009).   Of those polymorphisms investigated in AD, the 
only one to also have been studied in DLB is COMT val158met in the catechol-O-methyl 
transferase (COMT) gene.  Some, but not all (Sweet, Devlin et al. 2005, Proitsi, Lupton et al. 
2010, Borroni, Agosti et al. 2004), previous studies in AD have implicated the COMT gene as a 
candidate for psychosis based on an association with COMT val158met, while in DLB/PDD there 
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has been just one previous study which, like those in AD, reported an association with the high 
activity val allele and psychosis (Borroni, Di Luca et al. 2006).  More broadly in Lewy body 
disease, one study in PD psychosis found no association with COMT val158met (Camicioli, 
Rajput et al. 2005).  These findings collectively suggest that there may be shared mechanisms 
underlying psychotic symptoms in AD and DLB/PDD.  Establishing such mechanisms would have 
important implications for treatment approaches in dementia, however further research is urgently 
required to confirm this.   
 
Finally, it has been proposed that, because of the faster rate of cognitive decline that 
accompanies psychotic symptoms, the high heritability and the higher burden of NFT pathology, 
AD with psychotic symptoms represents a phenotype of AD distinct from patients who present 
without psychosis (Sweet, Nimgaonkar et al. 2003).  It is hypothesised there are genes that 
specifically contribute to AD with psychotic symptoms (the heterogeneity model) and those that 
only contribute to psychosis after the neurodegeneration of AD has set in (disease modifier 
model).  Testing to which scenario a particular polymorphism contributes requires the addition of 
a non-dementia control group with which to compare genotype frequencies in patients with 
symptoms.  This study will therefore evaluate both models in AD and DLB/PDD.  However, a 
significant finding is not expected for the heterogeneity model because there is no evidence to 
suggest that 5HTTLPR or COMT val158met are involved in AD or DLB/PDD risk. 
 
This study examines the relationship between 5HTTLPR and COMT val158met and persistent 
delusions and hallucinations in two cohorts of patients with DLB/PDD and AD.  It will also explore 
the nature of these polymorphisms’ contributions to psychotic symptoms by evaluating them in 




 Patients with the LL genotype will carry an increased risk of both delusions and 
hallucinations in DLB/PDD and AD. 
 The COMT val/val genotype will be associated with the presence of psychotic symptoms 
in DLB/PDD and AD. 
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 There will be no support for the heterogeneity model of psychotic symptoms in either AD 
or DLB/PDD. 





STATA/SPSS: data analysis and coding. 
 
3.3.2 Inclusion/exclusion criteria 
 
Inclusion criteria: 
 A diagnosis of probable, possible or definite AD according to the NINCDS-ADRDA criteria 
(McKhann, Drachman et al. 1984) or; 
 A diagnosis of DLB/PDD according to the McKeith et al. (2005) consensus criteria 
(McKeith, Dickson et al. 2005) or; 
 Queen Square criteria for PD (Hughes, Daniel et al. 1992) and DSM-IV criteria for 
dementia occurring >1 year after the onset of PD symptoms. 
 At least two assessments of delusions and/or hallucinations six months or more apart. 
 MMSE or other measure of dementia severity at last assessment. 
 
Exclusion criteria: 
 History of a psychotic disorder not related to dementia. 
 
3.3.3 Design and cohort 
 
The DLB/PDD patients were drawn from the brain bank and DEMVEST cohorts.  By definition all 
21 of the brain bank patients were suitable for this study while 80 from the DEMVEST cohort also 
met the criteria.  The AD patients were drawn from the MAIN-AD, OPTIMA, Norway, WHELD, 
DEMVEST, Greek, ARUK, DCR and ANM cohorts.  The 111 cognitively normal controls from the 
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ANM and POCD cohorts were included as a comparison group for the AD study and 92 controls 
from the POCD cohort served as the comparison group for the DLB/PDD study. 
 
See sections 2.6.1 and 2.6.2 for genotyping methods. 
 
3.3.4 Classification of symptoms 
 
For the AD patients the Cambridge Mental Disorders of the Elderly Examination (CAMDEX) semi-
structured assessment was used to assess psychotic symptoms in 87 individuals while the 
Neuropsychiatric Inventory (NPI) was used in the remaining 487.  Those from the DLB/PDD 
cohort were either assessed with the Present Behavioural Examination (PBE)/Columbia 
University Scale to Assess Psychopathology in AD (CUSPAD) (brain banks) or NPI (DEMVEST).  
Because of the different rating scales used a binary present/absent approach to symptom 
classification was adopted (see section 2.2.2). 
 
Patients were first either rated as having persistent, transient or no symptoms.  Symptoms were 
considered persistent if they were present for more than six months continuously or recurred 
more than six months after resolution.  Being ‘present’ at a visit was in this case defined as a 
score >0 on any of the assessment scales.  Any individuals with transient symptoms, that is those 
with symptoms not falling under the definition of persistent, were classified as not having the 
symptom.  The diagnostic criteria for AD psychosis set out by Jeste and Finkel (Jeste, Finkel 
2000) stipulates that symptoms must occur, at least intermittently, for 1 month or longer and not 
occur exclusively during delirium.  In this study as one month follow-up data was not universally 
available and as there were no measurements specifically for delirium it was considered prudent 
to employ the six month threshold for persistent symptoms in order to exclude these episodes of 
delirium from the hallucination and delusion groups.  This threshold is supported by a recent study 
which indicated that subsyndromal delirium can be persistent but usually resolves within six 
months from baseline (Cole, McCusker et al. 2012).   
 
3.3.5 Other data 
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Demographic data, cognitive evaluations with the Mini Mental State Examination (MMSE) at the 
last assessment and the presence of PD (based upon the Unified Parkinson’s Disease Rating 
Scale or the Hoehn and Yahr staging system and applying only to the DLB/PDD cohort) were also 
recorded.   
 
For the AD samples exposure to antipsychotics and anti-dementia drugs was coded as either 
‘ever’ during the period of follow up or ‘never.’ 
 
3.3.6 Statistical analysis 
 
The analyses that follow are split by disease but follow the same plan outlined below (except 
where noted). Section 3.4 examines DLB/PDD patients and section 3.5 AD patients. 
 
The frequency of dementia with delusions versus dementia without delusions and dementia with 
hallucinations versus dementia without hallucinations was evaluated in two separate binary 
logistic regression models for each polymorphism.  Two explanatory variables were included in 
each model: genotype as a categorical variable with three levels (LL, LS and SS or val/val, 
val/met and met/met) and MMSE score as a continuous variable (or for the AD analysis disease 
severity was treated as another categorical variable with three levels: mild, moderate and severe).  
On the basis of previous data in AD the SS genotype was used as the reference for 5HTTLPR 
genotype and the met/met as the reference for the COMT analysis.  Analysis of symptom 
frequency by allele was also conducted. 
 
The cognitively normal controls were included in a subsequent analysis.  Four further regression 
models were run analysing those with delusions versus controls, those without delusions versus 
controls and likewise for hallucinations.  The 5HTTLPR or COMT val158met polymorphism was 
the single explanatory variable in these models and was treated in the same way as above.   
 
A final secondary analysis explored the use of 6 months threshold for persistent symptoms.  In 
this analysis, patients classified as having only transient symptoms were excluded, leaving those 
with persistent delusions analysed again those with no delusions at all, and likewise for 
hallucinations.   
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The significance threshold was set at 0.01. 
 
3.3.6.1 Power calculation 
 
In all cases genotypes were examined in an additive model.  For DLB/PDD assuming minor allele 
frequency (MAF) of 0.45 and a symptom frequency of 45% this sample size would have 80% 
power to detect an effect size (expressed as odd ratio, OR) of 2.4 associated with the risk allele 
and 50% power for OR 1.8 
 
For AD, a lower frequency of symptoms would be expected.  Therefore, assuming a symptom 
frequency of 20% and the remaining parameters to be otherwise as above the AD sample would 





3.4 Results: Lewy body dementias 
 
3.4.1 Descriptive statistics 
 
Of the 101 DLB/PDD patients, 11 were confirmed at autopsy.  Ninety-eight were successfully 
genotyped for the 5HTTLPR and COMT val158met polymorphism.  The three that were 
unsuccessfully genotyped were different for each polymorphism therefore in the analysis that 
follows they are presented separately.  One patient had data for delusions but not hallucinations 
and one patient had data for hallucinations but not delusions.  The remainder of the patients had 
data for both symptoms (n=96).  Prospective data regarding persistent delusions and 
hallucinations were available for all of these individuals.  Eighty-seven had PDD and 10 had DLB.   
 
Ninety-two controls from the POCD cohort were used as a comparison group, they did not differ in 
terms of gender frequency (70% female: 
2
=0.35, df=1, p=0.9) or age (mean age 77: U=-0.1, 
df=185, p=0.06).  Two samples could not be successfully genotyped for 5HTTLPR, leaving 90 in 
this analysis. 
 
Genotype frequencies for 5HTTLPR and COMT val158met did not deviate significantly from 
Hardy-Weinberg equilibrium (χ
2
=0. 3, p>0.05; χ
2
=0.1, p>0.05 respectively).  Descriptive statistics 
by 5HTTLPR and COMT val158met polymorphism are shown in Table 3-1 and 
 
 
Table 3-2 respectively (N=98 because the two patients missing delusions or hallucinations were 
both included): there were no differences in frequencies or means for age (5HTTLPR: 
F(2,94)=2.3, p=0.1; COMT val158met: F(2,94)=0.4, p=0.7), gender (5HTTLPR: 
2
=2.4, df=2, 
p=0.3; COMT val158met: 
2
=0.6, df=2, p=0.7) or MMSE (Kruskal-Wallis test, 5HTTLPR: 
2
=2.4, 
df=2, p=0.3; COMT val158met: 
2
=2.7, df=2, p=0.3) by genotype. 
 5HTTLPR 
[Mean±SD/ Frequency(%)] 
SS (n=21) LS (n=46)  LL (n=31) 
Age
1 
74 (5.4) 78 (6.8) 75 (5.9) 
Gender
3 
Female 12 (57) 29 (63) 14 (45) 
 Male 9 (43) 17 (37) 17 (55) 
MMSE
3 
 19 (7.9) 18 (7.9) 21 (5.6) 
1. F(2,94)=2.3, p=0.1;2. 
2
=2.4, df=2, p=0.3; 3. 
2





Table 3-1 Participant demographics by 5HTTLPR genotype (N=98) 
 
 
Table 3-2 Participant demographics by COMT val158met genotype (N=98) 
 
The primary analyses for the DLB/PDD patients below are organised by genotype, starting with 
5HTTLPR and followed by COMT val158met. 
 
3.4.2 Primary analysis: 5HTTLPR 
 
Twenty-nine (30%) individuals had persistent delusions and of the 68 (70%) classified has having 
no delusions 20 (29%) had non-persistent delusions.  These groups were termed the delusions 
group and no delusions group respectively.  Most of those with delusions (75%) and 24 (35%) of 
those with no delusions also had hallucinations.  MMSE among those with persistent delusions 
was significantly lower than those without (t=4.3, df=95, p<0.001).  There were no differences in 
age (t=-0.5, df=94, p=0.6) or gender (
2 
= 0.4, df=1, p=0.8) between these groups (Table 3-3, 




SS (n=21) LS (n=46)  LL (n=31) 
Age
1 
74 (5.4) 78 (6.8) 75 (5.9) 
Gender
3 
Female 12 (57) 29 (63) 14 (45) 
 Male 9 (43) 17 (37) 17 (55) 
MMSE
3 
 19 (7.9) 18 (7.9) 21 (5.6) 
1. F(2,94)=2.3, p=0.1;2. 
2
=2.4, df=2, p=0.3; 3. 
2
=2.4, df=2, p=0.3 
 COMT val158met 
[Mean±SD/ Frequency(%)] 
val/val (n=21) Val/met (n=50)  met/met (n=27) 
Age
1 
76 (5.8) 77 (5.7) 76 (7.1) 
Gender
2 
Female 11 (52) 30 (60) 14 (52) 
 Male 10 (48) 20 (40) 13 (48) 
MMSE
3 
 17 (8.3) 19 (7.3) 20 (6.4) 
1. F(2,94)=0.4, p=0.7; 2. 
2
=0.6, df=2, p=0.7; 3. 
2
=2.7, df=2, p=0.3 
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Hallucinations were the most common symptom with 46 individuals (47%) classified as having 
persistent symptoms, henceforth known as the hallucination group.  Of the 51 (53%) people 
classified as having no hallucinations, 20 (41%) had non-persistent hallucinations.  Among those 
with hallucinations 22 (48%) also had delusions, while in the no hallucinations group 7 (14%) had 
delusions.  There were no differences in mean age (t=-0.3, df=94, p=0.74), mean MMSE (t=1, 
df=95, p= .3) or gender (χ
2 
= 1.1, df=1, p=0.3) between those with and without hallucinations 
(Table 3-4, page 111). 
 
3.4.2.1 Univariate analysis: 5HTTLPR 
 
Univariate analysis was conducted first (Table 3-3).  For delusions, there was a trend for LL 
genotypes to carry an increased risk for delusions but this did not meet the more stringent 0.01 
alpha level used for this study.  For every one point decrease in MMSE an individual’s odds of 
having persistent delusions were increased by 1.1 (p<0.001).  Analysis by allele indicated a non-
statistically significant trend effect of the L allele for persistent delusions (OR=2, 95% CI=1.05-3.8, 




Table 3-3 Logistic regression: persistent delusions in DLB/PDD (N=97) 
In univariate analysis for hallucinations none of the variables presented in Table 3-4 emerged as 
a significant risk factor for persistent hallucinations. 
Table 3-4 Logistic regression: persistent hallucinations in DLB/PDD (N=97) 
  




[Mean ±SD / Frequency (%)] Odd ratio 
(95% CI) 
p-
value No  (n=68) Yes (n=29) 
Age 76 (5.9) 76 (7) 1 (0.9-1.1) 0.6 
Gender Female 39 (57) 16 (55) Reference - 
 Male 29 (43) 13 (45) 1.1 (0.5-2.6) 0.8 
MMSE  21 (6.1) 15 (7.5) 0.9 (0.8-0.9) <0.001 
5HTTLPR SS 18 (26) 2 (7) Reference - 
 LS 31 (46) 15 (52) 4.3 (0.8-21.2) 0.07 
 LL 19 (28) 12 (41) 5.6 (1.1-29) 0.04 
      
5HTTLPR allele S 67 (49) 19 (33) Reference - 





[Mean ±SD / Frequency (%)] Odd ratio (95% 
CI) 
p-value 
No (n=51) Yes (n=46) 
Age 76 (6) 76 (6.4) 1 (0.9-1.1) 0.7 
Gender Female 29 (56) 28 (61) Reference - 
 Male 22 (44) 18 (39) 1.6 (0.7-3.5) 0.3 
MMSE  20 (6.9) 19 (7) 0.97 (0.9-1.03) 0.97 
5HTTLPR SS 12 (24) 8 (17) Reference - 
 LS 23 (45) 23 (50) 1.5 (0.5-4.4) 0.5 
 LL 16 (31) 15 (33) 1.4 (0.5 -4.4) 0.6 
      
5HTTLPR allele S 47 (46) 39 (42) Reference - 
 L 55 (54) 53 (58) 1.2 (0.66-2.05) 0.6 
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Multivariate analyses for delusions and hallucinations by 5HTTLPR genotype are shown in the 
two tables below.  Although MMSE was not a significant predictor of hallucinations it was still 
included as a covariate due to evidence suggesting cognitive impairment is associated with 
psychotic symptoms in DLB/PDD.  For delusions, the risk associated with the 5HTTLPR LL 
increased to 11.5 (Table 3-5), while for hallucinations there continued to be no effect of 5HTTLPR 
genotype (Table 3-6).  Multivariate analysis by allele, controlling for MMSE, again showed a 
significant effect of the L allele with (OR: 3.27, df=1, 95% CI: 1.54-6.94, p=0.002). 
 
Table 3-5 Logistic regression: 5HTTLPR persistent delusions (N=97) 
 
Table 3-6 Logistic regression 5HTTLPR persistent hallucinations (N=97) 
 
3.4.2.3 Role of 5HTTLPR polymorphism in DLB/PDD sub-phenotypes 
 
To analyse whether 5HTTLPR was associated with a specific DLB/PDD with psychotic symptoms 
phenotype, genotype frequencies were compared between DLB/PDD individuals with persistent 
symptoms and cognitively normal controls and DLB/PDD without persistent symptoms and 




[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=68) Yes (n=29) 
5HTTLPR SS 18 (26) 2 (7) Reference - 
 LS 31 (46) 15 (52) 5.3 (0.9-32) 0.07 
 LL 19 (28) 12 (41) 11.5 (1.7-77) 0.01 
Adjusted for MMSE  
Risk Factor 
Persistent hallucinations 
[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=51) Yes (n=46) 
5HTTLPR SS 12 (24) 8 (17) Reference - 
 LS 23 (45) 23 (50) 1.4 (0.5-4.2) 0.5 
 LL 16 (31) 15 (33) 1.5 (0.5-4.6) 0.5 
Adjusted for MMSE 
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Genotype frequencies by the presence/absence of persistent symptoms and for cognitively 
normal controls are shown in Table 3-7.  There was no overall difference in the genotype 
frequencies between patients with dementia and cognitively normal controls (
2
=0.4, df=2, p=0.9).   
 
Comparisons between DLB/PDD with psychosis and controls and DLB/PDD without persistent 
symptoms and controls did not show any significant differences (persistent delusions vs. control: 

2
=2, df=2, p=0.4; persistent hallucinations vs. control: 
2
=0.3, df=2, p=0.9; no delusions vs. 
control: 
2
=2.3, df=2, p=0.3; no hallucinations vs. control: 
2
=0.8, df=2, p=0.7). 
 
Table 3-7 5HTTLPR genotype frequencies for DLB/PDD patients (by the presence/absence of 
symptoms) and controls (N=187) 
 
3.4.3 Primary analysis: COMT val158met 
 
The analysis for the COMT val158met polymorphism followed the same plan as above for 
5HTTLPR. 
 
Twenty-nine individuals (31%) had persistent delusions and 68 (70%) were classified as having 
no delusions. Twenty-one (31%) of the no delusion group also had non-persistent delusions. 
MMSE among those with persistent delusions was significantly lower than those without (t = 4.3, 
p < 0.001). There were no differences in age (t = −1.3, p = 0.2) or gender (χ
2
 = 0.4, df = 1, 
p = 0.6) in this group (Table 3-8, page 114). 
 
Forty-six (47%) people had persistent hallucinations. Of the 51 (53%) people classified as having 
no hallucinations, 20 (39%) had non-persistent hallucinations. There were no differences in mean 
1. no
 
hallucinations vs. control: 2=0.8, df=2, p=0.7; 2.
 
persistent hallucinations vs. control: 
2
=0.3, 
df=2, p=0.9; 3. no delusions vs. control: 
2















5HTTLPR SS 12 (24) 8 (17) 18 (26) 2 (7) 16 (18) 
LS 23 (45) 23 (50) 31 (46) 15 (52) 41 (46) 
LL 16 (31) 15 (33) 19 (28) 12 (41) 33 (36) 
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age (t = − .3, p = 0.8), mean MMSE (t = 0.8, p = 0.4) or gender (χ
2
 = 1.1, df = 1, p = 0.3) between 
those with and without hallucinations (Table 3-9, page 115). 
 
3.4.3.1 Univariate analysis: COMT val158met 
 
In univariate analysis of persistent delusions, MMSE was the only significant predictor (Table 3-8). 
 
Table 3-8 Logistic regression: persistent delusions in DLB/PDD (N=97) 
 




[Mean ±SD / Frequency (%)] Odd ratio 
(95% CI) 
p-
value No  (n=70) Yes (n=27) 
Age 78 (6.5) 76 (5.9) 1.1 (0.97-1.1) 0.2 
Gender Female 41 (59) 14 (52) Reference - 
 Male 29 (41) 13 (48) 1.3 (0.5-3.2) 0.6 
MMSE  21 (6.1) 15 (7.7) 0.9 (0.8-0.94) <0.001 
COMT  met/met 17 (24) 5 (19) Reference - 
 val/met 41 (59) 16 (59) 1.9 (0.5-7.6) 0.3 
 val/val 12 (17) 6 (22) 1.9 (0.6-5.8) 0.3 
      
COMT allele met 75 (54) 26 (48) Reference - 
 val 65 (46) 28 (52) 2 (0.9-4.4) 0.1 
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Table 3-9 Logistic regression: persistent hallucinations in DLB/PDD (N=97) 
 
3.4.3.2 Multivariate analysis: COMT val158met 
 
In both multivariate logistic regression analyses MMSE was included as a covariate.  There was 
still no significant effect of genotype on either persistent delusions or persistent hallucinations 
(Table 3-10 and Table 3-11 respectively). 
 









No (n=51) Yes (n=46) 
Age 77 (5.7) 76 (6.4) 1.01 (0.9-1.1) 0.8 
Gender Female 31 (61) 23 (50) Reference - 
 Male 23 (39) 23 (50) 1.6 (0.7-3.5) 0.3 
MMSE  19 (7.1) 20 (7.1) 0.97 (0.9-1.03) 0.4 
COMT  met/met 16 (31) 11 (24) Reference - 
 val/met 23 (45) 27 (59) 0.9 (0.3-3.1) 0.9 
 val/val 12 (23) 8 (17) 1.8 (0.7-4.6) 0.2 
      
COMT allele met 55 (54) 49 (53) Reference - 





Odd ratio (95% CI) p-value 
No (n=68) Yes (n=29) 
COMT met/met 17 (24) 5 (19) Reference - 
 val/met 41 (59) 16 (59) 1.2 (0.3-5.6) 0.8 
 val/val 12 (17) 6 (22) 1.7 (0.5-5.7) 0.4 
Adjusted for MMSE  
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Table 3-11 Logistic regression: COMT val158met persistent hallucinations (N=97) 
 
3.4.3.3 Role of COMT val158met polymorphism in Lewy body dementia sub-phenotypes 
 
To analyse whether COMT val158met was associated with a specific DLB/PDD with psychotic 
symptoms phenotype, genotype frequencies were compared between DLB/PDD individuals with 
persistent symptoms and cognitively normal controls and DLB/PDD without persistent symptoms 
and cognitively normal controls.   
 
Genotype frequencies by the presence/absence of persistent symptoms and for cognitively 
normal controls are shown in Table 3-12.  There was no overall difference in the genotype 
frequencies between cases with dementia and cognitively normal controls (
2
=0.1, df=2, p=0.9).   
 
Comparisons between DLB/PDD with psychosis and controls and DLB/PDD without persistent 
symptoms and controls did not show any significant differences (persistent delusions vs. control: 

2
=0.7, df=2, p=0.7; persistent hallucinations vs. control: 
2
=0.2, df=2, p=0.9; no delusions vs. 
control: 
2
=0.5, df=2, p=0.8; no hallucinations vs. control: 
2





[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=51) Yes (n=46) 
COMT met/met 16 (31) 11 (24) Reference - 
 val/met 23 (45) 27 (59) 0.86 (0.3-3) 0.8 
 val/val 12 (23) 8 (17) 1.8 (0.7-4.6) 0.2 
Adjusted for MMSE 
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Table 3-12 COMT val158met genotype frequencies for DLB/PDD cases (by the 
presence/absence of symptoms) and controls (N=189) 
 
3.4.4 Secondary analysis 
 
The secondary analysis consisted of a sensitivity analysis of the results presented in sections 
3.4.2 and 3.4.3.  The split of symptoms used in the primary analysis was evaluated by only testing 
those with persistent symptoms and those with no symptoms (i.e. transient symptom cases were 
excluded).  For the COMT polymorphism, this made no difference to the results, they were still not 
significant for both hallucinations (val/met: OR 0.8, 95% CI 0.2-3.4, p=0.8; val/val: OR 1.2, 95% CI 
0.4-3.6, p=0.4) and delusions (val/met: OR 0.8, 95% CI 0.2-4.3, p=0.8; val/val: OR 1.4, 95% CI 
0.4-5.4, p=0.6).   
 
For 5HTTLPR, the LL genotype still carried an increased risk for persistent delusions (OR: 14, 
95% CI: 1.5-131, p=0.02), but not persistent hallucinations where ORs were similar to those 
presented in section 3.4.2.2 (LS: OR 1.6, 95% CI 0.5-5.6, p=0.4; LL: OR 1.7, 95% CI 0.5-6.3, 
p=0.4).  Although it should be acknowledged that this analysis reduced the sample size to 78, 
hence the very wide confidence intervals. 
 
  
1. no hallucinations vs. control: 2=1.1, df=2, p=0.6; 2. persistent hallucinations vs. control: 2=0.2, 
df=2, p=0.9; 3. no delusions vs. control: 2=0.5, df=2, p=0.8; 4. persistent delusions vs. control: 
2=0.7, df=2, p=0.7 
 











COMT met/met 14 (31) 12 (24) 21 (30) 5 (19 24 (26) 
val/met 21 (45) 30 (59) 34 (49) 16 (59) 50 (54) 




3.4.5.1 Summary of primary analysis 
 
1. LL genotype and L allele were associated with an 11.5- and 2-fold increased risk 
respectively for persistent delusions in DLB/PDD.  There was no association with 
hallucinations. 
2. There was no evidence to support the hypothesis that either polymorphism is associated 
with an increased risk for a DLB/PDD with psychotic symptoms phenotype. 
 
3.4.5.2 Summary of secondary analysis  
 
1. Restricting the analysis to only those with persistent symptoms and those with no 
symptoms did not change the results significantly:  The association with the LL genotype 
persisted and there was still no association with hallucinations and the 5HTTLPR 




3.5 Results: Alzheimer’s disease 
 
3.5.1 Descriptive statistics 
 
Of the 1,353 cases from the nine databases eligible for screening, 584 met the inclusion/exclusion 
criteria for this study.  Of these, 10 patients were known to be of an ethnic origin other than 
European and were excluded, leaving 574 AD patients in the final analysis.  One-hundred and 
fifteen were of unknown ethnic origin but were retained for the analysis given the extremely low 
frequency of non-Europeans among those with known ethnicities (2%).  A pathological diagnosis 
of AD was available for 95 patients. 
 
One hundred and eleven cognitively normal controls were available from the ANM and POCD 
cohorts.  They did not differ significantly by gender frequency (60% female: 
2
=1.4, df=1, p=0.2) 
or age (mean 78: t=-1.3, df=683, p=0.2). 
 
Genotype frequencies for both COMT val158met and 5HTTLPR did not deviate from Hardy-
Weinberg equilibrium (5 TTLPR: χ
2




Participant demographics by COMT val158met and 5HTTLPR genotype are present in Table 3-13 
and  
Table 3-14 respectively.  There were no significant differences in frequencies of means of any of 
the variables presented for COMT val158met (age: F(2,571)=1.7, p=0.2; gender: χ
2
=0.5, df=2, 
p=0.8; dementia severity: χ
2
=7.5, df=4, p=0.1; anti dementia drug: χ
2
=3.8, df=2, p=0.1; 
antipsychotic: χ
2
=0.3, df=3, p=0.9) or 5HTTLPR (age: F(2,571)=0.6, p=0.6; gender: χ
2
=3.1, df=2, 
p=0.2; dementia severity: χ
2
=2.6, df=4, p=0.6; anti dementia drug: χ
2
=1, df=2, p=0.6; 
antipsychotic: χ
2
=0.9, df=3, p=0.6). 
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Table 3-13 Participant demographics by COMT genotype (N=574) 
 
 
Table 3-14 Participant demographics by 5HTTLPR genotype (N=574) 
 
 
Delusion ratings were available for the full 574 patients while one patient was missing 
hallucination ratings, meaning 573 cases were included in the analysis of hallucinations.  
 COMT val158met 
[Mean±SD / Frequency(%)] 
val/val (n=143) val/met (n=280) met/met (n=151) 
Age
1 
78 (8.8) 80 (8) 79 (8.2) 
Gender
2 
Female 95 (66) 187 (67) 96 (64) 
 Male 48 (34) 93 (33) 55 (36) 
Dementia severity
3 
Mild 38 (27) 74 (26) 51 (34) 
 Moderate 38 (27) 76 (27) 49 (32) 
 Severe 67 (46) 130 (46) 51 (34) 
Anti dementia drug
4 
No 103 (72 ) 178 (64) 106 (70) 
 Yes 40 (28) 102 (36) 45 (30) 
Antipsychotic
5 
No 82 (57) 168 (60) 88 (58) 
 Yes 61 (43) 112 (40) 63 (42) 
1. F(2,571)=1.7, p=0.2; 2. χ
2
=0.5, df=2, p=0.8; 3. χ
2
=7.5, df=4, p=0.1; 4. χ
2





[Mean±SD / Frequency(%)] 
SS (n=120) LS (n=273) LL (n=181) 
Age
1 
79 (8.2) 80 (8.6) 79 (7.8) 
Gender
2 
Female 86 (72) 171 (63) 121 (67) 
 Male 34 (28) 102 (37) 60 (33) 
Dementia severity
3 
Mild 38 (32) 73 (27) 52 (29) 
 Moderate 37 (31) 80 (29) 46 (25) 
 Severe 45 (38) 120 (44) 83 (46) 
Anti dementia drug
4 
No 77 (64) 189 (69) 121 (67) 
 Yes 43 (36) 84 (31) 60 (33) 
Antipsychotic
5 
No 66 (55) 163 (60) 109 (60) 
 Yes 54 (45) 110 (40) 72 (40) 
1. F(2,571)=0.6, p=0.6; 2. χ
2
=3.1, df=2, p=0.2; 3. χ
2
=2.6, df=4, p=0.6; 4. χ
2
=1, df=2, p=0.6 
5. χ
2
=0.9, df=3, p=0.6 
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Seventy-eight (14%) and 119 (21%) cases were classified as having persistent hallucinations and 
delusions respectively.  One-hundred and nine (19%) and 156 (27%) were classified as having 
transient hallucinations and delusions respectively. 
 
For the primary analysis the transient symptom group and no symptom group were analysed 
together as a no symptom group.  Among those without persistent delusions 37 (8%) had 
persistent hallucinations, while there were twice as many cases with persistent delusions among 
those without persistent hallucinations (78, 16%).    
 
3.5.2 Primary analysis 
 
3.5.2.1 Univariate analysis 
 
One hundred and nineteen (21%) individuals had persistent delusions and of the 299 (52%) 
classified has having no delusions 156 (27%) had transient delusions.  Patients with transient 
delusions were grouped with the no delusion group.  Forty-one (34%) of those with persistent 
delusions and 37 (8%) of those with no delusions also had persistent hallucinations.   
 
The univariate analyses for persistent delusions and hallucinations are presented in Table 3-15.  
Taking an anti-dementia drug was associated with a 2-fold increased risk of persistent delusions.  
No other risk factors were associated with persistent delusions, including 5HTTLPR and COMT 




Table 3-15 Logistic regression: persistent delusions in AD (N=574) 
 
Seventy-eight individuals (14%) were classified as having persistent hallucinations.  Of the 386 
(67%) people classified as having no hallucinations, 109 (22%) had transient hallucinations.  
Among those with persistent hallucinations 41 (52%) also had persistent delusions, while in the 
no hallucinations group 78 (16%) had persistent delusions.   
 
With regard to persistent hallucinations, both younger age and severe dementia stage carried a 
significantly increased risk (OR: 0.96, 95% CI: 093-0.98, p=0.004; OR: 3.3, 95% CI: 1.7-6.6, 
p=0.001).  Again, no other risk factors were associated with persistent hallucinations (Table 3-16). 
Risk Factor 
Persistent delusions 
[Mean ±SD / Frequency (%)] Odd ratio (95% 
CI) 
p-
value No  (n=455) Yes (n=119) 
Age 79 (8.2) 78 (8.4) 0.97 (0.9-1) 0.08 
Gender Female 298 (65) 80 (67) Reference - 
 Male 157 (35) 39 (33) 0.9 (0.6-1.4) 0.7 
Dementia severity Mild 137 (30) 26 (22) Reference - 
 Moderate 125 (27) 38 (32) 1.6 (0.9-2.8) 0.1 
 Severe 193 (42) 55 (46) 1.5 (0.9-2.5) 0.1 
Antipsychotic No 267 (59) 71 (60) Reference - 
 Yes 188 (41) 48 (40) 0.96 (0.6-1.5) 0.8 
Anti dementia drug No 322 (71) 65 (55) Reference - 
 Yes 133 (29) 54 (45) 2 (1.3-3) 0.001 
COMT  met/met 118 (26) 33 (28) Reference - 
 val/met 222 (49) 58 (49) 0.9 (0.6-1.5) 0.8 
 val/val 115 (25) 28 (24) 0.9 (0.5-1.5) 0.6 
5HTTLPR SS 94 (21) 26 (21) Reference - 
 LS 214 (47) 59 (50) 0.9 (0.6-1.7) 0.9 
 LL 147 (32) 34 (29) 0.8 (0.5-1.5) 0.5 
      
COMT allele A 458 (50) 124 (52) Reference - 
 G 452 (50) 114 (48) 0.9 (0.7-1.2) 0.6 
5HTTLPR allele S 402 (44) 111 (47) Reference - 




Table 3-16 Logistic regression: persistent hallucinations in AD (N=573) 
 
3.5.2.2 Multivariate analysis 
 
Although dementia severity was not associated with an increased risk for delusions it was still 
included as a covariate because of the strong association highlighted in previous research.  Along 
with dementia severity, anti-dementia drug exposure highlighted from the univariate analysis was 
also included as a covariate.  For the hallucination analysis, age and dementia severity were 
included as covariates.  
Risk Factor 
Hallucinations 




No (n=495) Yes (n=78) 
Age 80 (8.1) 77 (8.9) 0.96 (0.93-0.98) 0.004 
Gender Female 324 (65) 53 (68) Reference  
 Male 171 (35) 25 (32) 0.9 (0.5-1.5) 0.7 
Dementia severity Mild 152 (31) 11 (14) Reference - 
 Moderate 144 (29) 19 (24) 1.8 (0.8-4) 0.1 
 Severe 199 (40) 48 (62) 3.3 (1.7-6.6) 0.001 
Antipsychotic No 297 (60) 40 (51) Reference - 
 Yes 198 (40) 38 (49) 1.4 (0.9-2.3) 0.1 
Anti dementia drug No 339 (68) 47 (60) Reference  
 Yes 156 (32) 31 (40) 1.4 (0.9-2.3) 0.2 
COMT  met/met 131 (26) 20 (26) Reference - 
 val/met 243 (49) 36 (46) 0.97 (0.54-1.7) 0.9 
 val/val 121 (24) 22 (28) 1.2 (0.6-2.3) 0.6 
5HTTLPR SS 104 (21) 16 (21) Reference - 
 LS 231 (47) 41 (53) 1.2 (0.6-2.1) 0.7 
 LL 160 (32) 21 (27) 0.9 (0.4-1.7) 0.7 
      
COMT allele met 505 (51) 76 (49) Reference - 
 val 485 (49) 80 (51) 1.1 (0.8-1.5) 0.6 
5HTTLPR allele S 439 (44) 73 (47) Reference - 




Multivariate analyses for delusions and hallucinations by 5HTTLPR and COMT genotype are 
shown in the four tables below (Table 3-17 to Table 3-20).  There continued to be no evidence of 
an association with either genotype and either symptom.   
 
Table 3-17 Logistic regression: COMT val158met persistent delusions (N=574) 
 





[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=455) Yes (n=119) 
COMT met/met 118 (26) 33 (28) Reference - 
 val/met 222 (49) 58 (49) 0.9 (0.5-1.4) 0.5 
 val/val 115 (25) 28 (24) 0.8 (0.5-1.5) 0.5 
Adjusted for dementia severity and anti-dementia drug exposure  
Risk Factor 
Persistent delusions 
[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=455) Yes (n=119) 
5HTTLPR SS 94 (21) 26 (21) Reference - 
 LS 214 (47) 59 (50) 1.02 (0.6-1.7) 0.9 
 LL 147 (32) 34 (29) 0.8 (0.5-1.5) 0.5 
Adjusted for dementia severity and anti-dementia drug exposure  
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Table 3-19 Logistic regression: COMT persistent hallucinations (N=573) 
 
 
Table 3-20 Logistic regression 5HTTLPR persistent hallucinations (N=573) 
 
3.5.2.3 Role of COMT val158met and 5HTTLPR polymorphisms in AD sub-phenotype 
 
To analyse whether each of the polymorphisms was associated with a specific AD with psychotic 
symptoms phenotype, genotype frequencies were compared between AD individuals with 
persistent symptoms and cognitive normal controls and AD without persistent symptoms and 
cognitively normal controls.   
 
Genotype frequencies by the presence/absence of psychotic symptoms and controls for 
5HTTLPR and COMT val158met are shown in Table 3-21 and Table 3-22 respectively.  There 
was no overall difference in frequencies between AD cases and controls for either 5HTTLPR or 
COMT val158met (
2
=0.4, df=2, p=0.8 and 
2
=0.7, df=2, p=0.7 respectively). 
 
There was no evidence to support the heterogeneity model for either 5HTTLPR (persistent 
delusions vs. control: 
2
=0.5, df=2, p=0.8; persistent hallucinations vs. control: 
2
=1.05, df=2, 
p=0.6; no delusions vs. control: 
2
=0.7, df=2, p=0.7; no hallucinations vs. control: 
2
=0.6, df=2, 
p=0.7) or COMT val158met (persistent delusions vs. control: 
2
=0.05, df=2, p=0.9; persistent 
Risk Factor 
Persistent hallucinations 
[Frequency (%)] Odd ratio (95% CI) p-value 
No (n=495) Yes (n=78) 
COMT met/met 243 (49) 36 (46) Reference - 
 val/met 121 (24) 22 (28) 0.9 (0.5-1.6) 0.6 
 val/val 104 (21) 16 (21) 1 (0.5-1.9) 0.9 




Odd ratio (95% CI) p-value 
No (n=495) Yes (n=78) 
5HTTLPR SS 104 (21) 16 (21) Reference - 
 LS 231 (47) 41 (53) 1.1 (0.6-2.1) 0.8 
 LL 160 (32) 21 (27) 0.78 (0.4-1.6) 0.5 
Adjusted for dementia severity and age 
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hallucinations vs. control: 
2
=0.8, df=2, p=0.6; no delusions vs. control: 
2
=0.6, df=2, p=0.8; no 
hallucinations vs. control: 
2
=0.3, df=2, p=0.8).   
 
Table 3-21 5HTTLPR genotype frequencies for AD cases (by presence/absence of symptoms) 
and controls (N=685) 
 
 
Table 3-22 COMT val158met genotype frequencies for AD cases (by presence/absence of 
symptoms) and controls (N=685) 
 
 
3.5.3 Secondary analysis 
 
The secondary analysis consisted of a sensitivity analysis of the results presented in section 
3.5.2.  The split of symptoms used in the primary analysis was evaluated by only testing those 
with persistent symptoms and those with no symptoms (i.e. transient symptom cases were 
excluded).  This made no difference to the results, the ORs and p-values were similar to those 
presented in section 3.5.2.2 for both delusions (COMT val/met: OR 0.9, 95% CI: 0.6-1.6, p=0.8; 
COMT val/val: OR 0.8, 95% CI: 0.4-1.5, p=0.5; 5HTTLPR LS: OR 1.2, 95% CI: 0.7-2, p=0.5; 
5HTTLPR LL: OR 1.2, 95% CI: 0.6-2.1, p=0.7) and hallucinations (COMT val/met: OR 0.8, 95% 
1. no hallucinations vs. control: 2=0.6, df=2, p=0.7; 2. persistent hallucinations vs. control: 2=1.05, 
df=2, p=0.6; 3. no delusions vs. control: 2=0.7, df=2, p=0.7; 4. persistent delusions vs. control: 
2=0.5, df=2, p=0.8 











5HTTLPR SS 104 (21) 16 (20)
 
94 (21) 26 (22) 34 (31) 
LS 231 (47) 41 (53) 214 (47) 59 (50) 50 (45) 
LL 160 (32) 21 (27) 147 (32) 34 (28) 27 (24) 
1. no hallucinations vs. control: 2=0.3, df=2, p=0.8; 2. persistent hallucinations vs. control: 2=0.8, 
df=2, p=0.6; 3. no delusions vs. control: 2=0.6, df=2, p=0.8; 4. delusions vs. control: 2=0.05, df=2, 
p=0.9 











COMT Met/met 131 (26) 20 (26) 118 (26) 33 (28) 32 (29) 
Val/met 243 (49) 36 (46) 222 (49) 58 (49) 54 (49) 
Val/val 121 (24) 22 (28) 115 (25) 28 (23) 25 (22) 
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CI: 0.4-1.6, p=0.6; COMT val/val: OR 0.97, 95% CI: 0.5-2, p=0.9; 5HTTLPR LS: OR 1.5, 95% CI: 
0.8-2.6, p=0.2; 5HTTLPR LL: OR 1.1, 95% CI: 0.5-2.4, p=0.7). 
 
All of the OPTIMA patients were evaluated using the CAMDEX scale, while the remainder were 
assessed using the NPI.  Thus in the second part of the secondary analysis these cases were 
excluded in order to test for any bias arising from measurement of symptoms on different rating 
scales.  Again this made no significant differences to the results for delusions (COMT val/met: OR 
0.8, 95% CI: 0.4-1.3, p=0.3; COMT val/val: OR 0.8, 95% CI: 0.4-1.5, p=0.5; 5HTTLPR LS: OR 
1.2, 95% CI: 0.7-2, p=0.6; 5HTTLPR LL: OR 1.3, 95% CI: 0.7-2.4, p=0.4) or hallucinations (COMT 
val/met: OR 0.8, 95% CI: 0.4-1.6, p=0.6; COMT val/val: OR 0.7, 95% CI: 0.3-1.6, p=0.4; 






3.5.4.1 Summary of primary analysis 
 
1. No association was found between either the 5HTTLPR or COMT val158met 
polymorphisms and persistent delusions or hallucinations in AD. 
 
3.5.4.2 Summary of secondary analysis 
 
1. Restricting the analysis to only those with persistent symptoms and no symptoms or to 






This is the first study to show that the LL genotype of the 5HTTLPR polymorphism is a risk factor 
for persistent delusions in DLB/PDD patients, while there was no association between the COMT 
val158met polymorphism and either symptom.  Individuals carrying the LL genotype were 11.5 
times more likely to have persistent delusions than individuals homozygous for the S allele and for 
each one point decrease in MMSE score persistent delusions risk increased significantly by a 
factor of 1.1.  Furthermore, sensitivity analysis demonstrated that the L allele was associated with 
a 3.3 fold increase in risk for persistent delusions relative to the S allele.  In contrast, neither 
5HTTLPR genotype nor MMSE score were significant predictors of persistent hallucinations, 
demonstrating that these symptoms may have distinct underlying mechanisms, a finding 
supported by post-mortem and in-vivo imaging studies (Nagahama, Okina et al. 2010, Ballard, 
Piggott et al. 2000).  Moreover, there was no association found between the COMT val158met 
polymorphism and delusions or hallucinations in DLB/PDD. 
 
In contrast there was no evidence to support a role for the 5HTTLPR polymorphism in the 
aetiology of persistent delusions and hallucinations in AD.  This was both in univariate and 
multivariate analyses after controlling for dementia severity.  This is in contrast to a substantial 
body of previous literature (Sweet, Pollock et al. 2001, Borroni, Grassi et al. 2006, Quaranta, 
Bizzarro et al. 2009, Proitsi, Lupton et al. 2010), although it should be noted that there have also 
been some negative reports previously (Albani, Prato et al. 2009, Rocchi, Micheli et al. 2003, 
Ueki, Ueno et al. 2007).  The fact that the positive previous findings are in opposite directions may 
reflect the complexity of the psychotic phenotype, an issue which has been addressed in this 
study by the use of serial assessment and the adoption of stringent criteria for the classification of 
a symptom as present.  Therefore this finding can be considered a robust negative. 
 
As expected neither COMT val158met nor 5HTTLPR were associated with AD or DLB/PDD.  
Moreover, there was no evidence to suggest that either of these polymorphisms represent an 
increased risk for a dementia with psychotic symptoms sub-phenotype (the heterogeneity model).  
This analysis of course rests on the assumption that such a phenotype does exist and although 
not been conclusively proven there is evidence to support this (Sweet, Nimgaonkar et al. 2003).  
Moreover the control group comparison in this study was from the UK while the dementia groups 
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were from the UK and other parts of Europe, this is a significant limitation as it makes population 
stratification more likely and therefore the results of this secondary, minor analysis should be 
treated with caution.  Therefore, it appears that both polymorphisms have no involvement in any 
kind of delusion or hallucination phenotype in AD.  In DLB/PDD the evidence presented here 
suggests that, similarly, COMT val158met does not contribute to any hallucination or delusion 
phenotype while the role of 5HTTLPR appears to be restricted to that of disease modification; 
causing an increased risk for persistent delusions, but not hallucinations. 
 
Review of the previous literature strongly suggests that both COMT val158met and 5HTTLPR are 
pleiotropic, influencing a number of traits and disorders besides psychosis.  Therefore, for a 
complete understanding of the role of these polymorphisms in psychosis in dementia their role in 
traits that are associated with psychotic symptoms should be investigated.  Of particular note is 
the body of literature surrounding both COMT val158met and 5HTTLPR, and more broadly 
serotoninergic and dopaminergic neurotransmission, and cognitive decline in AD.  Indirect 
associations with psychosis such as this cannot be ruled out and indeed may be one reason for 
the inconsistency in the literature surrounding 5HTTLPR and COMT val158met, however, below 
the specific reasons for the findings reported here will be discussed. 
 
3.6.1 COMT val158met  
 
There have been two positive reports of the COMT val allele or val/val genotype being associated 
with psychosis in AD (Borroni, Grassi et al. 2006, Sweet, Devlin et al. 2005, Proitsi, Lupton et al. 
2010).  In DLB and PDD this area is less well studied.  The only previous genetic association 
study in DLB reported a significant association between COMT val158met and psychosis 
(delusions or hallucinations), but a further evaluation of delusions and hallucinations separately 
did not show a significant relationship (Borroni, Di Luca et al. 2006).  Camicioli et al. (Camicioli, 
Rajput et al. 2005) also failed to find an association with COMT val158met in PD patients with 
visual hallucinations. 
 
From a neurochemical point of view, the negative COMT val158met finding in both AD and 
DLB/PDD is perhaps not surprising.  There is little evidence that dopaminergic drugs are effective 
in the treatment of psychosis in AD or DLB/PDD, with primarily non-dopaminergic drugs offering 
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the best response profile in both diseases (Corbett, Smith et al. 2012, Ballard, Aarsland et al. 
2013).  The best evidence in AD is for atypical antipsychotics which are characterised by high 
affinity 5HT2A receptor antagonism, rather than solely by D2 antagonism as is the case for typical 
antipsychotic agents, and in DLB/PDD cholinesterase inhibitors appear to confer the greatest 
benefit.  While the exact mechanism of benefit of atypical antipsychotic agents is unclear because 
of their actions at multiple receptor sites, this DA activity-based distinction between typical and 
atypicals may be of relevance, suggesting a relative importance of 5HT modulation in 
antipsychotic action.  Furthermore, DLB/PDD levodopa studies showing no evidence of increased 
psychosis prevalence following administration of this drug support the notion that CNS dopamine 
levels do not underpin psychosis (Goetz, Pappert et al. 1998).  To explore this further future 
studies should examine the relationship between dopamine and cholinergic receptor 
polymorphisms and psychosis, in particular in DRD1, DRD3 and CHRNA7 as these have been 
associated with psychosis in AD (Sweet, Nimgaonkar et al. 1998, Holmes, Smith et al. 2001, 




Preliminary evidence in PD patients with psychosis in the absence of dementia suggests that the 
5HT2A inverse agonist pimavanserin may confer benefits in the treatment of psychotic symptoms, 
with a preferential response to delusions (Meltzer, Mills et al. 2010, Cummings, Isaacson et al. 
2013).  Pimavanserin is a very selective 5HT2A blocker with no dopaminergic activity and its 
efficacy is therefore supportive of a key role of serotonergic neurotransmission at 5HT2A in the 
aetiology of psychosis in PD.  Whether it is also effective in DLB/PDD is not yet known, but that 
5HTTLPR was associated with delusions in this study highlights the possibility of extending this 
line of research, and indicates the potential value of treatments targeting the 5HT system for the 
treatment of persistent delusions in DLB and PDD patients (Meltzer, Mills et al. 2010).  The 
evidence from the pimavanserin trials is supportive of the excess 5HT2A receptor stimulation 
hypothesis of psychosis but it is not clear how the 5HTTLPR polymorphism may fit into this 
mechanism.  If the L allele is associated with greater efficiency in removal of 5HT from the 
synaptic cleft, thus decreasing serotonergic neurotransmission relative to the S allele, then one 
would expect it to be protective against psychosis as this action is more in line with pimavanserin 
as a 5HT2A antagonist.  Serotonergic neurotransmission is complex and not completely 
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understood with respect to the aetiology of psychosis, however there are other plausible attributes 
of 5HTTLPR that may serve to explain this finding in the context of the excess serotonin 
hypothesis.   There is evidence from two PET imaging studies that the 5HTTLPR S allele is 
associated with a higher density of 5HT1A receptors in some areas of the neocortex (including 
frontal and temporal areas) and the cingulate (David, Murthy et al. 2005, Lee, Bailer et al. 2005, 
Lothe, Boni et al. 2009).  A mechanistic explanation of psychosis involving 5HT1A is supported by 
evidence that increased 5HT1A activation in the frontal cortex resulting from 5HT2A and D2 
blockade is a key property of atypical antipsychotics (Ichikawa, Ishii et al. 2001).  Accordingly, 
lower numbers of 5HT1A
 
receptors and lower concentrations of 5HT associated with the L allele 
may lead to less signalling at 5HT1A thereby conferring less resistance to psychosis among 
carriers of this allele. 
 
A phase II trial of pimavanserin for psychotic symptoms in AD is to commence within the next 
year and based on its pharmacological profile and efficacy in PD positive results are expected.  
Along with the other evidence implicating serotonergic neurotransmission in psychotic symptoms 
in AD, it is therefore somewhat surprising that no association was found in this study between 
5HTTLPR and psychotic symptoms in AD.  This is difficult to interpret but given the design of this 
study this should be considered a robust negative and in light of this the possibility that the 
positive finding in the DLB/PDD cohort was a false positive should not be ignored.  Nonetheless, 
there are several strengths which should also be acknowledged, these will be discussed in more 
detail below.   
 
The results relating to AD do not rule out serotonergic dysfunction in the aetiology of psychotic 
symptoms, they do however strongly suggest that 5HTTLPR is not involved.  Polymorphisms in 
the 5HT2A gene were not examined in this study but present an interesting avenue for future 
research.  The common 5HT2A T102C SNP is relatively well studied in AD psychosis, it is a 
synonymous SNP and although there is a promoter variant which has been shown to be in 
complete linkage disequilibrium (Spurlock, Heils et al. 1998), because of the known biological 
effects of 5HTTLPR and the equal amount of previous literature as 5HT2A the decision was taken 
to investigate it here.  Given the recent evidence surrounding pimavanserin and the plans to 
commence trials in AD it would be of great interest to examine the role of this polymorphism and 
indeed the 5HT2A gene in psychosis in AD. 
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3.6.3 Strengths and limitations 
 
The strengths of this design include the prospective follow up of individuals to ensure accurate 
clinical data, assessments of cognitive impairment and controlling for it in the statistical analysis.  
This is the largest DLB/PDD genetic association study focussing on neuropsychiatric symptoms to 
date and among the largest in AD although the number of patients was modest compared with 
many genetic association studies in other areas. The number of individuals eligible was restricted 
by the stringent criteria for persistent psychotic symptoms which were adopted to increase power 
by ensuring accurate symptom classification, an issue which has presented substantial problems 
in retrospective studies.  This is particularly evident in the AD cohort where over 1300 patients 
were screened but only 574 met the criteria.  However it was felt necessary to adopt these criteria 
in order to increase the confidence with which cases were assigned to groups. 
 
A further strength of this study is that all groups were matched on the demographic variables. 
There were however differences with respect to cognitive function, where those with delusions 
had a significantly lower MMSE than those without in the DLB/PDD cohort.   The same bias was 
also apparent for hallucinations in the AD cohort (i.e. in those with more severe dementia there 
was a significantly higher proportion of people with hallucinations), see sections 3.4.2, 3.4.3 and 
3.5.2.  The inclusion of MMSE (DLB/PDD) or dementia severity (AD) as an explanatory variable 
statistically mitigated its effect on the genotypic association, however there is a risk that 
symptoms in some individuals with mild dementia scores may not have had sufficient time to 
emerge. For this reason a post-hoc analysis was undertaken where patients with an MMSE >19 
or with mild dementia measured by FAST who had not already presented with delusions or 
hallucinations were excluded.   This still supported the presence of a significant association with 
the LL genotype and delusions in the DLB/PDD cohort (n=47, 
2
=7.15, df=2, p=0.03), however it 
made no difference to any of the other comparisons in DLB/PDD or AD. 
 
Comprehensive standardised drug histories for the participants in the DLB/PDD cohorts that 
came from brain banks were not available.  Although there is limited evidence suggesting 
levodopa induces psychosis, it is possible that other drugs used for the treatment of PD could 
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contribute to psychosis and this may have impacted these results.  Issues such as this should be 
addressed in future cohorts with detailed medication histories attached.  In contrast, cases in the 
AD cohort did include details of medical history which allowed the identification of anti-dementia 
drug exposure as a predictor of persistent delusions (Table 3-15), which could then be controlled 
for in the multivariate analysis. 
 
It is not uncommon for genetic association studies not to be replicated and there can be a number 
of reasons for this, the most obvious of which is ethnicity, which applied to both the DLB/PDD and 
AD parts of the study.  This a broad issue and will be returned to in detail in the General 
Discussion.  Another reason for non-replication is phenotype classification.  There are a number 
of different ways in which psychotic symptoms, or indeed any neuropsychiatric symptoms, can be 
classified for analysis.  With regard to 5HTTLPR and COMT val158met Sweet et al. (2001 and 
2005), Quaranta et al. (2009) and Borroni et al. (2006) all used a psychosis phenotype which 
consisted of delusions and/or hallucinations.  Proitsi et al. (2010) considered psychosis, delusions 
and hallucinations separately and instead of treating psychosis as a binary variable they treated it 
as continuous level data.  With respect to 5HTTLPR, of the studies reporting significant 
associations, two identified the L allele/LL genotype as the risk (Sweet, Pollock et al. 2001, 
Quaranta, Bizzarro et al. 2009) and one the S allele/SS genotype (Borroni, Grassi et al. 2006).  
With respect to COMT val158met, both Sweet et al. (2005) and Borroni et al. (2006) found the val 
allele to carry the increased risk.  Proitsi et al. (2010) found no association with either 
polymorphism and delusions or hallucinations but did report a significant COMT 
met/met*5HTTLPR SS genotype interaction on psychosis.  Although in contrast to most of the 
previous literature the present study examined delusions and hallucinations separately and the 
classification of symptoms was based on stringent criteria designed to increase sensitivity and 
specificity which lend more confidence to the finding of no association with COMT val158met or 
5HTTLPR. 
 
Patients were only selected for inclusion in these studies if they had at least two assessments 
covering a period of at least six months.  This criterion is strict and applied not only to those with 
psychotic symptoms but also to those without.  Psychotic symptoms in AD are persistent, being 
likely to recur once they have emerged (Ballard, O'Brien et al. 2001, Craig, Mirakhur et al. 2005).  
Estimates of familial aggregation and heritability also provide support for this method being 
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applied.  Specifically, estimates of both are highest for multiple or recurrent symptoms, suggesting 
these may have the strongest genetic basis (Sweet, Bennett et al. 2010, Bacanu, Devlin et al. 
2005, Sweet, Nimgaonkar et al. 2002).  Conversely, psychotic symptoms occurring transiently 
and not recurring may be more likely to be part of a concurrent delirium. 
 
Multiple symptoms (i.e. a psychosis syndrome) were not examined in this study although there 
were a number of individuals who experienced both symptoms (see section 3.4.2 for DLB/PDD 
and 3.5.2 for AD).  It could be argued that the familial and heritability evidence supports the 
concept of a psychotic syndrome that should be examined in genetic studies.  However there is 
also neuropathological and neurochemical evidence that separate mechanisms underpin different 
psychotic symptoms in AD and DLB/PDD (Ballard, Piggott et al. 2000, Reeves, Brown et al. 2009, 
Christie, Shofer et al. 2012) and it is important that genetic association studies are used to 
explore this, which was one of the aims of the present study.  Moreover, recent evidence from 
genetic association studies in AD supports treating delusions and hallucinations separately.  
Christie et al. (2012) reported an association between the APOE*4 allele and patients with 
hallucinations (most of whom also had delusions) but not with delusions only. 
 
Several different rating scales were used as a basis for symptom classification in the present 
study and as a result a binary present/absent coding symptom was employed.  Again because of 
the different scales used, the broadest criterion was employed to determine whether a symptom 
was present or absent; that is the severity of any symptom was not taken into account.  This is a 
potential limitation as it is possible that psychotic symptoms are a quantitative trait, however even 
if this were the case the ratings scales used in each of these studies may not be appropriate.  The 
CAMDEX and CUSPAD scales only rate the presence of a symptom, while the PBE rates the 
frequency of symptoms over the past 28 days; all are ordinal or categorical level scales.  The NPI 
composite score (the product of the frequency and severity scores) is often treated as a 
continuous variable (Proitsi, Lupton et al. 2012, Assal, Alarcon et al. 2004).  However there are 
only nine possible scores: 0, 1, 2, 3, 4, 6, 8, 9, 12 and the difference between a score of 8 and 12 
is not necessarily the same as the difference between 2 and 6.  By using existing cohorts the 
design of the study presented here was necessarily limited by the data collected in each 
composite study.  Therefore by using binary ratings any issues resulting from the treatment of the 
NPI as an interval level measurement were avoided and in order to capture the persistence of 
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With regard to DLB/PDD, these findings demonstrate that the 5HTTLPR polymorphism is 
associated with persistent delusions, which provides important mechanistic information to inform 
the development of new treatment approaches and the prioritisation and design of clinical trials. 
 
In AD, although negative, this finding is robust due to the comprehensive clinical assessments 
from which the symptom phenotypes were drawn and therefore strongly suggests that 5HTTLPR 
and COMTval158met are not associated with delusions or hallucinations.  It is also strengthened 
by a secondary analysis restricted to only those with no symptom and those with persistent 
symptom which showed no difference.  Other genetic variation may be exerting influences in the 
different populations studied; again this will be returned to in the General Discussion.  Moreover, 
at the phenotype level the next important stage in this line of research is to examine whether each 
of these polymorphisms is associated with other clinical correlates of psychotic symptoms, 
notably cognitive decline, in order to establish whether there is an indirect association present.  





Chapter 4 COMT val158met is associated with rate of cognitive 
decline in Alzheimer’s disease 
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4.1 Summary introduction 
 
It has been proposed that AD with psychosis represents a distinct form of the disease (Sweet, 
Nimgaonkar et al. 2003).  One of the key tenets of this hypothesis is the link between cognitive 
impairment and rate of cognitive decline and psychosis, particularly as the former appears to also 
precede the onset of the latter (Paulsen, Salmon et al. 2000). 
 
Dopamine and serotonin are both key neurotransmitters which have been implicated in the 
pathogenesis of psychosis in AD.  Two polymorphisms that may regulate neurotransmission in 
each of these systems have also been associated with psychotic symptoms (COMT val158met 
and 5HTTLPR).  However, both serotonin and dopamine are also implicated in cognitive 
functioning.  It therefore follows that if psychotic symptoms in AD are actually part of a phenotype 
that includes more rapid cognitive decline, the associations found between COMT val158met and 
5HTTLPR and psychosis may be indirect via more rapid cognitive decline which may contribute to 
the emergence of the symptoms.  
  
With regard to the polymorphisms specifically, there is a good body of literature linking COMT 
val158met to cognition, rate of cognitive decline and physiological responses associated with 
cognition.  In particular, the val/val genotype has been associated with more rapid cognitive 
decline in two large studies, one of cognitively normal adults and one in 22q11.2 deletion 
syndrome (de Frias, Annerbrink et al. 2004, Gothelf, Eliez et al. 2005).  The evidence surrounding 
5HTTLPR is not so extensive and that which exists does not support a relationship (Payton, 
Gibbons et al. 2005).  Nevertheless, in order to elucidate fully the role of these polymorphisms in 
psychosis it is essential that their impact on other biologically plausible aspects of the clinical 
syndrome is investigated.  Cognitive decline is the most notable of these with regard to dementia.  
The results that follow are therefore an investigation of the association between the COMT 
val158met and 5HTTLPR polymorphisms and rate of cognitive decline in AD with the aim of 






 The COMT val/val genotype will be associated with a faster average annual cognitive 
decline than val/met and met/met genotypes. 
 It is not expected that the 5HTTLPR polymorphism will impact upon cognitive decline. 








Excel: data cleaning, coding and organisation. 
STATA: data analysis and coding. 
 
4.2.2 Inclusion/exclusion criteria 
 
Inclusion criteria: 
 MMSE conducted at baseline and at least one time point after 6 months or more, dates 
available for both MMSE assessments. 
 Clinical or pathological diagnosis of possible, probable or definite Alzheimer’s disease. 
 Baseline MMSE greater than 9. 
 Medication information relating to anti-dementia drug and antipsychotic exposure 
available. 
 Serial assessment of psychotic symptoms available, meeting the criteria set out in section 
3.3.2.  Briefly, at least two assessments separated by six months or more. 
 
Exclusion criteria: 
 History of a psychotic disorder not related to dementia. 
 
4.2.3 Design and cohort 
 
COMT val158met and 5HTTLPR genotypes were available from 237 patients meeting the 
inclusion criteria specified in section 4.2.2 (see section 2.6 for genotyping methods).  Patients 





4.2.4 Calculating cognitive decline 
 
Cognition was evaluated using the MMSE and only those with a baseline score of 9 or more were 
included to avoid floor effects.  An estimation of annual change in MMSE score was calculated 
using the baseline and last available scores (or the first point at which MMSE reached 0 provided 
it was 6 months or more after the first assessment) in three steps: 
 
1) The date of the last MMSE assessment was subtracted from the date of the first to give 
the time elapsed between the two (in years). 
2) MMSE score at last assessment subtracted from baseline MMSE score to give the 
change in number of points over the time period calculated above. 
3) The number calculated in part 2) was then divided by the time elapsed calculated in part 
1) to give an estimate of the change in MMSE score each year. 
 
4.2.5 Statistical Evaluation 
 
Relationships between annual MMSE decline and other clinical and demographic variables were 
assessed using Pearson’s correlations, t-tests and one-way ANOVA as appropriate, any 
significant associations were controlled for in the main analysis.  Of particular interest was the 
relationship between psychotic symptoms and cognitive decline.  However because of the 
relatively low number of people with persistent symptoms, this relationship and its association 
with both polymorphisms was not statistically tested to keep comparisons to a minimum. 
 
The primary analysis consisted of cases with a baseline MMSE greater than 9.  A comparison 
between mean annual MMSE decline across the three genotypes of each polymorphism was 
conducted using ANOVA.  Post-hoc analyses compared genotypes in the event of a significant 
ANOVA.  The sample was then stratified by dementia severity, creating two groups: mild 
dementia and moderate dementia (defined by MMSE>19 and between 10 and 19 respectively) in 
order to examine whether the effect of genotype differs by dementia severity.  Finally, a 
multivariate ANOVA was run to test the interaction between genotypes and dementia severity.  
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4.2.5.1 Power calculation 
 
Assuming a MAF of 0.45 and an additive genetic model this sample size would have >80% power 
to detect 4% of the variance associated with rate of cognitive decline and approximately 60% 





4.3.1 Descriptive statistics: COMT val158met and 5HTTLPR 
 
This sample consisted of 32 patients with pathologically confirmed possible, probable or definite 
Alzheimer’s disease and 2 5 cases with clinically diagnosed possible or probable Alzheimer’s 
disease.   
 
Neither COMT val158met nor 5HTTLPR genotype differed significantly from HWE (COMT: 
val/met: 
2




Average annual MMSE decline for the group as a whole was 2.2 (SD±4.1).  Neither age (r=-0.1, 
p=0.09) nor MMSE at baseline (r=0.09, p=0.2) correlated with rate of MMSE decline and mean 
annual decline did not differ by gender (mean difference: -0.4, t=-0.7, df=235, p=0.5).  Likewise, 
average annual decline was not associated with persistent hallucinations (mean difference -0.4, 
t=-0.4, df=234,p=0.7) or delusions (mean difference: -1.4, t=-1.7, df=235, p=0.07) nor exposure to 
antipsychotics (mean difference: -0.4, t=-0.8, df=235, p=0.4) or anti-dementia drugs (mean 
difference: -0.55, t=-0.9, df=235, p=0.4) at any point during follow up.  
 
Other participant characteristics by COMT val158met and 5HTTLPR genotypes are summarised 
in Table 4-1 and Table 4-2.  None of the clinical or demographic variables listed differed 
significantly by COMT val158met genotype. 
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Table 4-1 Participant characteristics by study at baseline by COMT val158met genotype (N=237) 
 
With regard to 5HTTLPR, participant characteristics are summarised in Table 4-2.  Again 
participants were well matched on each of the variables, with the exception of age where LS 
genotypes were significantly older (mean age 80 compared with 77 for LL and SS genotypes). 
 
Table 4-2 Participant characteristics by study at baseline by 5HTTLPR genotype (N=237) 
 
 COMT val158met genotype 
[Freq(%)/Mean±SD] 




78 (7.2) 78 (7.7) 78 (6.6) 
Gender
2 
Female 36 (62) 84 (64) 35 (69) 
 Male 22 (38) 47 (36) 16 (31) 
MMSE
3 
20 (5.1) 19 (5) 20 (5.2) 
Mean follow up time (months)
4 
17 (12.6) 18 (15.2) 16 (13.4) 
Anti dementia drugs
5 
No 38 (68) 99 (76) 37 (74) 
 Yes 18 (32) 32 (24) 13 (26) 
Antipsychotics
6 
No 31 (55) 74 (56)  28 (56) 
 Yes 25 (45) 57 (44) 22 (44) 
1.F(2,234)=0.19, p=0.8; 2.χ2=1, df=2, p=0.6; 3. F(2,234)=0.39, p=0.7; 4. F(2,234)=0.16, p=0.9; 5. 
χ2=1.2, df=2, p=0.5; 6. χ2=0.02, df=2, p=0.9 
 5HTTLPR genotype 
[Freq(%)/Mean±SD] 
LL (n=81) LS (n=111)  SS (n=45) 
Age
1 
77 (7.4) 80 (7.4) 77 (6.5) 
Gender
2 
Female 53 (65) 69 (62) 31 (69) 
 Male 28 (35) 42 (38) 14 (31) 
MMSE
3 
20 (5.2) 19 (5.1) 20 (4.7) 
Mean follow up time (months)
4 
17 (15.4) 17 (14.3) 17 (11.9) 
Anti dementia drugs
5 
No 60 (74) 82 (74) 32 (71) 
 Yes 21 (26) 29 (26) 13 (29) 
Antipsychotics
6 
No 40 (49) 69 (62) 24 (53) 
 Yes 41 (51) 42 (38) 21 (47) 
1.F(2,234)=4.3, p=0.02; 2.χ2=0.7, df=2, p=0.7; 3. F(2,234)=0.95, p=0.4; 4. F(2,234)=0, p=0.9; 5. 
χ2=1.2, df=2, p=0.9; 6. χ2=3.3, df=2, p=0.2 
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The remainder of the analysis is grouped by polymorphism, beginning with COMT val158met 
followed by 5HTTLPR.  
 
4.3.2 COMT val158met and average annual MMSE decline 
 
The first part of the analysis was descriptive, examining average annual decline by COMT 
val158met genotype and the presence/absence of persistent psychotic symptoms.  This 
relationship was not statistically tested due to small numbers, the results are presented below.  
The differences between genotypes were similar for the delusions/no delusions groups and 
hallucinations/no hallucinations groups (Table 4-3 and Table 4-4 respectively).  Overall, persistent 
delusions were associated with an annual MMSE decline of 3.4 points compared to 2 points 
among those without persistent delusions.   For hallucinations there was no meaningful difference 
(symptom present: 2.1; no symptom: 2.3).  With regard to COMT genotype, val/val carriers had an 
approximately 2-3.5 point higher annual decline than met/met carriers in each case.   
 
Table 4-3 Average annual MMSE decline by COMT val158met and persistent delusions (N=237) 
 
Table 4-4 Average annual MMSE decline by COMT val158met  and persistent hallucinations 
(N=236) 
 
 Average Annual MMSE Decline 
[Mean ± SD] 
Persistent delusions (n=51) No delusions (n=186) 
COMT val/met Val/val 5 (4.2) 3.4 (3.2) 
 Val/met 2.4 (5.1) 1.8 (4.1) 
 Met/met 2.9 (5.3) 0.77 (3.2) 
 
 Average Annual MMSE Decline 
[Mean ± SD] 
Persistent hallucinations 
(n=26) 
No hallucinations (n=210) 
COMT val/met Val/val 3.8 (3) 3.7 (3.9) 
 Val/met 2.1 (4.5) 1.8 (4.2) 
 Met/met 0.25 (1.9) 1.3 (3.6) 
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The effect of COMT val158met genotype was first analysed on the total number of cases 
(N=237).  The analysis was then extended to examine the same effect, with the sample stratified 
by dementia severity.   
 
Average annual decline in MMSE for each COMT genotype group is depicted in Figure 4-1 and 
summarised in Table 4-5 (‘total group’ column).  One-way ANOVA demonstrated a significant 
effect of COMT val158met genotype on average annual decline (F(2,234)=5.92, p=0.003).  Post-
hoc Bonferroni comparisons showed COMT val/val genotypes to have a significantly higher 
annual decline in MMSE than val/met and met/met genotypes (p=0.005 and p=0.01 respectively).  
Heterozygotes did not have a significantly faster rate of decline than met/met genotypes, although 
the mean for this group fell in between the other two. 
 
 
Figure 4-1 Average annual MMSE decline by COMT val158met genotype (N=237) 
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Table 4-5 Average annual MMSE decline and baseline MMSE score by COMT genotype (N=237) 
 
 
This effect of COMT was then examined by severity of AD.  The analysis was stratified by MMSE, 
creating two groups, those with mild (20-30, n=125) and those with moderate AD (10-19, n=112), 
also summarised in Table 4-5 above and depicted in Figure 4-2 below.  In the moderate group 
there was no difference in mean decline between val/val, val/met and met/met genotypes 
(F(2,109)=1.38, p=0.3).  However, the association between COMT val158met and cognitive 
decline persisted in the mild group, with larger differences than those in the total group 
(F(2,123)=5.82,p=0.004).  A post-hoc Bonferroni test in the mild group again showed val/val 
genotypes to be associated with a significantly higher average annual decline than met/met and 
val/met genotypes (p=0.007 and p=0.04 respectively).  There continued to be no difference 
between the val/met and met/met groups.  Finally, a multivariate ANOVA was run to test if any 
interaction between AD severity and COMT val158met genotype was present.  Under this model, 
there was still a main effect of COMT (F(2,231)=5.55,p=0.004) but not of severity or the 
interaction. 
 
1. F(2,109)=1.38, p=0.3; 2. F(2,122)=5.33,p=0.006; 3. F(2,234)=5.92, p=0.003 
  Baseline MMSE 
[Mean±SD] 
Average Annual MMSE Decline 
[Mean±SD] 

















COMT  val/val 15 (2.6) 24 (2.2) 20 (5.1) 3.2 (3.6) 4.2 (3.9) 3.8 (3.8) 
 val/met 15 (2.8) 23 (2.4) 19 (5) 1.7 (4.6) 2.1 (4.1) 1.9 (4.3) 
 met/met 15 (2.7) 24 (2.9) 20 (5.1) 1.7 (3.3) 0.8 (3.8) 1.3 (3.5) 
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Figure 4-2 Average annual MMSE decline by COMT genotype and AD severity (N=237: moderate 




4.3.2.1 Secondary analysis of COMT val158met including cases with severe AD 
 
As a consequence of the finding that the effect of COMT val158met genotype on rate of cognitive 
decline does not appear to be present among those with moderate dementia a final exploratory 
analysis was carried out including cases with severe dementia (i.e. a baseline MMSE of less than 
10 but greater than 4 in order to still provide some control over floor effects).  Widening the 
inclusion criteria to include the individuals with severe AD resulted in another 29 patients in the 
analysis.  Figure 4-3 shows average annual MMSE decline for all AD severities.  Extending the 
analysis to include more severe cases as well as those in the less severe stages resulted in a 
weak but significant correlation between age and annual decline (r=-0.13, p=0.04), therefore age 
was included as a covariate in this ANOVA model.  COMT val/val genotypes declined an average 
of 3.2 points per year on the MMSE compared with 2.3 and 1.3 for val/met and met/met 
genotypes respectively and this difference was found to be significant (F(2,262)=3.74, p=0.03). 
 
 
Figure 4-3 Average annual MMSE decline by COMT genotype, including severe cases (N=266) 
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Examination of the severe AD group only (n=29) was restricted to descriptive statistics only as 
there was only one case with the met/met genotype in this group.  Average annual MMSE decline 
was 4.2, 4.7 and 1.1 for the met/met, val/met and val/val groups respectively.  Although this 
relationship cannot be tested, it is worth noting that the val/val genotypes had the lowest rate of 
annual decline, whereas the reverse was true in the mild group. 
 
4.3.3 5HTTLPR and average annual MMSE decline 
 
The analysis for 5HTTLPR followed the same plan as COMT described above.   
 
Descriptive statistics for average annual decline by genotype and symptom presence are 
summarised in Table 4-6 and Table 4-7, again these differences were not statistically tested.  
Regarding delusions, the biggest numerical difference was between the LL genotype (average 
annual decline 4.5) and the other genotypes (LS: 2.3, SS: 2.6) among those with persistent 
delusions, while the rate of decline was similar among those without persistent delusions. 
 
With regard to hallucinations, the biggest difference was again in the persistent symptom group 
with SS genotypes having a rate of 5.8 compared to 2.5 and 0.46 in the LS and SS groups 
respectively.  Again, in the no symptom group the rate of decline between genotypes was similar. 
 
Table 4-6 Average annual MMSE decline by 5HTTLPR and persistent delusions (N=237) 
 
  
 Average Annual MMSE Decline 
[Mean ± SD] 
Persistent delusions (n=51) No delusions (n=186) 
5HTTLPR LL 4.5 (5.3) 2.1 (4.3) 
 LS 2.3 (4.4) 1.7 (3.4) 
 SS 2.6 (5.6) 2.1 (3.9) 
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Table 4-7 Average annual MMSE decline by 5HTTLPR and persistent hallucinations (N=236) 
 
Average annual decline in MMSE for each 5HTTLPR genotype in the total group is shown in 
Figure 4-4, and in the right-most column of Table 4-8.  There was no association between 
average annual decline and 5HTTLPR genotype in the total group (F(2,234), p=0.4,Table 4-8).   
 
 
Figure 4-4 Average annual MMSE decline by 5HTTLPR genotype (N=237) 
 
  
 Average Annual MMSE Decline 
[Mean ± SD] 
Persistent hallucinations 
(n=26) 
No hallucinations (n=210) 
5HTTLPR LL 0.46 (4.5) 2.8 (4.6) 
 LS 2.5 (3.4) 1.6 (3.5) 
 SS 5.8 (3.1) 1.9 (4.2) 
 
 152 




Table 4-8 above and Figure 4-5 below show average annual MMSE decline by 5HTTLPR 
genotype stratified by AD severity.  There remained no significant effect of genotype on annual 
decline in participants with moderate (F(2,109)=0.63, p=0.5) and mild (F(2,122)=0.23, p=0.8) AD.  
There was also no significant interaction between AD severity and 5HTTLPR genotype. 
1. ANOVA: F(2,109)=0.63, p=0.5; 2. ANOVA: F(2,122)=0.23, p=0.8; 3. ANOVA: F(2,234)=0.86, p=0.4 
  Baseline MMSE 
[Mean±SD] 
Average Annual MMSE Decline 
[Mean±SD] 

















5HTTLPR LL 15 (2.6) 24 (2.9) 20 (5.2) 2.7 (3.6) 2.6 (5.3) 2.6 (4.6) 
 LS 15 (2.8) 24 (2.2) 19 (5.1) 1.7 (4.1) 2.1 (3.1) 1.9 (3.6) 




Figure 4-5 Average annual MMSE decline by 5HTTLPR genotype and dementia severity (N=237: 
moderate n=112; mild n=125) 
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4.3.3.1 Secondary analysis of 5HTTLPR including cases with severe AD 
 
The analysis was extended to include those with an MMSE below 10 and above 4.  Figure 4-6 
shows average annual MMSE decline for all dementia severities.  Age was again included as a 
covariate due to the weak but significant correlation (r=-0.13, p=0.04).   There was no significant 
difference in annual decline between 5HTTLPR genotypes (F(2,262)=0.56, p=0.6).  
 
 
Figure 4-6 Average annual MMSE decline by 5HTTLPR genotype including severe cases (N=266) 
 
Examination of the severe dementia group only (n=29) was restricted to descriptive statistics as 
there were only two cases with the SS genotype in this group.  Average annual MMSE decline 
was 4.3, 3.9 and -0.6 (i.e. a very small improvement) for the LL, LS and SS groups respectively.  
Again, although not statistically tested, SS genotypes did have a lower rate of decline than the 
other groups, whereas the LS genotypes had the lowest rate of decline in the mild and moderate 
groups.   
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4.4 Summary of findings 
 
4.4.1 Summary of primary analyses  
 
1. COMT val/val genotype is associated with a higher average annual MMSE decline than 
val/met and met/met genotypes (mean annual decline: 3.8, 1.9 and 1.3 respectively). 
2. This finding was particularly pronounced in people with Mild AD (val/val: 4.2; val/met: 2.1; 
met/met: 0.8) but not in moderate cases in an analysis stratified by dementia severity. 
3. There was no association between 5HTTLPR genotype and average annual MMSE 
decline. 
 
4.4.2 Summary of secondary analyses 
 
1. The inclusion of participants with MMSE<10 but >4 did weaken the effect of COMT 
val158met genotype, however it was still significant (val/val: 3.4; val/met: 2.3; met/met: 
1.3, p=0.03). 
2. The addition of the severe cases made no difference to the impact of 5HTTLPR upon 






In the 237 individuals with mild to moderate AD the COMT val158met polymorphism was 
significantly associated with average annual MMSE decline: val/val carriers declined at a rate of 
3.8 points per year, compared with 1.9 and 1.3 for val/met and met/met carriers respectively.  
Subsequent planned analysis demonstrated that this difference was mostly driven by those with 
mild AD, in whom the difference was particularly pronounced.  In this latter stratified analysis 
there was no significant difference in decline among the moderate AD group, however the 
differences became more pronounced in the mild AD group with the val/val carriers having an 
average decline of 4.2, compared with 0.8 among met/met carriers.  Widening the inclusion 
criteria to include 29 patients with an MMSE >4 weakened the effect of the COMT val158met 
genotype, although val/val carriers still had a significantly faster rate of decline (p=0.03).  
Although nominally significant, not meeting a more stringent significance threshold adjusted for 
multiple comparisons, this provides further support that this effect is restricted to people with mild 
AD.  Moreover in a descriptive analysis the severe AD results are the reverse of mild, though this 
needs statistical confirmation.  The 5HTTLPR polymorphism was not found to effect rate of 
decline in this AD cohort.  These findings are therefore in line with the bulk of the non-AD 
literature suggesting that COMT is a key mediator of cognitive function, while the evidence around 
5HTTLPR is much weaker.   
 
Every patient in this sample was included in the AD results presented in Chapter 3; it was 
therefore assumed that there was no association between each polymorphism and psychosis.  In 
the case of COMT val158met, the suggestion here is that some of its observed association with 
psychosis in previous studies may be indirect via an association with more rapid cognitive decline 
and this could explain some of the variability in the results (Sweet, Devlin et al. 2005, Borroni, 
Grassi et al. 2006, Proitsi, Lupton et al. 2010).  
 
The average annual decline of people with persistent delusions was 1.2 points higher than those 
without.  Although not statistically significant (p=0.07), in light of it being consistent with previous 
reports it is worth noting (see section 4.3.1) (McShane, Keene et al. 1997, Drevets, Rubin 1989, 
Paulsen, Salmon et al. 2000).  The McShane et al. (1997) study only found persecutory delusions 
to be associated with more rapid cognitive decline.  Not being able to distinguish these from other 
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types of delusions may have masked an effect in the present study.  However the other two 
studies both examined psychosis as a composite of both delusions and hallucinations and still 
reported a significant effect.  The rating of psychosis in the present study was captured over a 
period of at least six months and the calculation of cognitive decline would not necessarily be 
based on the same period of time (that is, it could be based on a period before the emergence of 
symptoms, or after, or both).  However, based on previous results an association with more rapid 
cognitive decline would still be expected because it has been shown to precede the onset of 
psychosis (Paulsen, Salmon et al. 2000).  None of the aforementioned studies employed the 
Folstein (the original) MMSE as a measure of change, as was the case in this study (a full 
description of the MMSE is included in section 2.2.3.1).  McShane et al. (1997) used a modified 
version of the MMSE, which includes additional items relating to recent episodic memory, short 
term recall and language.  The Mattis Dementia Rating Scale (as well as other tests of executive 
function) which  was employed by Paulsen et al. focuses less on language and more on 
conceptualisation and construction, while memory and attention are still covered.  In contrast, The 
Blessed Dementia Rating Scale focuses very heavily on memory, with a small section on 
concentration.  The fact that three different rating scales have been used and all have found an 
association between psychosis and rate of cognitive decline could be taken as indicating quite a 
robust association, which would make it all the more puzzling why no effect was found here.  
However, it could be that the relatively greater focus on language in the original MMSE makes it 
less sensitive to the specific cognitive domains associated with psychosis, which at present 
remain to be elucidated but may be those related to executive functioning (Paulsen, Salmon et al. 
2000).   
 
These points notwithstanding the results here highlight another important dimension in genetic 
association studies of psychosis in AD.  It has been noted earlier in this thesis (Creese, Ballard et 
al. 2013) that cognitive impairment, by virtue of being a correlate of psychosis in AD, may have 
confounded previous studies on 5HTTLPR and the arguments made in that section are still 
relevant to COMT val158met.  Although there is no evidence to suggest 5HTTLPR is associated 
with more rapid cognitive decline in this study, the COMT val158met association may be an 
important source of the variance in the psychotic phenotype in AD attributable to genetic variation.  
To evaluate this thoroughly would require an extremely well characterised cohort and analysis of 
the COMT val158met polymorphism in individuals with and without psychotic symptoms.  
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Although the present cohort is characterised in this way, there were only 51 (22%) cases with 
persistent delusions and 26 (11%) with persistent hallucinations, the decision was therefore taken 
not to undertake statistical comparisons in view of the low power and to restrict the number of 
hypotheses being tested.  However, it is worth noting that there was a modest numerical 
difference in average annual decline between COMT val/val genotypes with and without 
persistent delusions and there was a much larger difference relating to 5HTTLPR.  LL genotypes 
declined two points per year more than SS genotypes among those with persistent delusions, and 
SS genotypes declined over five points more per year that LL genotypes among those with 
persistent hallucinations.  In the no symptom groups average annual decline was approximately 
two for all 5HTTLPR genotypes.  No conclusions can be reliably drawn about this relationship 
until it has been statistically examined in much larger samples.  However, in an area of literature 
where the relationship between 5HTTLPR and psychosis in AD is still inconclusive it would be 
prudent to consider interactions with cognitive decline to explain the relationship fully. 
 
The finding presented here relating to the COMT val158met polymorphism is in line with the 
previous literature in cognitively normal adults.  Two out of three studies of longitudinal cognitive 
decline have reported that the val/val genotype is associated with more rapid decline in several 
different domains (de Frias, Annerbrink et al. 2005, Starr, Fox et al. 2007, de Frias, Annerbrink et 
al. 2004).  The implication from the findings presented here is therefore that reduced levels of DA 
in the prefrontal cortex (PFC) are not only detrimental to cognition over time in control participants 
but also in AD.  However, COMT is not likely to be a risk factor for AD itself (Harold, Abraham et 
al. 2013).  The association in healthy controls is therefore not necessarily pathological; indeed the 
effects observed in these groups are not of a size such that it would interfere with daily 
functioning.  The annual decline observed in the mild group in this study however is clinically 
meaningful: 4.2 for val/val carriers compared to 0.8 against a baseline MMSE of 24.  It might 
therefore be hypothesised that the decreased PFC DA levels associated with the val/val genotype 
are particularly detrimental to cognition once dementia is present.  The exact reason for this 
heightened sensitivity to the val/val genotype in AD is not known, but evidence from neuroimaging 




In a study of grey matter volume associated with the COMT val158met polymorphism, Gennatas 
et al. (2012) found that the val/val genotype was associated with a statistically significant 
decrease in a combined cohort of  169 dementia patients (77 with AD) and 83 controls (Gennatas, 
Cholfin et al. 2012).  Stratification by disease status led the authors to conclude that this effect 
was being driven mostly by the patient group.  The authors did not examine cognitive decline in 
their cohort, and although the COMT val158met polymorphism was not associated with level of 
cognitive impairment it is possible that the decline observed in the present study is a clinically 
observable result of the increased grey matter loss associated with the val/val genotype reported 
by Gennatas et al.  The dementia participants in the Gennatas et al. study were overall mildly 
impaired (mean MMSE 21).  Taken together with the results presented here, identifying COMT 
val/val individuals may therefore prove a useful clinical trial enrichment strategy.  If val/val 
genotypes represent a sub group with a 4-fold higher rate of decline in mild AD compared to 
met/met genotypes this would be the optimum population from which to draw RCT participants as 
the faster decline would give much greater statistical power.  More specifically, one class of drug 
where this application might be beneficial is in the use of COMT inhibitors.  Under this hypothesis, 
the rapid cognitive decline in val/val genotypes would be due to DA deficiency in the PFC caused 
by the relatively higher activity of this genotype, which could be mitigated by inhibition of COMT.  
Clearly, much more work needs to be conducted before this hypothesis can be tested in AD, not 
least the initial step of reliable replication of the present results which is most important at this 
stage. 
 
Although an overall effect of the COMT polymorphism was observed in the sample presented 
here as a whole, the results in this study were driven by the mild dementia group.  Although there 
was a numerical increase in decline among the val/val genotypes compared to heterozygotes and 
met/met genotypes in the moderate group, this failed to reach significance.  Both severity groups 
had a similar average annual decline (moderate 2.2; mild 2.3), ruling out the possibility that rate of 
decline in moderate dementia increases to an extent that the variance explained by the COMT 
val158met polymorphism becomes too small to detect with the sample size.  It is, however, worth 
considering whether the decline in the type of cognitive domain may change across the course of 
AD.  The influence of COMT val158met on the full range of cognitive domains remains to be 
elucidated but decline in both declarative memory (in particular recall) and executive functioning 
have been associated with the val/val genotype (de Frias, Annerbrink et al. 2004, de Frias, 
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Annerbrink et al. 2005).  In the case of the de Frias et al. (2004) study, declarative memory 
specifically referred to performance on memory recall tests.  In the case of the latter 2005 study 
executive function, specifically working memory and planning, was tested in a composite 
measure.  There are aspects of working memory and recall in the registration and recall sections 
of the MMSE as well as the attention/calculation section.   In the case of the former, three words 
have to be encoded then held for a short period of time before being repeated and in the case of 
the latter the word “world” has to be retained in memory in order to be able to spell it backwards.  
Recent recall and short term memory are two of the domains that are affected particularly early in 
the course of AD (Forstl, Kurz 1999, Storandt 2008).  It therefore may be possible that the 
observed association with rate of decline in cognition and COMT val158met genotype in mild AD 
cases reflects the effect of COMT on these domains as measured by the MMSE.  While in the 
moderate stages the decline principally takes places in domains such as language 
(comprehension and expression) (Forstl, Kurz 1999), which may be less likely to be associated 
with the COMT val158met polymorphism, but still captured by the MMSE, hence no effect is 
observed.  Another avenue for future research would therefore be to examine the effect of the 
COMT val158met polymorphism on tests specific to executive functioning, or alternatively to 
determine whether indeed it is specific sub-scale scores of the MMSE that are associated with the 
COMT val158met polymorphism in different stages of dementia.  The average annual MMSE 
decline for the severe group in this study was not tested due to there being only one met/met 
genotype among the 29 cases in this category.  It would be interesting for future research to 
examine whether there is also no relationship with COMT and cognitive decline in people with 
severe AD.  It is hypothesised here that there would be no such relationship as the main area of 
decline at this stage would be language and perhaps long-term episodic memory which are not 
domains typically associated with COMT functioning. 
 
The same observation could be applied to the finding regarding 5HTTLPR.  Although there is no 
support for 5HTTLPR being associated with more rapid cognitive decline, in keeping with the only 
other previous piece of published research in this area (Payton, Gibbons et al. 2005), it cannot be 
excluded that 5HTTLPR may be related to other cognitive functions not captured by the MMSE.  
 
It is important to note that the wider literature is still not completely conclusive about the role of 
COMT val158met in cognition.  This is illustrated in two meta-analyses that have been conducted 
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in this area examining performance on different tests, one reporting an association and the other 
reporting no association (Barnett, Jones et al. 2007, Barnett, Scoriels et al. 2008).  However, this 
is offset somewhat by the stronger evidence of PFC function in cognition, the high expression of 
COMT in this brain region and the knowledge of the functional consequences of the COMT 
val158met polymorphism (Robbins, Arnsten 2009, Akil, Kolachana et al. 2003, Williams-Gray, 
Hampshire et al. 2007).  This leads on to one of the primary caveats of interpretation on this 
study, which has already been noted above: replication.  Overall, the strengths of this study 
include the good characterisation of relevant medication (anti-dementia drugs and antipsychotics) 
and the presence of psychotic symptoms, both of which have been associated with improvements 
or worsening of cognition.  This therefore gives greater confidence that the observations noted in 
this study are the result of genetic association.  Even so, this is the first study examining the role 
of the COMT val158met polymorphism in cognitive decline in AD and therefore it will be important 
for this result to be independently replicated before the conclusions presented can be widely 
accepted.   
 
More specific to this study, it must be acknowledged that annual cognitive decline was an 
approximation (the first and last recorded MMSE divided by the number of years followed up).  
Ideally, this study should be repeated in a sample where MMSE is measured at the start and end 
of a year, or every year for a set number of years.  This would allow an exact decline to be 
calculated and for MMSE to be treated as a within-subjects variable in a repeated measures 
design, which is perhaps the most appropriate form of analysis for this type of study.  Taking 
either of these approaches would have been possible in the present study however it would have 
severely limited the sample size.  Following the decision to use an approximation, descriptive 
statistics were examined, which indicated that the estimated of decline of 2.2 points per year on 
the MMSE generated here is a reasonable one.  Firstly because it is broadly similar to previous 
estimates, with most studies placing annual MMSE decline between 2 and 4 points (Holmes, 
Ballard et al. 2005, Ballard, O'Brien et al. 2001, Roselli, Tartaglione et al. 2009, McCarten, 
Rottunda et al. 2004).  Secondly it was based on a mean length of follow up of 17 months, with a 
lower cut off of 6 months or more.  Moreover, the vast majority of cases were followed up for not 
more than three years (mean follow up 17 months SD±14.2) indicating that the approximation to 
one year was based on figures close to that. 
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In summary, this study presents the first evidence that the COMT val/val genotype is associated 
with more rapid cognitive decline in AD, suggesting reduced DA in the PFC may be an important 
target for treatment of cognitive decline among individuals with this genotype.  Furthermore, it 
also brings greater clarity to current understanding of the role of COMT val158met in the wider AD 
psychosis literature by suggesting an indirect association with psychosis may be present via more 





Chapter 5 The extended MAPT haplotype and worsening of 
psychotic symptoms in Alzheimer’s disease 
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5.1 Summary introduction 
 
There is a solid body of research linking neurofibrilliary tangle (NFT) pathology with the presence 
of psychotic symptoms in people with AD (Farber, Rubin et al. 2000, Zubenko, Moossy et al. 
1991, Forstl, Burns et al. 1994, Murray, Kirkwood et al. 2013), although not universally (Sweet, 
Hamilton et al. 2000).  A finding common to three of these studies is increased NFT burden in the 
frontal cortex, with the entorhinal cortex also being implicated in two studies, suggesting frontal 
regions or possibly hippocampal-neocortical pathways may be implicated in the pathogenesis of 
psychotic symptoms in AD.  
 
NFT pathology is one of the hallmark features of AD and understanding its role in the disease 
course will in turn further understanding of the place of psychotic symptoms in people with AD.  
Sweet et al. (2003) have proposed that AD with psychosis constitutes a distinct phenotype 
(Sweet, Nimgaonkar et al. 2003).  It is hypothesised that disease modification genes may exist 
that are only a risk for psychosis in the context of AD (the disease modification pathway) and also 
that there may be genes that predispose individuals to develop AD with psychotic symptoms (the 
heterogeneity pathway).  Therefore to fully understand the genetic architecture of psychotic 
symptoms in AD, putative AD risk genes should be investigated.  Given the aforementioned 
pathological findings concerning NFT burden and psychosis, the MAPT gene, which codes for the 
tau protein, is a good candidate.  A further advantage of a genetic association approach in this 
context is that it is possible to examine individuals over a period of time.  While pathological 
studies have indicated that NFT burden is associated with psychosis, not all have been able to 
address the concern of dementia severity as a confounding variable (Forstl, Burns et al. 1994, 
Zubenko, Moossy et al. 1991).  Therefore establishing the true correlate of psychosis (NFT 
burden itself or an indirect association with disease severity) is difficult.  With a genetic 
association approach individuals can be examined longitudinally and the course of symptoms 
evaluated with respect to genotype, something that is impossible in pathological studies. 
 
The extended haplotype of MAPT has previously been associated with AD and other tauopathies, 
although not consistently.  It has been proposed that upregulation of the 4R isoform, which has a 
greater propensity to aggregate into NFTs, resulting from carriage of the H1c variant of the H1 
haplotype (which is suggested to drive the previous associations between H1 and tauopathies) is 
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in part the reason for this increased risk (Myers, Pittman et al. 2007).  There has only been one 
previous report of an investigation into the MAPT gene and psychosis in AD, which proved to be 
negative (DeMichele-Sweet, Klei et al. 2011).  However, although participants were well 
characterised for the presence of symptoms this was a prevalence study and did not take into 
account the longitudinal course of symptoms, something which is important in establishing 
whether some genes adversely affect disease course.   
 
The clinical trials from which patients for this study were drawn (MAIN-AD and MAGD) were 
examining memantine as a treatment for neuropsychiatric symptoms in patients with AD living in 
care homes.  Memantine is an interesting candidate for treatment of psychosis given its putative 
role in inhibiting and reversing tau phosphorylation, however treatment with memantine for these 
symptoms has to date only demonstrated a very modest effect in RCTs (Wilcock, Ballard et al. 
2008, Gauthier, Loft et al. 2008, Fox, Breitner et al. 2012).  Although research into memantine 
and tau phosphorylation is in its very early stages a preliminary experiment was also undertaken 
to evaluate whether the extended MAPT haplotype modified response to memantine. 
 
Thus, in the present study the aim was to examine the effect of the extended MAPT haplotype on 
the likelihood of delusions and hallucinations worsening or emerging during 12 weeks of follow up 
during the two RCTs.  A second preliminary analysis sought to identify whether the extended 












Excel: data cleaning, coding and organisation. 
STATA: data analysis and coding. 
 
5.2.2 Inclusion/exclusion criteria 
 
Inclusion criteria: 
 As per MAIN-AD and MAGD clinical trial protocols (see General Materials and Methods 
section), briefly: 
o Met NINCDS-ADRDA criteria for possible or probable AD. 
o Living in a care home. 
o Stable dose of psychotropic medication for at least 4 weeks prior to starting the 
trial. 
o Not taking medication which is contraindicated to memantine.   
 Consent for DNA obtained and sample taken. 
 Neuropsychiatric Inventory (NPI) and Functional Assessment Staging Tool (FAST) both 
recorded. 
Exclusion criteria: 
 As per MAIN-AD and MAGD clinical trial protocols (see General Materials and Methods 
for full description), briefly: 
o Taking memantine. 
o Previous history of intolerance to memantine or related drugs. 
o DMS-IV Axis I disorder other than in the context of AD. 
o Severe renal impairment. 




5.2.3 Design and cohort 
 
Ninety-five buccal swab samples from patients identified from the MAIN-AD and MAGD 
databases were genotyped for the extended MAPT haplotype and analysed by electrophoresis 
(see sections 2.4 and 2.6.3  for methods concerning DNA collection/extraction and genotyping 
respectively).  Demographic data was available for all participants, baseline cognitive impairment 
was measured using the MMSE and dementia severity was measured using the FAST. 
 
5.2.3.1 Memantine exposure and efficacy evaluation 
 
As part of MAGD and MAIN-AD, participants were randomly assigned to receive either 
memantine or placebo (MAGD) or memantine or antipsychotic (MAIN-AD) in a 1:1 allocation.  For 
the present analysis, participants were coded as either receiving memantine (1) or not (0).   
 
The efficacy of treatment with memantine was evaluated separately for delusions and 
hallucinations over 12 weeks by measuring change in the NPI subscale scores.  Baseline and 12 
week symptom scores were calculated by multiplying the frequency and severity ratings.  The 12 
week score was then subtracted from the baseline score giving a figure either below zero 
(symptom worsened), zero (no change) or above zero (symptom improved).  Participants were 
then classified into one of two treatment outcome groups: no change/ improved (0) or worsened 
(1), see section 5.2.4.1 for justification of this treatment. 
 
5.2.4 Statistical Evaluation 
 
5.2.4.1 Treatment of NPI subscale scores 
 
The single symptom subscales of the NPI are non-parametric when analysed alone, and in the 
case of the present study so was the symptom change score (derived from subtracting the 12 
week score from the baseline score).  Summed variables describing syndromes identified by 
statistical techniques and comprising several NPI subscale scores are often used for analysis and 
are more likely to be normally distributed.  However as noted in several previous sections, this 
approach is not felt to be appropriate for the analysis of the underlying biology of psychotic 
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symptoms due to evidence that that the aetiology of delusions and hallucinations is at least in part 
heterogeneous.  In the current data set both log and square root transformation failed to correct 
the substantial deviation from normality.  Therefore the decision to divide the scale into categories 
was taken.  There were a substantial number of zeros in the data set therefore splitting into 
tertiles or about the median was not possible.  The decision was therefore taken to dichotomise 
the sample based on the change in symptom scores.  Examination of Figure 5-1 and Figure 5-2 
below shows that a number of participants’ symptoms worsened during the course of the study.  
Given that this is the least desirable clinical outcome for a patient, this group was compared to an 
aggregated group comprising those whose symptoms remained the same (a score of 0) and 
those whose symptoms improved (a score >0).  This decision was also based upon the meta-
analysis by Gauthier et al. (2008) which showed that significant difference in delusions scores 
after 12 weeks of memantine vs. placebo was driven by a worsening of the latter group, while the 
memantine group remained stable  (Gauthier, Loft et al. 2008). 
 
Figure 5-1 Histogram of change in NPI delusions score from baseline to 12 weeks   
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Figure 5-2 Histogram of change in NPI delusions score from baseline to 12 weeks 




ANOVA, t-tests (or non-parametric equivalents) and chi square were used to compare means and 
frequencies of participant demographics respectively.  Binary logistic regression models with 
treatment outcome as the dependent variable were used to generate odds ratios (ORs) for 
treatment arm, MAPT haplotype and other clinical and demographic variables.  The sample was 
then stratified by memantine treatment arm and further logistic regression models were run on 
each stratum.  Finally the interaction between treatment arm and MAPT haplotype was generated 
and included in the model. 
 
5.2.4.3 Power calculation 
 
This is an exploratory study on which to base future research, therefore a power calculation was 
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5.3.1 Descriptive statistics 
 
Baseline MMSE score was only available for 64 participants, therefore when evaluating the 
impact of dementia severity the FAST rating was used.  The one patient with a rating of 4 was 
grouped with the 5 rated group to create a mild/moderate group which was compared with the 6 
and 7 rated groups (i.e. three groups in total). 
 
Demographic variables were then examined by memantine treatment and MAPT haplotype; the 
results are presented in Table 5-1.  There were no significant differences in mean values of 
frequencies across any of the treatment/haplotype group combinations.  Due to the low frequency 
of MAPT H2/H2 carriers, these patients were analysed in combination with the heterozygote 
group, creating two groups (H1/H1 and H2*).   
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Table 5-1 Participants characteristics at baseline by treatment and MAPT haplotype (N=95)
1
 
 No memantine (n=47) 
[Mean ±SD / Frequency (%)] 
Memantine (n=48) 
[Mean ±SD / Frequency (%)] 




MAPT H2/H2 (n=4) MAPT H1/H1 (n=33) 
MAPT H1/H2 
(n=13) 
MAPT H2/H2 (n=2) 
Age
2 
84 (6.3) 84 (7.6) 81 (11) 84 (8.3) 79 (9) 80 (2) 
Antipsychotic 
3 
No 5 (17) 4 (29) 2 (50) 29 (88) 11 (85) 1 (50) 
 Yes 24 (83) 10 (71) 2 (50) 4 (12) 2 (15) 1 (50) 
FAST stage
4 
5 4 (14) 3 (21) 1 (25) 4 (12) 2 (15) 0 (0) 
 6 19 (66) 8 (58) 1 (25) 21 (64) 10 (77) 1 (50) 
 7 6 (20) 3 (21) 2 (50) 8 (24) 1 (8) 1 (50) 
Withdrawal before 12 weeks
5 
No 24 (83) 11 (79) 3 (75) 23 (70) 10 (77) 1 (50) 
 Yes  5 (17) 3 (21) 1 (25) 10 (30) 3 (23) 1 (50) 
Gender
6 
Female 23 (79) 10 (71) 4 (100) 21 (64) 9 (69) 1 (50) 
 Male 6 (21) 4 (29) 0 (0) 12 (36) 4 (31) 1 (50) 
Delusions 
7 
No 22 (79) 9 (64) 3 (75) 24 (73) 9 (69) 2 (100) 
 Yes 6 (21) 5 (36) 1 (25) 9 (27) 4 (31) 0 (0) 
Hallucinations 
8 
No 24 (86) 10 (71) 4 (100) 21 (64) 12 (92) 0 (0) 
 Yes 4 (14) 4 (29) 0 (0) 12 (36) 1 (8) 2 (100) 
1. 12 week score missing from 4 cases, therefore final N=91; 2. No memantine: F(2,45)=1.6, p=0.2; memantine: F(2,44)=0.3, p=0.7; 3. No memantine: Fisher’s exact p= .2; memantine: 
Fisher’s exact p= .4; 4. No memantine: Fisher’s exact p= .5; memantine: Fisher’s exact p= .6; 5. No memantine: Fisher’s exact p=1; memantine: Fisher’s exact p=6; 6. No memantine: 
Fisher’s exact p= .6; memantine: Fisher’s exact p=1; 7. Baseline score missing for one individual from the no memantine group, no memantine group based on n=46.  No memantine: 
Fisher’s exact p= .7; memantine: Fisher’s exact p=1; 8. Baseline score missing for one individual from the no memantine group, no memantine group based on n=46.  No memantine: 
Fisher’s exact p= .4; memantine: Fisher’s exact p= . 1.
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5.3.2 Primary analysis: MAPT haplotype and worsening psychotic symptoms 
 
A subset of patients had MMSE scores recorded at both baseline and 12 weeks. Cognitive 
decline over 12 weeks was examined in cases from this subset with a baseline MMSE greater 
than 4 (chosen to avoid floor effects, n=38).  The non-parametric Mann-Whitney U test showed no 
evidence of a relationship between change in MMSE score over the 12 week period and the 
MAPT haplotype (z=-0.1, p=0.9).  Similarly there was no evidence of an effect of memantine on 
change in MMSE score (z=0.2, p=0.8). 
 
Four patients (all from the MAIN-AD cohort) did not have complete 12 week data for 
neuropsychiatric symptoms, and these were there excluded, leaving 91 patients.  Participants 
with a baseline NPI score of 12 were removed from the analysis to avoid floor effects: three 
participants had the maximum delusions score and one had the maximum hallucination score.  
Therefore 88 cases were included in the delusions analysis and 90 in the hallucinations analysis. 
 
The primary analysis used logistic regression to evaluate the effect of MAPT haplotype and 
memantine treatment on worsening delusions and hallucinations.   
 
Firstly, the demographic and clinical variables along with memantine treatment and MAPT 
haplotype were assessed in univariate analyses.  The resulting odds ratios for worsening 
delusions and hallucinations are shown in Table 5-2 and Table 5-3 respectively. 
 
With respect to delusions, there was no main effect of either memantine or MAPT haplotype and 
the worsening of this symptom.  However in allelic analysis the H2 allele (shown in the lower 
section of Table 5-2 was associated with a 1.7 fold elevated risk for worsening of delusions (95% 
CI: 1.03-2.7, p=0.04). 
 




Table 5-2 Logistic regression: change in delusions (N=88) 
 
For hallucinations, there was also no main effect of memantine however the H2* group was 
associated with worsening hallucinations after 12 weeks (OR: 4.8, 95% CI: 1.2-20.3, p=0.03).  
Carriage of the H2 allele (see lower section of Table 5-3) was associated with a 1.9 fold increased 
risk of worsening hallucinations over the 12 week period (95% CI: 1.2-3.1, p=0.01). 
 





[Mean ±SD / Frequency (%)] Odd ratio (95% 
CI) 
p-
value No change/better 
(n=78) 
Worse (n=10) 
Age 83 (7.7) 80 (9.2) 0.96 (0.9-1.03) 0.3 
Gender Female 56 (72) 7 (70) Reference - 
 Male 22 (28) 3 (30) 1.1 (0.3-4.6) 0.9 
FAST stage 5 13 (17) 1 (10) Reference - 
 6 46 (59) 7 (70) 2 (0.2-17.6) 0.5 
 7 19 (24) 2 (20) 1.4 (0.1-16.7) 0.8 
Delusions 
baseline 
No 60 (77) 7 (70) Reference - 
 Yes 18 (23) 3 (30) 1.4 (0.3-6.1) 0.6 
Antipsychotic No 42 (54) 7 (70) Reference  
 Yes 36  (46) 3 (30) 0.5 (0.1-2.1) 0.3 
Memantine No 38 (49) 4 (40) Reference - 
 Yes 40 (51) 6 (60) 1.4 (0.4-5.4) 0.6 
MAPT H1/H1 52 (67) 4 (40) Reference - 
 H2* 26 (33) 6 (60) 3 (0.8-11.6) 0.1 
      
MAPT allele H1 126 (81) 12 (60) Reference  
 H2 30 (19) 8 (40) 1.7 (1.03-2.7) 0.04 
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Table 5-3 Logistic regression: change in hallucinations (N=90) 
 
5.3.3 Secondary analysis: stratification by memantine treatment 
 
The second part of the analysis aimed to assess the interaction between MAPT haplotype and 
memantine treatment.  The sample was first stratified by memantine treatment and the effect of 
the MAPT haplotype was examined in each stratum.  The risk associated with the H2* haplotype 
and worsening hallucinations was still present in the memantine group (OR: 7.3, 95% CI: 1.2-
43.4, p=0.03) and not present in the placebo group.  Similarly, worsening delusions was 
significantly associated with the H2* group (OR: 15. 95% CI: 1.56-144.2, p=0.02), this effect was 
not observed in the placebo group.  The memantine by MAPT interaction was then tested in the 
final regression model. For hallucinations there was no significant interaction between the 
Risk Factor 
Hallucinations 
[Mean ±SD / Frequency (%)] Odd ratio (95% 
CI) 
p-
value No change/better 
(n=80) 
Worse (n=10) 
Age 83 (7.2) 79 (11.8) 0.9 (0.9-1.02) 0.1 
Gender Female 57 (70) 8 (80) Reference - 
 Male 24 (30) 2 (20) 0.6 (0.1-3) 0.5 
FAST stage 5 11 (14) 3 (30) Reference - 
 6 49 (61) 6 (60) 0.5 (0.1-2.1) 0.3 
 7 20 (25) 1 (10) 0.2 (0.02-2) 0.2 
Hallucinations 
baseline  
No 60 (74) 8 (80) Reference 
- 
 Yes 21 (26) 2 (20) 0.8 (0.2-3.8) 0.7 
Antipsychotic No 40 (50) 10 (100) Reference - 
 Yes 40 (50) 0 (0) -
1
 - 
Memantine No 41 (51) 3 (30) Reference - 
 Yes 39 (49) 7 (70) 2.5 (0.6-10.2) 0.2 
MAPT H1/H1 54 (68) 3 (30) Reference - 
 H2* 26 (32) 7 (70) 4.8 (1.2-20.3) 0.03 
      
MAPT allele H1 130 (81)  11 (55) Reference  
 H2 30 (19) 9 (45) 1.9 (1.2-3.1) 0.01 
1
OR generation not possible due to zero cases worsening among those taking antipsychotics  
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memantine and the MAPT haplotype, whereas for delusions a significant interaction was 
observed (p=0.04).  Although significant, the very wide confidence intervals and inspection of the 
regression diagnostics for this final model indicate that neither are a good fit for the data.  The 
best models generated from this analysis are therefore those that do not include the interaction 
term, i.e. the stratified analyses (Table 5-4 and Table 5-5). 
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Table 5-4 Logistic regression: change in hallucinations stratified by treatment arm (N=90) 
 
 
Table 5-5 Logistic regression: change in delusions stratified by treatment arm (N=88) 
 




Risk Factor Delusions 
Odds ratio (95% CI) p-value 
Delusions 
Odds ratio (95% CI) p-value No change/better 
(n=38) 




MAPT H1/H1 22 (58) 3 (75) Reference - 30 (75) 1 (17) Reference - 
 H2* 16 (42) 1 (25) 0.46 (0.04-4.82) 0.51 10 (25) 5 (83) 15 (1.56-144.2) 0.02 
P value for interaction =0.04
 






Odds ratio (95% CI) p-value 
Hallucinations 
Odds ratio (95% CI) p-value No change/better 
(n=41) 




MAPT H1/H1 25 (61) 1 (33) Reference - 29 (74) 2 (73) Reference - 
 H2* 16 (39) 2 (66) 3.1 (0.26-37.36) 0.37 10 (26) 5 (27) 7.3 (1.21-43.44) 0.03 
P-value for interaction=0.58 
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5.4 Summary of findings 
 
5.4.1 Summary of primary analysis 
 
1. 4.8-fold increased risk of worsening hallucinations over 12 weeks associated with 
individuals with at least one H2 allele. 
2. 1.9-fold and 1.7-fold increased risk of hallucinations and delusions worsening respectively 
associated with the H2 allele. 
 
5.4.2 Summary of secondary analysis 
 
1. The association described above was still present in individuals taking memantine but not 






These results are the first to implicate the H2 allele of the extended MAPT haplotype in the 
worsening of psychotic symptoms in dementia.  Specifically carriers of at least one H2 allele (the 
H2* group) had a nearly 4.8-fold increased risk of worsening hallucinations over 12 weeks than 
H1 homozygotes, while there was no significant increased risk for delusions.  Allelic analysis 
supported this conclusion with the H2 allele being associated with a 1.9-fold increased risk of 
worsening hallucinations and also a 1.7-fold increased risk of worsening delusions.  This study 
brings an important dimension to research on tau and psychotic symptoms in AD.  Previously, 
research has been limited to post-mortem studies, which can only draw conclusions about the 
extent of pathology at death, and genetic studies which do not examine progression of symptoms.  
Here it has been shown that the extended MAPT haplotype may cause worsening delusions and 
hallucinations in individuals matched for clinical disease severity, suggesting that the effect on 
psychotic symptoms of the tau pathology previously reported (Zubenko, Moossy et al. 1991, 
Forstl, Burns et al. 1994, Murray, Kirkwood et al. 2013) may not simply be mediated through 
greater disease severity. 
 
It is important to highlight that there was no association between the MAPT haplotype and 
delusions or hallucinations at baseline.  The evidence from this study would therefore suggest 
that the MAPT haplotype plays a disease modification role in AD such that H2 allele carriers have 
a greater risk of their psychotic symptoms worsening.  This is supported by post-hoc analysis 
where there was no association with the MAPT haplotype and people who experienced psychotic 
symptoms at any stage of the 12 weeks (delusions: χ
2
=1.7, df=1, p= .2; hallucinations: χ
2
=1, 
df=1, p=0.3).  Twenty-four weeks of follow up data was available for the participants from the 
MAIN-AD study (n=58) and a further post-hoc analysis was conducted on this group under the 
same conditions as described for the 12 weeks analysis.  The results supported the primary 
analysis in that the H2* group was significantly more likely to experience worsening delusions 
(
2
=4.9, df=2, OR: 4.6,
 
p=0.03), although in contrast to the 12 week analysis there was no 
association with hallucinations, perhaps indicating that longer term follow up periods are 
necessary to fully capture the course of psychotic symptoms. 
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This finding may have important clinical implications with respect to the treatment of psychotic 
symptoms in AD.  The effective treatment of psychotic symptoms is an urgent unmet clinical need 
and there are significant challenges in addressing this while balancing the risks of unnecessary 
pharmacological treatment.  The MAPT H2 allele may help in identifying people whose disease 
course is characterised by more enduring delusions and hallucinations who would therefore be 
most in need of close monitoring and treatment with pharmacological agents. 
 
Given that more rapid cognitive decline is associated with psychosis and, more generally, 
cognitive decline is a central feature of AD, the MAPT haplotype was also examined in relation to 
this.  The sample was restricted to 38 patients who had complete data for baseline and 12 week 
MMSE assessments and there was no evidence of a difference in rate of cognitive decline over 
this period between the haplotypes.  Although a very small sample, this would suggest that the 
MAPT haplotype is not exerting its effect on the psychotic symptoms via more rapid cognitive 
decline, as is suggested previously in section 4.5 in relation to the COMT val158met 
polymorphism.  The question of how the H2 allele would worsen psychotic symptoms when H1c is 
the putative risk allele for AD itself still remains however.  This is a difficult question to answer 
based on the results here and also those that precede them pertaining to the functional 
significance of the MAPT haplotype and its role in AD generally. 
 
With regard to the MAPT haplotype, in AD associated with Down’s syndrome the  2 allele has 
been associated with an earlier disease onset (Jones, Margallo-Lana et al. 2008).  In FTD that 
same association has been reported with the H2 allele along with the finding that it is also 
associated with glucose hypometabolism in the frontal cortex (Borroni, Yancopoulou et al. 2005, 
Laws, Perneczky et al. 2007).   
 
Interestingly, PET studies in AD have identified frontal lobe hypometabolism as a correlate of 
delusional and, more broadly, psychotic symptoms (Sultzer, Brown et al. 2003, Sultzer, Mahler et 
al. 1995) while NFT burden in frontal areas has also been correlated with the same symptoms 
(Farber, Rubin et al. 2000, Zubenko, Moossy et al. 1991, Murray, Kirkwood et al. 2013).  The 
underlying dysfunction associated with this PET neural correlate is not known but it will be 
important to establish whether the finding reported in FTD of frontal hypometabolism and the 
MAPT H2 haplotype is present in AD.  This would help better explain the current findings although 
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a more complete explanation still could be arrived at from incorporating psychotic symptom data 
into the analysis as well.  
 
The only other study to examine the MAPT gene in relation to psychosis in AD did not find an 
association (DeMichele-Sweet, Klei et al. 2011).  It is important to highlight here that DeMichele-
Sweet et al. examined the presence/absence of psychosis, whereas here the worsening of 
individual psychotic symptoms was analysed, these are two different types of analysis, the former 
being prevalence, the latter having a focus on disease course and how genetic variation may 
affect it.  It is therefore possible that a different association would be found under each analysis 
even in a cohort of the same individuals, indeed there was no association between the MAPT 
haplotype and symptom status at baseline in this study.  The DeMichele-Sweet et al. study was 
much larger than that reported here and in a well characterised cohort so it can be considered a 
robust negative with the respect to the phenotype investigated, but a second important distinction 
concerns just this.  Specifically, the authors examined a psychosis phenotype (multiple/recurrent 
symptoms vs. no symptoms).  However, in another subsequent study examining APOE in AD with 
psychosis, the APOE*4 allele was found to be protective against hallucinations but not delusions 
in a dose dependent manner (Christie, Shofer et al. 2012).  This finding raises several interesting 
points when considered alongside those reported in this study.  The first is a justification for 
analysing delusions and hallucinations separately.  There is strong indication that, for APOE at 
least, grouping psychotic symptoms as single/multiple recurrent symptoms or multiple one off 
symptoms may have masked associations in some of the large previous APOE studies 
(DeMichele-Sweet, Klei et al. 2011).  It is not unreasonable to apply this logic to other genes, as 
was done here. 
 
A second more general but noteworthy link between this study and that of Christie et al. is that the 
*4 allele was found to be protective against hallucinations while the H2 allele was found to be a 
risk factor for worsening symptoms in the present study.  The *4 allele of APOE is the largest 
known genetic risk factor for sporadic AD itself and the H1 haplotype of MAPT has also been 
identified, although less consistently, as a risk factor for AD.  It is therefore worth highlighting that 
the disease course of AD, specifically with respect to psychotic symptoms, may be negatively 
influenced by the very same alleles that are protective against AD. 
 
 181 
The results presented here also include emerging evidence suggesting that memantine efficacy 
may be moderated by the MAPT haplotype.  Inhibition and reversal of phosphorylated tau by 
memantine has been demonstrated in animal models and a reduction in CSF phospho-tau has 
been noted after one year of treatment in humans (Degerman Gunnarsson, Kilander et al. 2007, 
Li, Sengupta et al. 2004).  This research is in itself in its very early stages and the mechanism by 
which memantine may exert this effect in humans is not known, therefore the current results 
should be considered as preliminary.  In an analysis stratified by treatment, the worsening of 
delusions and hallucinations associated with the H2 haplotype persisted in the memantine group 
whereas no significantly increased risk of worsening was observed in the no memantine group, 
suggesting the H2 in combination with memantine may worsen delusions.  There is precedent for 
psychotic symptoms worsening with memantine but it is only drawn from a limited number of case 
reports (Ridha, Josephs et al. 2005, Monastero, Camarda et al. 2007) and clinical trials have 
overwhelming found it to be a safe and well tolerated drug.  In view of this and the limited 
understanding of memantine’s mechanism of action, it would not be prudent to draw conclusions 
about this finding beyond stating that it may be an interesting avenue for future research and 
perhaps has the potential to shed some light on why memantine has been found to be ineffective 
in the treatment of neuropsychiatric symptoms in AD. 
 
The most evident limitation of this study is the sample size.  Even the largest RCTs are small by 
genetic standards but they do provide the optimum design for pharmacogenetic research and 
these two points are the principal limitation and strength of the pharmacogenetic component of 
this study.  Ninety-five DNA samples were collected from a pool of 353 people who participated in 
the MAIN-AD and MAGD clinical trials.  This is a reasonable number considering the frailty of this 
population of people (DNA collection commenced four years after the start of MAGD and three 
years after the start of MAIN-AD). 
 
Measuring change using the NPI is not ideal, but in view of the parametric data assumptions 
being quite substantially violated there was no option but to create a new categorical outcome 
variable.  This would have affected the statistical power of the study but grouping the participants 
into those who worsened and those who did not was considered to be the most clinically relevant 
grouping.  There is of course a risk that an emerging symptom was not emerging at all but simply 
recurring and the time at which it first occurred was simply not during the follow up period of this 
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study.  Similarly, a symptom which ameliorated may just represent the reverse.  However, this is 
not a criticism unique to this study and is a product of investigating a psychiatric symptom which 
fluctuates with varying degrees of severity within individuals.  There was only one mild dementia 
case in this sample, indicating that the vast majority of people were in the stage of dementia 
where psychotic symptoms are most likely to emerge.  In AD, generally psychotic symptoms 
would occur frequently enough to be detected by the NPI (i.e. several times in a month), however 
it cannot be excluded that some episodes of delirium may have caused symptoms to be rated 
incorrectly as psychotic. 
 
In summary, the evidence presented here is the first to indicate that the H2 allele of the extended 
MAPT haplotype negatively affects the course of delusions and hallucinations in AD.  The next 
steps in this line of research should examine MAPT transcription in people with AD with and 
without psychotic symptoms in order to help understand the exact mechanisms underlying the 
results presented here.  The results also suggest that genotyping for the H2 allele may enable the 
identification of a patient group with more enduring symptoms of psychosis and may contribute to 
the identification of individuals where pharmacological treatment may be necessary. Preliminary 
evidence also suggests that the MAPT haplotype may modify treatment response to memantine 





Chapter 6 Histamine H1 affinity of antipsychotics: relationship to 
mortality and a possible role of HNMT polymorphism 
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6.1 Summary introduction 
 
Although there is a well established effect of long-term antipsychotic prescription on mortality in 
people with AD, the increased risk being around 1.5- to 1.8-fold (Schneider, Dagerman et al. 
2005, Ballard, Hanney et al. 2009, Wang, Schneeweiss et al. 2005), the mechanisms causing this 
risk are not known.  One working hypothesis is that the sedating effect of antipsychotics leads to 
secondary medical complications such as pneumonia and oedema which in turn lead to death 
(Ballard, Creese et al. 2010). 
 
Not all antipsychotics are sedating and this is explained in part by their different affinities for the 
histamine H1 receptor.  Blockade of H1 is the principal mechanism responsible for the sedative 
effect of antihistamines and the sedation observed in antipsychotics has been found to be closely 
related to their affinity for the H1 receptor. 
 
Histamine is also of potential importance to mortality in dementia because of its role in the 
maintenance of fluid balance via vasopressin.  Vasopressin induces water retention and is 
released during states of dehydration.  Dehydration-induced vasopressin release is impaired in 
people with dementia and histamine action at H1 has been linked to vasopressin release 
(specifically, H1 antagonism suppresses vasopressin release in rats).  Dehydration in people with 
dementia, particularly those in the moderate-severe stages, is common and a major challenge 
(Begum, Johnson 2010).  The existing difficulties of maintaining hydration in people with dementia 
may be compounded by chronic blockade of H1 during long-term treatment with some 
antipsychotics and could therefore not only cause sedation but also further restrict the natural 
response to dehydration in people with dementia. 
 
Although there are no polymorphisms in the H1 gene common enough in European samples, 
there is a non-synonymous SNP in the HNMT gene.  HNMT is the enzyme responsible for the 
termination of histamine’s action in the CNS.  The less common T (ile) allele of the thr105ile 
polymorphism is associated with a decrease in enzyme activity, which is thought to lead to 
increased levels of histamine.  Consistent with this, pharmacological inhibition of HNMT has been 
shown to increase histamine levels in animal studies.  
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Two experiments were therefore undertaken in order to examine the role of histamine in the 
mortality associated with antipsychotic treatment in AD and specifically the hypothesis that the 
histaminergic system plays an important role in mortality associated with antipsychotic drugs in 
AD.  The first aimed to establish whether histamine H1 acting antipsychotics were associated with 
greater mortality than non-histamine H1 antipsychotics and the second investigated whether this 




 High affinity histamine H1 antagonist antipsychotics will be associated with a greater risk 
of mortality over one year than those taking non-H1 antipsychotics and no antipsychotics 
at all. 
 The HNMT polymorphism will modify mortality risk during exposure to H1 antipsychotics 






Excel: data cleaning, coding and organisation. 
STATA: data analysis and coding. 
 
6.2.2 Inclusion/exclusion criteria 
 
Inclusion criteria: 
 Probable, possible or definite Alzheimer’s disease either clinically (according to the 
NINCDS-ADRDA criteria) or pathologically (according to CERAD/NIA-REAGAN criteria) 
confirmed. 
 MMSE score available at first recorded antipsychotic visit. 
Exclusion criteria: 
 Baseline medication not recorded or recorded unknown. 
 Baseline antipsychotic dose recorded as ‘as required’ (PRN). 
 All medication not recorded or recorded unknown. 
 Taking two antipsychotics of different classes at any stage during one year follow up. 
 
6.2.3 Design and cohort 
 
A total of 718 patients meeting the inclusion/exclusion criteria listed above were genotyped for the 
HNMT polymorphism (see section 2.6.1 for methods concerning genotyping) and analysed 
retrospectively.  Patient data came from the following sources: ANM, ARUK, DCR, DEMVEST, 
Greek, Norway, OPTIMA. 
 
In the event of the electronic databases lacking required information, the investigators responsible 




6.2.3.1 Antipsychotic exposure and time 
 
The antipsychotics prescribed to individuals were determined from individual databases and this 
list was cross-referenced with the MHRA website by a pharmacist (Dr Denise Taylor, University of 
Bath) who then classified each drug according to its H1 affinity (see Table 6-1). 
 
Table 6-1 Antipsychotic classification according to H1 affinity and typical/atypical 
 
Antipsychotic exposure was coded with three levels: 
 
0) no antipsychotic during follow up period (No AP) 
1) Low or medium affinity histamine H1 receptor antagonist antipsychotic at some stage 
during follow up period (H1AP-) 
2) High affinity antipsychotic during follow up (H1AP+). 
 
Criteria for exposure classification: 
 
 No AP:  No record of any antipsychotic at any point during follow up. 
 H1AP-: At least one record of a regular dose of antipsychotic. 
 H1AP+: At least one record of a regular dose of antipsychotic. 
 
Antipsychotic H1 affinity Typical/atypical 
Chlorpromazine High Typical 
Olanzapine High Atypical 
Promazine High Typical 
Quetiapine High Atypical 
Thioridazine High Typical 
Prochlorperazine Medium Typical 
Flupentixol
1
 Low Typical 
Haloperidol Low Typical 
Metoclopramide Low Typical 






 Low Typical 
Zuclopenthixol Low Typical 
1
Little or no data available to classify drug 
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Calculation of start date and time of follow up 
 
The actual date of antipsychotic prescription was not available in any of the cohorts, therefore for 
those classified as prescribed antipsychotics the date of the first visit at which an antipsychotic 
was recorded was taken as the start date.  The full decision process for calculating start date is 
shown in Figure 6-1.  Dates of death were collected routinely as part of each cohort; any 
participant that left the study for any other reason was coded as censored.  In the latter scenario 
















Is this date more than 1 year 
before the scheduled end visit of 









 All AP doses 
PRN? 
Use visit date of first 
recorded AP dose 
 
Use visit date of first 




AP dose any time 
during follow up? No 
Yes 
 
Use visit date where 
dementia first recorded 




Figure Error! No text of specified style in document.-1 Algorithm for 
calculating antipsychotic start date 
Figure 6-1 Decision process for estimating antipsychotic start date 
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6.2.4 Demographics and participant characteristics 
 
Diagnosis, gender, age, level of cognitive impairment and concomitant medications were 
collected in all studies.  Cognitive impairment was measured by MMSE while concomitant 
medication was recorded from patient records or by patient self-report (see section 2.3).  The 
values of MMSE and age at recalculated start date were used for the analysis. 
 
Missing MMSE scores were handled using the following criteria: 
 
1) If MMSE score was available on both the prior visit and the visit after then the mean of 
those two scores was used to fill the missing value.   
2) If the MMSE score had reached 2 or less (chosen because annual decline in AD is 
approximately 4 points on the MMSE and visits were spread a minimum of six months 
apart) in previous visits then zero was used to fill the missing value.   
3) If three or more consecutive preceding scores were present then the average decline was 
taken from these three and subtracted from the score immediately before the blank to 
give the value to be used.  The approach was also used for the reverse scenario.  That is, 
the average decline for three or more subsequent scores was added to the score 
immediately after the blank. 
 
Six and one blank MMSE scores were filled using criteria 2) and 3) respectively.  No patients 
were suitable to be changed using criteria 1). 
 
In instances where a clinical diagnosis of any dementia was present in life but the diagnosis 
changed on post mortem, the post mortem diagnosis was taken.  Patients where dementia was 
not diagnosed in life but confirmed post mortem were not included in the analysis. 
 
6.2.5 Statistical Evaluation 
 
ANOVA, t-tests (or non-parametric equivalents) and chi square were used to compare means and 
frequencies of participant demographics respectively.  Kaplan-Meier survival curve estimates 
were produced to assess mortality among the three drug groups and two HNMT groups (CC vs. 
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CT/TT) at one year.  Following this, univariate Cox regression (with no AP and HNMT CC as the 
reference groups) was employed to generate and test the hazard ratios (HRs) of mortality 
associated with drug exposure and HNMT genotype.  Antipsychotic mortality and it’s modification 
by HNMT at 1 year was assessed in a Cox proportional hazards model with gender, age at first 
visit and MMSE at first visit included as covariates. 
 
6.2.5.1 Power calculation 
 
 Assuming survival time as a quantitative trait, a MAF of 0.1 and a dominant genetic model (CC 
vs. CT/TT) this study would have >80% power to detect 2% variance in survival time while the 
same figures are arrived at for antipsychotic exposure, assuming 10% of people are taking 
antipsychotics.  The interaction between HNMT genotype and antipsychotic exposure, assuming 
the same parameters just described, would have 75% power to detect 1% variance in survival 





6.3.1 Descriptive statistics 
 
Five hundred and sixty six (79%) participants were classified as not receiving an antipsychotic (no 
AP group) while thioridazine, risperidone and quetiapine were the most commonly prescribed 
antipsychotics (full details shown in Table 6-2).  In total 60 patients were classified as receiving a 
non H1 acting antipsychotic (H1AP- group), while 102 were classified as receiving an H1 acting 
antipsychotic (H1AP+ group).  A total of 12 patients were prescribed more than one antipsychotic 
during the one year follow up.  Ten of these cases were receiving both a non-H1 acting 
antipsychotic and an H1 acting antipsychotic.  As this study is concerned with identifying whether 
H1 blocking antipsychotics lead to increased mortality compared to non H1 blockers these 10 
cases were excluded.  The remaining two were receiving both olanzapine and quetiapine, so they 
were both classified as H1AP+, leaving 718 patients in the final analysis. 
 
Table 6-2 Frequency of prescribed antipsychotics (N = 718) 
 
Of the 718 patients, 3, 24 and 4 were clinically diagnosed with vascular dementia (VaD), mixed 
AD/VaD, and DLB respectively (Table 6-3).  However, at post-mortem all were found to either 
Antipsychotic Frequency (%) 
None 566 (78.8) 
Thioridazine 34 (4.7) 
Chlorpromazine 14 (2) 
Promazine 11 (1.5) 
Sulpiride 5 (0.7) 
Haloperidol 12 (1.7) 
Zuclopenthixol 1 (0.1) 
Trifluoperazine 2 (0.3) 
Flupentixol 2 (0.3) 
Olanzapine 15 (2.1) 
Quetiapine 20 (2.8) 
Risperidone 36 (5) 
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have possible, probable or definite AD and so were included in the study (see table caption for 
further details).  
 
Table 6-3 Dementia diagnosis frequency (N=718) 
 
Demographics by HNMT genotype are summarised in Table 6-4.  CC genotypes were 
significantly more common among women (chi-square: 
2
 =5.5, df=1, p=0.02) and were 
associated with 1.7 point lower MMSE score than CT/TT genotypes (16.7 and 15 respectively, 
Mann-Whitney U: z=-2, p=0.03). 
  
Clinical diagnosis Frequency (%) 
VaD 3 (0.4)
1 
Mixed AD and VaD 24 (3)
1 
Possible AD 26 (4)
2 
Probable AD 661 (92)
2 
Dementia with Lewy bodies 4 (0.6)
1 
1
All pathologically confirmed as possible (n=3), probable (n=5) or definite (n=23) AD.  
2
Pathological 
diagnosis available for 119 cases clinically diagnosed with possible or probable AD.  Of these 7, 17 
and 95 were pathologically diagnosed with, possible, probable and definite AD respectively. 
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Table 6-4 Demographic characteristics of participants by HNMT genotypes (N = 718) 
 
Demographics by antipsychotic exposure are summarised in Table 6-5.  MMSE was significantly 
lower among those prescribed any type of antipsychotic, compared to those in the No AP group 
(Kruskal-Wallis: 2=113.9, df=2, p<0.001).  There were no differences in mean age or gender 
distribution between the three antipsychotic groups.  With respect to concomitant medication, 
43% of No AP cases were prescribed anti-dementia drugs (cholinesterase inhibitors or 
memantine), compared with 38% and 28% in the H1AP- and H1AP+ groups respectively (chi-
square: 
2
=7.8, p=0.02).  Both the prescription of sedatives and non-antipsychotic H1 antagonists 









 =5.5, df=1, p=0.02. 
 HNMT Genotype 
[Mean ±SD / Frequency (%)] 
 
CC (n=564) CT/TT (n=154) 
MMSE 15 ± 8.7 16.7 ± 7.9
1
 
Age 78 ± 7.6 78 ± 7.9 
Gender Female 383 (68) 89 (58)
2
 
Male 181 (32) 65 (42) 
Dementia drug No 342 (61) 86 (56) 
Yes 222 (39) 68 (44) 
Antidepressant No 465 (82) 123 (80) 
Yes 99 (18) 31 (20) 
Sedative No 505 (90) 140 (91) 
Yes 59 (10) 14 (9) 
H1 antagonist No 555 (98) 150 (97) 
Yes 9 (2) 4 (3) 
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Table 6-5 Demographic characteristics of participants by antipsychotic status (N = 718)   
 
6.3.2 Primary analysis: antipsychotic mortality and HNMT genotype  
 
The primary analysis consisted of univariate Cox regression to identify clinical and demographic 
risk factors for mortality.  Significant predictors of mortality were then entered into a multivariate 
Cox regression model along with antipsychotic exposure and HNMT genotype to provide the final 
model.  First, Kaplan-Meier survival curves were generated to illustrate mortality associated with 
different antipsychotics and HNMT genotypes.  These illustrated a significant difference in survival 
estimates according to level of antipsychotic exposure (log-rank: 
2
=20.1, df=2, p<0.001, Figure 
6-2), while there was no difference in survival when HNMT genotypes were compared (Error! 
Reference source not found.).  After generating the Kaplan-Meier curves it became apparent 
that study drop out date for 60 patients was the same as the start date, precluding them from 
entering into survival analysis, leaving 658 patients suitable for this part of the analysis. 
 
 Antipsychotic Status 
[Mean±SD / Frequency (%)] 
 No AP (n=566) H1AP- (n=58) H1AP+ (n=94) 
MMSE
1 
17.2 ± 8 8.8 ± 8.4 8.6 ± 6.7
 
Age 78 ± 7.5 78 ± 7.2 78 ± 8.5
 
Gender Female 373 (66) 42 (72) 57 (61) 
Male 193 (34) 16 (28) 37 (39) 
Dementia drug
2 
No 324 (57) 36 (62) 68 (72) 
Yes 242 (43) 22 (38) 26 (28) 
Antidepressant No 473 (84) 42 (72) 73 (78)
 
Yes 93 (16) 16 (28) 21 (22) 
Sedative No 518 (92) 49 (84) 78 (83) 
Yes 48 (8) 9 (16) 16 (17) 
H1 antagonist No 557 (98) 58 (100) 90 (96) 
Yes 9 (2) 0 (0) 4 (4) 
1




























0 100 200 300 400
Analysis time (days)
95% CI 95% CI 95% CI
No AP H1AP- H1AP+
Kaplan-Meier Survival Estimates




























0 100 200 300 400
Analysis time (days)
95% CI 95% CI
HNMT CC HNMT CT/TT
Kaplan-Meier survival estimates
Figure 6-3 Kaplan-Meier curves for one year survival, comparing HNMT genotypes (Log-rank test: 
2
=0.3, df= 2, p=0.6):  
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The difference in antipsychotic survival shown in Figure 6-2 was supported by univariate Cox 
regression analysis yielding a hazard ratio (HR) of 3.3 (p<0.001) for mortality over one year in the 
H1AP+ group compared with the No AP group.  Although an elevated risk for mortality was 
identified on the H1AP- group, it failed to reach significance (HR: 1.5, p=0.4).  The full list of 
covariates examined is presented in Table 6-6.  A lower MMSE and higher age were also strongly 
associated with mortality and anti-dementia drugs were found to be protective. 
 





Mean±SD / Frequency (%) 
Hazard Ratio (95% CI) P-Value Alive (n=596) Dead (n=62) 
Age first visit 78 (7.5) 82 (7.7) 1.09 (1.05-1.13) <0.001 
MMSE first visit 16 (8.5) 8.7 (7.5) 0.91 (0.89-0.94) <0.001 
Gender Female 395 (66) 37 (60) Reference - 
 Male 201 (34) 25 (40) 1.3 (0.78-2.15) 0.3 
Antipsychotic  No AP 479 (80) 37 (59) Reference - 
 H1AP- 50 (8) 6 (10) 1.5 (0.65-3.62) 0.3 
 H1AP+ 67 (11) 19 (31) 3.3 (1.9-5.75) <0.001 
HNMT CC 466 (78) 50 (81) Reference - 
 CT/TT 130 (22) 12 (19) 0.84 (0.45-1.58) 0.6 
Dementia drug No 345 (58) 53 (85) Reference - 
 Yes 251 (42) 9 (15) 0.25 (0.12-0.5) <0.001 
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6.3.2.1 Multivariate analysis of antipsychotic mortality 
 
The hazard ratio associated with antipsychotic exposure and HNMT genotype was adjusted for 
the covariates identified in the univariate analysis: age, gender, and MMSE. 
 
There was a strong association between MMSE and anti-dementia drugs, with those exposed at 
baseline having significantly higher score than those not (median: 18 and 13 respectively, Mann-
Whitney: z=-7.3, p<0.001).  Due to the issue of colinearity between MMSE score and prescription 
of anti-dementia drugs, anti-dementia drug exposure was avoided as a covariate in the final 
model. 
 
The multivariate Cox regression models for antipsychotic exposure and HNMT genotype are 
shown in Table 6-7 and Table 6-8 respectively.  The association between the H1AP+ group and 
mortality persisted, albeit at a smaller effect size (HR: 1.9, p=0.04) in multivariate analysis 
adjusted for MMSE, age and gender.  There was no significantly altered risk associated with the 
H1AP- group when compared with the no antipsychotic group (HR: 0.86, p=0.7).  There was no 
association between the HNMT genotype and mortality.  
 














Adjusted for MMSE, age, gender 
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Table 6-8 Multivariate analysis outcome of HNMT genotypes for one year mortality (N = 658) 
 
The antipsychotic exposed groups were then stratified by HNMT genotype to establish whether 
any effect modification was present.  The results of this analysis are shown in Table 6-9.  The 
effect of H1AP+ observed in the whole sample was still present at a similar effect size among the 
CC genotypes but not among the CT/TT genotypes (HR: 2.1, p=0.02; HR: 1.1, p=0.9 
respectively).  Among CC genotypes there was no significant increased risk associated with the 
H1AP- group (HR: 1.1, p=0.39).  There was a zero mortality rate in the H1AP- group for CT/TT 
genotypes and as such it was not possible to estimate a meaningful hazard ratio and therefore 
not possible to suitably model the interaction between HNMT and antipsychotic exposure for this 
group.  In order to estimate the model for this relationship one case from the H1AP- CC genotype 
group who died before one year was randomly allocated to the equivalent CT/TT genotype group 
and assigned the median survival time of 179 days.  This was then repeated with two cases and 
finally three cases.  Although the HR for the interaction did decrease with each additional 
allocation, in all cases it failed to reach significance (HR: 0.8, p=0.5; HR: 0.74, p=0.4; HR: 0.7, 
p=0.3 respectively). 







Adjusted for MMSE, age, gender 
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Table 6-9 Multivariate analysis outcomes of antipsychotics exposure for one year mortality, stratified by HNMT genotypes (N = 658)  
Adjusted for MMSE, age, gender 
P-value for the Interaction term=0.7 
1
Unable to estimate hazard ratio due to zero deaths in this group, see text 
Risk Factors 
HNMT CC (n=516) HNMT CT/TT (n=142) 
Alive (n=466) Dead (n=50) 
Hazard ratio (95% CI) P-value 
Alive (n=130) Dead (n=12) 







































6.3.3 Secondary analyses 
 
6.3.3.1 Analysis of mortality by anti dementia drugs 
 
The association between anti-dementia drugs and reduced mortality in the context of 
antipsychotic exposure was then explored in more detail.  Patients were classified as either 
exposed to an antipsychotic (of any type) or never exposed to an antipsychotic because of the 
very low cell numbers generated by stratification by anti-dementia drug.  The dataset was 
stratified by anti-dementia drug exposure and Cox proportional hazard models were once again 
generated for each stratum.  No significant increased risk was found in either those taking or not 




Table 6-10 Multivariate analysis outcomes of antipsychotics exposure for one year mortality, stratified by anti-dementia drug exposure (N = 658) 
Adjusted for MMSE, age, gender and antidepressant exposure 
P-value for the interaction term=0.6 
 
Risk Factors 
No anti-dementia drug (n=398) Taking anti-dementia drug (n=260) 
Alive (n=345) Dead (n=53) 
Hazard ratio (95% CI) P-value 
Alive (n=251) Dead (n=9) 





























6.4 Summary of findings 
 
6.4.1 Summary of primary analysis 
 
1. The H1AP+ group (histamine acting antipsychotics) carried a significantly greater risk of 
mortality over one year compared to the No AP group (HR: 1.9).  There was no 
significantly increased risk associated with the H1AP- group. 
2. The above association persisted in an analysis stratified by HNMT genotype:  carriers of 
the CC genotype in the H1AP+ group had a 2.1-fold increased risk of mortality while there 
was no statistically significant increased risk among CT/TT genotypes. 
 
6.4.2 Summary of secondary analysis 
 




In this study, patients taking high affinity H1 antipsychotic agents (H1AP+ group) had a significant 
1.9 fold increased mortality risk compared with individuals not prescribed antipsychotics.  
Moreover, people taking non H1 blocking antipsychotics (H1AP-) had around the same mortality 
risk as the no antipsychotic group.  This finding suggests that the histamine blocking action of 
antipsychotics may be a relevant mechanism in the already established mortality risk associated 
with their use.  Further support for this hypothesis comes from the genetic component of this 
study.  No increased mortality risk was found in the H1AP- group, across either of the HNMT 
groups, while the significant association with H1AP+ group persisted in CC genotypes, supporting 
the hypothesis that the histamine system may be important in mortality associated with 
antipsychotics in AD.  It would be expected that relatively less sedation occurs with H1AP- 
antipsychotics and their lack of histaminergic action is the reason that no evidence of effect 
modification was observed by HNMT.  Conclusions about the exact level of effect of H1AP- 
antipsychotics among CT/TT genotypes are hampered by the lack of deaths in this group, which 
made generation of HRs impossible.  Excluding this group, collectively the HRs for each 
antipsychotic*HNMT group were in the expected pattern.  That is, H1AP- group carried the least 
risk (HR: 1.1), followed by the H1AP+ CT/TT genotypes (HR: 1.3) then finally by the H1AP+ CC 
genotypes (HR: 2.1).  Although this is evidence of effect modification, as the interaction term was 
not significant it cannot be conclusively stated that this was a result of HNMT genotype. 
 
Although the CC genotype is associated with greater HNMT enzyme activity which would lead to 
increased efficiency in the termination of action of histamine relative to CT and TT genotypes, the 
exact mechanism by which this may impact mortality among histamine acting antipsychotics is not 
known.  Indeed, elucidating this is beyond the scope of a genetic association study and would 
need to be the subject of further molecular genetic work but what is already known about HNMT 
and histamine levels from in vivo studies is supportive of this hypothesis. 
 
Pharmacological inhibition of HNMT increases CNS histamine levels (Duch, Bowers et al. 1978, 
Klein, Gertner 1981), and has been shown to induce waking and have non-sedative effects in 
animals when compared to placebo (Lin, Sakai et al. 1988, Tuomisto, Tacke 1986).  The 
mechanism underlying increased mortality supported by the results presented here is therefore 
 206 
one in which carriage of the higher activity CC genotype leads to decreased brain histamine 
levels, which in itself is not harmful in AD but along with long-term H1 blockade by antipsychotics 
in the H1AP+ group causes relatively higher levels of sedation due to less competition from 
endogenous histamine.  Conversely, carriers of the HNMT CT/TT genotypes have relatively more 
endogenous histamine to compete with H1AP+ antipsychotics and thus have a greater level of H1 
activation and therefore less sedation.  Moreover, this mechanism may also impact mortality via 
dehydration.  Long-term blockade of H1 receptors would reduce dehydration-induced vasopressin 
release, due to less histamine signalling, which is necessary to increase water retention.  It is 
possible then that the relative depletion of histamine levels among HNMT CC genotypes would 
lead to a further relative decrease in histamine signalling and less histamine mediated 
vasopressin release.  It is important to note that although dehydration is very common among 
individuals in long-term care facilities (Begum, Johnson 2010) it is not known how many people in 
the present sample would have been affected.  It is therefore more appropriate to consider this as 
an additional risk mechanism, alongside sedation which, although again no measures of which 
were taken, would be much more predictably present among people in the H1AP+ group.   
 
Post-hoc descriptive analysis was carried out to examine individual crude HRs associated with 
each antipsychotic.  The table is shown in appendix A and as the frequencies of individual 
antipsychotics are very low in many cases it is difficult to draw firm conclusions.  However there 
are several points that should be noted.  Firstly, the very high HRs associated with 
chlorpromazine and thioridazine (7.1 and 5 respectively) suggest they may be driving much of the 
mortality among the H1AP+ group.  Chlorpromazine is rarely used in current practice and 
thioridazine is no longer available; their presence in this sample is a result of a number of patients 
from older cohorts being included.  This is a limitation of this study, they are both very high affinity 
H1 antagonists so this may be the main driver of the high mortality rate in these groups but it 
cannot be excluded that were they to be assigned to any arbitrary grouping of antipsychotics, that 
group would carry the increased mortality risk.  
 
It is also noteworthy that every antipsychotic for which HRs could be generated showed a higher 
risk of mortality than risperidone.  This does not support the hypothesis tested here as under this 
the H1AP+ antipsychotics would all be expected to carry greater risk than risperidone while the 
H1AP- antipsychotics would be expected to be carry a similar risk.  It does however raise some 
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interesting questions for further study.  Firstly, it could be that the hypothesis needs refining.  As 
previously noted, typical antipsychotics carry an increased risk of mortality over atypicals, the 
mechanisms underpinning this are not known and the role of histamine has not been previously 
tested.  The crude HRs, although not all statistically tested, suggest that perhaps the increased 
risk associated with typical antipsychotics is larger than that attributable to H1 antagonism.  This 
does not necessarily mean that H1 antagonism is irrelevant, but perhaps means that splitting by 
typical/atypical then by histamine H1 action would be a more appropriate approach.  This would 
certainly require a much larger sample and it is as such beyond the scope of the present study to 
statistically test this.   
 
Quetiapine and risperidone are the two most commonly prescribed antipsychotics in people with 
dementia (Barnes, Banerjee et al. 2012).  The crude HRs presented in appendix A indicate that 
quetiapine was associated with a higher mortality than risperidone.  This is contrary to previous 
research which has in general shown quetiapine to have a lower mortality and adverse event rate 
than risperidone, probably due to the lower dosing of quetiapine relative to the recommended 
adult dose (Ballard, Waite 2006, Jin, Shih et al. 2013, Kales, Valenstein et al. 2007).  Few 
antipsychotic mortality studies extend beyond 6 months and the one year difference in mortality 
observed here may represent a shift in the risk profile, although it should be acknowledged that 
this analysis was exploratory and the study was not powered to detect individual antipsychotic 
differences.  
 
The genetic findings of this study and the classification of antipsychotics by their antihistamine 
action together provide some support for the hypothesis that sedation is a key event on the 
pathway from antipsychotic use to mortality, and these results suggest this line of work should be 
extended to other H1 acting psychotropic drugs commonly used in AD.  This is covered in more 
detail in the General Discussion. 
 
Although not directly related to the hypotheses of this study, a further result which warrants brief 
explanation is that taking anti-dementia drugs was strongly associated with reduced mortality.  
Those exposed to anti-dementia drugs at the start of the one year follow up had a 4-fold reduced 
risk of mortality compared to those who were not.  This is perhaps an intuitive finding, but the 
literature surrounding mortality is mixed.  At least two studies have reported that there is no 
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protection against mortality (Courtney, Farrell et al. 2004, Lopez, Becker et al. 2002), and it 
should be stated here that those taking antipsychotic medication were more likely to not be taking 
anti-dementia medication (particularly the H1AP+ group).  It is therefore likely that this finding is in 
a large part the converse of the increased mortality associated with antipsychotics.  
 
The strengths of this study include the sample size; this is the largest of its kind to date by some 
margin and provides a good dataset for further pharmacogenetic analysis.  Moreover, all cases 
were well characterised in terms of concomitant medication and dementia severity.  However, in 
any mortality study it would be preferable to have information regarding chronic diseases but the 
information available from the constituent cohorts of this sample was not consistent or in some 
cases reliable enough.  It was the same case for cause of death.  Information was known to be 
gathered from a number of different sources including death certificates, nurses’ or family 
members’ verbal reports.  This was not considered reliable enough so only time to death was 
analysed in this study.  There are known specific risk factors associated with antipsychotic use 
that could lead to death and a more sensitive analysis would be one that examines cause of 
death likely to be a result of these, e.g. stroke, pneumonia or cardiovascular related illness, 
although this would require an even larger sample size.  Although this sample was large, and the 
overall number of people taking H1AP+ or H1AP- antipsychotics was comparable in size to other 
studies (n=94 and 58 respectively), once stratified by HNMT genotype the cell sizes did reduce 
significantly as a result of the T allele being relatively rare with a frequency of approximately 0.1.  
This would have significantly reduced the power of the genetic analysis, moreover it cannot be 
excluded that the different findings for CT/TT genotypes compared to CC genotypes was not a 
result of having 3 times as many individuals in the latter group and therefore much greater power 
to detect a difference.  The final noteworthy limitation is the date used for start of antipsychotic 
prescription.  This was an estimate and although participants were assessed at yearly, or more 
frequent, intervals it is still possible that the start date used could have been inaccurate by up to 
12 months.  In a cohort study such as this obtaining an exact start would be difficult but it would 
be preferable to have estimations of antipsychotic duration.  This leads on to a general limitation 
of the study concerning being restricted by the designs of the cohorts from which the cases were 
drawn and will be returned to in the General Discussion. 
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Pharmacogenetic research in AD psychosis is important as it has the potential to yield information 
about the mechanisms of current treatments which is much needed in this area due to the paucity 
of pharmacological interventions currently available.  Future research should seek to replicate this 
finding and extend research to the antipsychotic metabolising enzyme CYP2D6, which has been 
implicated in previous research (Pollock, Mulsant et al. 1995) but has not been investigated since.   
 
The results presented here, gathered from classifying antipsychotics according to their H1 
blocking action and supported by genetic data suggesting effect modification by HNMT genotype 
implicate the histaminergic system as an important mechanism in the mortality associated with 
these drugs.  Specifically it was found that H1 blocking antipsychotics were the most harmful 
among carriers of the HNMT CC genotype with these individuals having a 2-fold increased 
mortality risk compared to those not taking antipsychotics, while there was no increased risk 
associated with non-H1 blocking antipsychotics.  If replicated this may have clinically relevant 
implications for prescribing practice relating to other psychotropic H1 antagonists as well as 
confirming that sedation is indeed a key event in mortality associated with antipsychotic 




Chapter 7 General discussion 
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The key aims of this thesis were to examine the role of common genetic polymorphisms in the 
prevalence, course and treatment of delusions and hallucinations in people with AD and 
DLB/PDD with a view to advancing current understanding of the mechanisms that underlie these 
symptoms and the responses associated with their treatment.  Specifically, previous research and 
functional significance was used as a basis for examining the roles of the 5HTTLPR and COMT 
val158met polymorphisms in the prevalence of persistent delusions and hallucinations in some of 
the largest and best characterised cohorts of dementia to date.  In addition, for the first time these 
two polymorphisms were evaluated with respect to rate of cognitive decline which is itself a key 
correlate of psychotic symptoms.  The third approach used was to exploit the RCT methodology 
of two clinical trials in order to provide greater insight into the relationship between tau pathology 
and delusions and hallucinations by evaluating changes in these symptoms associated with the 
extended MAPT haplotype.  Finally, the hypothesis that histamine H1 receptor antagonism is a 
key property of the well established mortality associated with antipsychotic use in AD was tested 
for the first time in a genetic association study. 
 
7.1 Key themes 
 
Four key themes have been identified from the preceding results chapters.  They are discussed in 
detail below along with some broader interpretations. 
 
7.1.1 The 5HTTLPR polymorphism has different effects on persistent delusions in AD and 
DLB/PDD 
 
In this study the 5HTTLPR LL genotype has been found to be associated with a significantly 
higher risk for persistent delusions, but not hallucinations, in DLB/PDD relative to the SS 
genotype.  This was in keeping with the hypothesis that was derived from research in AD.  In 
contrast and contrary to the hypotheses there was no evidence of an association in AD.  The 
limitations of these studies have already been discussed and although further study is required 
these results may indicate that different mechanisms, specifically genetically determined 
alterations in serotonin neurotransmission, underlie persistent delusions in AD and DLB/PDD.  
Global serotonergic changes are prominent in both DLB/PDD and AD (Halliday, McCann et al. 
1992, Ohaea, Kondo et al. 1998, Chen, Eastwood et al. 2000).  The study by Ohaea et al. (1998) 
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directly compared DLB/PDD patients and AD patients and found no difference in serotonin levels 
in either the frontal or temporal cortices between the two groups.  There are few studies 
examining both AD and DLB/PDD but data from those that do and from analysis of individual 
diseases do not suggest that there are substantial differences in 5HTT sites between these 
dementias (Chen, Alder et al. 2002, D'Amato, Zweig et al. 1987).  However dorsal raphe nucleus 
(DRN) 5HT neurons are affected in almost every patient with DLB/PDD while pathology in AD is 
comparatively limited in this region (Braak, Braak 1991, Francis, Perry 2007, McKeith, Dickson et 
al. 2005).  It is therefore possible that the differential effect of the LL genotype found here is a 
reflection of the more severe involvement of brain stem 5HT synthesising nuclei in DLB/PDD than 
AD.  
 
Other possibilities for this difference may include the greater amount of environmental factors that 
influence the presentation of hallucinations in AD such as impairments in visual acuity.  From a 
neurobiological point of view, there are also much more widespread cholinergic deficits in 
DLB/PDD compared with AD (Perry, Haroutunian et al. 1994) which may be important given the 
substantial interaction between the cholinergic and serotonergic systems.  5HT plays both and 
inhibitory and excitatory role in ACh release via a number of different 5HT receptors, including 
5HT1A where it is excitatory (reviewed in (Lanctot, Herrmann et al. 2001).  Differences in 5HT 
concentration resulting from the 5HTTLPR polymorphism may therefore impact the two dementias 
differently due to the differing extent of cholinergic deficits. 
 
With respect to AD, tau pathology appears to be a key pathogenic correlate of psychotic 
symptoms, a hypothesis supported by the results presented here in Chapter 5.  Given that tau 
pathology is found to a much lesser extent in DLB/PDD, this may be another key distinguishing 
mechanism which influences the effect of 5HTTLPR. 
 
7.1.2 PFC dopamine levels may not underlie psychotic symptoms but may indirectly 
influence them via more rapid cognitive decline 
 
The findings presented in this thesis do not suggest any involvement of the COMT val158met 
polymorphism in the aetiology of persistent psychotic symptoms in DLB/PDD or AD; this is in 
contrast to some but not all previous literature (Borroni, Grassi et al. 2006, Proitsi, Lupton et al. 
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2012, Sweet, Pollock et al. 2001, Borroni, Di Luca et al. 2006).  However, a role for COMT 
val158met in the aetiology of psychotic symptoms in dementia cannot be ruled out.  However, 
evidence that it appears to modulate D1 receptor density, rather than D2 receptors, and its better 
established role in cognitive performance, rather than psychosis, in people without dementia 
strongly suggests this line of work should continue to be extended in AD.  This is also consistent 
with the evidence that DA blocking medications do not appear to alleviate psychotic symptoms in 
AD (Corbett, Smith et al. 2012).  Moreover there is evidence contravening the hypothesis that 
levodopa alone induces hallucinations, most notably in one study high dose levodopa delivered 
intravenously failed to induce hallucinations in PD patients (Goetz, Pappert et al. 1998). 
 
The fact that there was prior evidence of genetic association with both 5HTTLPR and COMT 
val158met was taken as a basis for further exploration of their possible roles in the aetiology of 
psychotic symptoms.  The data from the cohort of people with AD was of a quality such that it was 
possible to examine the rate of cognitive decline associated with each polymorphism.  This is 
important as there are plausible biological mechanisms to support a potential role of both 
5HTTLPR and COMT val158met as mediators of cognitive impairment in people with AD.  
Consistent with the hypothesis, this study was able to demonstrate that the val/val genotype was 
associated with a 4-fold higher rate of annual cognitive decline than met/met carriers among 
patients with mild dementia.  This is the first demonstration of this relationship in AD and 
potentially brings a new dimension to the current understanding of this polymorphism in the 
mechanisms underlying psychotic symptoms.  Specifically, some of the discrepancies in prior 
studies may be explained by this relationship.  More broadly, this finding may also have important 
implications for the enrichment of recruitment into clinical trials.  People with mild dementia are 
frequently the target group for recruitment into clinical trials and this study highlights a possible 
subgroup which may decline at a faster rate and therefore generate more statistical power for 
randomised controlled trials (RCTs). 
 
7.1.3 Evidence of genetic models of psychotic symptoms in dementia 
 
Two principal hypotheses exist concerning the genetic epidemiology of psychotic symptoms in 
dementia.  Firstly, in AD there is evidence (from heritability and post-mortem studies) to suggest 
that presence of persistent psychotic symptoms constitutes a distinct AD phenotype.  Under this 
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model there are genes that predispose individuals to AD with psychosis (the heterogeneity 
model).  Secondly there are genes that modify the course of AD to result in psychotic symptoms 
(Sweet, Nimgaonkar et al. 2003).  This study found no support for 5HTTLPR or COMT val158met 
under either of these models in AD.   
 
The finding that the MAPT haplotype is associated with a worse course of psychotic symptoms 
supports the disease modification model whereby in that the H2 allele was associated with a 
worsening of symptoms over 12 weeks (although full exploration of this would require the addition 
of a control group).  Interestingly however it was the allele associated with a protective effect 
against AD itself, H2, which was associated with the worse outcome in this study.  MAPT 
expression appears to be affected by the extended haplotype and it is proposed that the 4R 
isoform has a greater propensity to aggregate into NFTs and so increased expression by the H1c 
allele is a key driver of AD pathology.  However not enough is known about the composition of 
NFTs in AD patients with psychotic symptoms compared to those without and it is therefore 
difficult to offer a mechanistic explanation as to why the H2 allele is associated with an increased 
risk.  This will be an important area for future work.  This research has also highlighted the value 
of examining the course of psychotic symptoms in AD and other dementias.  Understanding risk 
factors for psychotic symptoms is important but it is also important to elucidate the finer detail of 
whether genes can affect the course of AD itself such that psychotic symptoms emerge more 
quickly or have a tendency to worsen.  Specifically the results here point towards a genetic 
marker that may identify individuals in which pharmacological treatment may be indicated. 
 
Although there has been no research into the existence of a psychotic sub-phenotype in 
DLB/PDD, the influence of the two polymorphisms under the two models outlined above was 
tested.  Here, there was only support for 5HTTLPR in a disease modification capacity, specifically 
indicating the LL genotype becomes a risk for delusions once the neurodegenerative process has 
set in. 
 
Finally, the results described in section 7.1.2 above concerning the COMT polymorphism and rate 
of cognitive decline suggest that perhaps the model of genetic influence on psychotic symptoms 
in AD should be expanded to include disease modifying genes that may indirectly affect psychotic 




7.1.4 Histaminergic neurotransmission is an important mechanism of mortality associated 
with antipsychotic treatment 
 
The results from Chapter 6 demonstrated that high affinity antihistaminergic antipsychotics carry a 
greater mortality risk.  Specifically, the high affinity antihistamine (H1AP+) antipsychotics carried a 
1.9 fold increased risk of mortality over one year when compared with people not taking 
antipsychotics, while those in the lower affinity (H1AP-) group had approximately the same 
mortality risk as those not taking antipsychotics.  Moreover, when stratified by HNMT 
polymorphism the risk persisted among carriers of the high activity CC genotype only, while there 
was no statistically increased risk associated with the low activity group (CT/TT).  Both of these 
lines of evidence support the hypothesis that histamine neurotransmission is an important 
pathway in the mortality associated with antipsychotic prescription.  Until now this question had 
not been empirically addressed, although high affinity H1 antagonist antipsychotics were already 
known to be sedative.  This evidence particularly justifies the removal of thioridazine and 
chlorpromazine from clinical practice in people with dementia and as they were among the 
highest affinity H1 antagonists with the highest individual mortality risks of the agents investigated 
also suggests a possible, though not a sole, mechanism for their harmful effects.   
 
At this stage the genetic evidence is not strong enough to warrant the screening of patients to 
predict who will be susceptible to increased mortality.  This is not least because it is likely that 
other pharmacological properties of antipsychotics are also likely to cause side effects associated 
with mortality and therefore histamine action is likely to explain just a portion of the variance.  
What is more immediately applicable, and itself worthy of further investigation, is that histamine 
H1 blockade in itself may be a harmful effect of pharmacological treatment in AD.  Many drugs 
besides antipsychotics are potent antagonists of H1, perhaps most notable of these are some of 
the non selective serotonin reuptake inhibitor (non-SSRI) antidepressants which are commonly 
used in dementia, like trazodone and mirtazapine.  Recently antidepressants in general were 
found to be significantly more common among people already prescribed antipsychotics (Barnes, 
Banerjee et al. 2012).  Specifically, the proportion of people prescribed trazodone among the 
antipsychotic group was twice that of the no antipsychotic group.  There were no specific figures 
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for mirtazapine but along with SSRIs, tri-cyclic antidepressants (of which mirtazapine is one) are 
commonly used types of antidepressants.  A recent RCT showed mirtazapine to be associated 
with significantly more adverse reactions (ARs), though not deaths, than placebo.  Of particular 
significance to the issues discussed here, the most common ARs were drowsiness and sedation 
(Banerjee, Hellier et al. 2011).  It will be important to monitor the prescribing patterns of other 
psychotropic drugs as antipsychotic use continues to fall.  The results presented here implicate 
histamine in the mortality associated with antipsychotics and a wider application would be to 
extend this hypothesis to other commonly used psychotropic drugs which block the H1 receptor.  
If it can be established that long-term blockade of H1 is indeed a common harmful mechanism of 
psychotropic drugs in AD then this information could be used to guide prescribing practice.  
Finally, with typical antipsychotics becoming increasingly uncommon and so making the 
traditional typical/atypical distinction redundant in dementia, these results highlight the possibility 
that classification according to H1 receptor affinity may be a useful system to identify the highest 
risk agents. 
 
7.2 Strengths and limitations 
 
7.2.1 The cohorts 
 
All of the experiments conducted in this project were based on data from participants recruited 
into other projects.  That is to say that some limitations were an unavoidable consequence of the 
limitations and diversity of the original studies.  These limitations are discussed in detail in each of 
the results chapters however it should be stated here that the cohorts were all extremely well 
characterised, particularly relative to other studies in this area and this is one of the main 
strengths of the work presented in the preceding results chapters.  In particular in the AD studies 
it was possible to control for exposure to antipsychotics which is of relevance given their use has 
been associated with lower serotonin concentration in AD (Chen, Alder et al. 2002).  Longitudinal 
data were available for the majority of patients and were of sufficient quality to enable the 
application of strict inclusion criteria and still yield good sized samples.  On this point, all of the 
samples were of a comparable or larger size than most of the previous literature. 
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Ideally patients with pathologically confirmed diagnoses would be used in all analyses; however 
there are simply not the numbers available in current UK brain banks with the quality of data 
required to fulfil the sample sizes necessary for these experiments.  All patients were from 
sources using standardised clinical diagnoses and because patients were assessed 
longitudinally, revisions were made when appropriate which would have increased the confidence 
with which diagnoses were made.   All AD patients were diagnosed in accordance with the 
NINCDS-ADRDA criteria (McKhann, Drachman et al. 1984).  The NINCDS-ADRDA criteria yield 
83% and 84% sensitivity and specificity respectively (Blacker, Albert et al. 1994), meaning that 
83% of AD patients and 84% of people without AD are correctly identified.  The figures for the 
consensus criteria for probable DLB are 83% sensitivity and 95% specificity (McKeith, Ballard et 
al. 2000).  Sensitivity and specificity for a diagnosis of PD are similarly high at 91% and 98% 
respectively (Hughes, Daniel et al. 2002).  The diagnosis of dementia in PD was made according 
to the DSM-IV criteria with the one year rule also being applied to distinguish from DLB.  No 
clinical diagnosis can ever offer 100% specificity and sensitivity and it is a fact of current research 
that it is likely that some individuals with other pathology or even with an entirely different 
diagnosis will be included in clinically diagnosed research samples.   
 
Current large scale brain donation programmes, such as the Brains for Dementia Research 
initiative underway in the UK, will lead to more longitudinally studied patients with pathologically 
confirmed diagnoses becoming available.  This of course is a complicated project and it will be 
some time before pathologically confirmed samples with high quality clinical data of the sort 






Data on ethnicity was not available for the following cohorts: OPTIMA, MAIN-AD (for sites except 
London), Norway and DEMVEST.  This does present issues with population stratification in 
genetic association studies and it is known that the frequencies of all the polymorphisms 
examined differ by ethnicity (the tau haplotype to the extent that H2 is not present at all in non-
Europeans).   
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Examination of the 1000 genomes browser indicates some variation in genotype frequencies by 
ethnicity of the polymorphisms investigated here (http://www.ncbi.nlm.nih.gov/-
variation/tools/1000genomes), particularly when comparing European and non-European 
populations and as highlighted previously in section 1.4.7.1 (Creese, Ballard et al. 2013) with 
respect to 5HTTLPR this can impact results. 
 
Whilst it is appropriate to acknowledge this as a limitation, there was very low percentage of non-
Europeans among the known ethnicities (2%) and there was no reason to suspect the 
frequencies of non-Europeans among the unknowns would be any different.  All of the unknowns 
were from UK or Norwegian samples where the percentage of non-Europeans in the elderly 
populations is very low.  
 
7.2.2.2 SNP selection 
 
The genes in this project were not fully interrogated; only a single polymorphism in each was 
examined.  Both SLC6A4 and COMT contain variations at other loci which are known to further 
alter either transcriptional or enzyme activity (in the case of SLC6A4 and COMT respectively), 
however these other variants mostly quite rare, occurring in less than 10% of individuals. 
 
It is worth singling out the a/g SNP contained in the 5HTTLPR L allele only, rs25531, which has 
been shown to reduce L allele transcription to that of the S allele.  As the triallelic 
5HTTLPR/rs25531 locus can be grouped in two classes based on functional differences (LA vs. 
S/LG) this can be genotyped without compromised sample sizes (essentially around 5-10% of L 
alleles would be moved to the S allele group).  The results of the AD and psychotic symptoms 
experiment were a resolute negative and it is considered unlikely that a relatively uncommon SNP 
would have shifted the results to significance.  This is perhaps more of an issue with the finding 
that persistent delusions are associated with the LL genotype in DLB/PDD.  The presence of the 
rs25531 G allele in this cohort could conceivably remove the association of the LL genotype, 
although based on the Wendland et al. (2008) MAF of 0.06 it would only be expected that 
approximately six people would be affected in the DLB/PDD cohort (Wendland, Moya et al. 2008).   
Future work should certainly genotype rs25531, this would have been done in the present project 
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were it not for time constraints: as outlined in section 2.6.2.1.2 of the methods chapter there were 
problems encountered in using the Wendland et al. (2006) protocol for genotyping 5HTTLPR and 
rs25531.  In future it would preferable to explore the use of a Taqman custom SNP genotyping 
assay for this polymorphism. 
 
The issues discussed above allude to a wider point relating to the candidate gene approach, 
whereby single genes or polymorphisms within them are examined for relationships with disorders 
or traits.  It is not only likely that other loci within the same gene will be associated with psychotic 
symptoms but also likely that a number of different genes will be.  It is commonly accepted that 
complex traits of psychiatric disorders are likely to be mediated by rare genetic variation at many 
loci, each contributing a small risk.  The studies presented in these thesis are only powered to 
detect relatively large risks (OR >1.3) in common polymorphisms.  While it cannot be excluded 
that these polymorphisms exert a large risk, it must be acknowledged that some of the 
comparisons presented here (e.g. Table 3-5 Logistic regression: 5HTTLPR persistent delusions 
(N=97) and Table 6-9 Multivariate analysis outcomes of antipsychotics exposure for one year 
mortality, stratified by HNMT genotypes (N = 658)are underpowered and the findings should not 
be over interpreted.  Larger sample sizes are the main barrier to overcoming this problem.  Here, 
over 1,300 samples were screened for adequate symptom evaluation but less than 700 (around 
600 AD and 100 DLB/PDD) met the stringent criteria for accurate diagnosis of psychosis.  On the 
one hand it is important to have a well powered study but on the other, there is little case for 
conducting a well powered genetic study if the phenotype under investigation is not satisfactorily 
characterised in the sample. 
 
The candidate gene approach remains a useful method for the investigation of the relationship 
between genetic variants and psychotic symptoms in AD, provided a hypothesis driven approach 
is used.  In this project two criteria were used to identify the polymorphisms to be investigated: 1) 
evidence that the gene in which the polymorphic locus lies plays a role in the pathogenesis of the 
symptom or trait; and 2) functional consequences: only polymorphisms where there is evidence of 
functional significance, either by alteration of enzyme activity or gene expression regulation (e.g. 
splicing and transcription) were chosen.  Moreover, only relatively common polymorphisms were 
examined in order to maximise the power of the experiments and evidence from prior association 
studies was also used to strengthen the case for selection where possible.   
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7.3 Future directions 
 
In general, this thesis brings together well-characterised cohorts from several sources, making a 
good foundation for subsequent research.  While many of the patients in each study were readily 
available from existing cohorts, the databases as used in the analyses were constructed 
specifically for this project.  There is much work still to be done on the questions addressed in this 
thesis and the databases in their current form therefore represent a good opportunity to extend 
research along the same themes outlined here with relative ease.  Moreover there are now clear 
criteria which can be used to add cases to the databases, potentially allowing for even larger 
sample sizes; the main difficultly in genetic epidemiological research. 
 
Broadly, it would be of great benefit to examine variation across all of COMT and SLC6A4, 
particularly when it is known that variation at other loci have functional consequences.  This would 
be the only way to fully characterise the role of each gene in the pathogenesis of psychosis and 
has the potential to greatly advance current understanding; a vital point given the current lack of 
effective treatments.  The arguably more intractable side of the psychosis research presented 
here is the phenotype.  Breaking down the psychosis syndrome into delusions and hallucinations 
makes fewer assumptions about the underlying mechanisms which may or may not be shared by 
each symptom.  This was also the rationale for investigating the rate of cognitive decline in 
Chapter 4.  The search for endophenotypes will be greatly aided by looking beyond the classic 
psychopathological features of psychosis to other clinical correlates.  Cognitive decline is perhaps 
the most important of these and future work should continue to examine the complex relationship 
between psychotic symptoms, rate of cognitive decline and genetic variation in order to help 
better characterise psychosis in AD and other dementias.  
 
The evidence surrounding the tau haplotype and worsening of psychotic symptoms is interesting 
in light of the literature suggesting tau pathology is associated with psychotic symptoms in AD.  
Extending the follow up time is the natural next step for this research.  Because MAPT is a 
putative AD risk gene it would be of particular interest to examine the disease course from the 
early stages through to the late to establish whether the tau haplotype shortens the time to 
psychosis onset or whether it causes symptoms to worsen once they do.  This would allow 
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exploration of how psychotic symptoms progress and exactly how they are related to the AD 
course as a whole. 
 
With regard to pharmacogenetics, this is a greatly understudied area in psychosis in AD, largely 
due to the practicalities of gathering cohorts large enough.  There has only been one well 
controlled study to date (Dombrovski, Mulsant et al. 2010) with a sample size of 92 (44 of whom 
were taking risperidone, the remainder were prescribed citalopram).  Although there were two 
smaller cohort studies prior to this they were less well controlled and only examined treatment 
efficacy with respect to the amelioration of psychosis (Engelborghs, Holmes et al. 2004, 
Angelucci, Bernardini et al. 2009).  The sample size of 658 in this study is therefore considerably 
larger and although accurate start dates for drugs were not available it nevertheless provides an 
excellent platform on which to build future research.  Firstly, the results presented here suggest 
that the histamine hypothesis of antipsychotic mortality is worth exploring in more detail.  Non-
genetic research should move towards atypical antipsychotic drugs as they are still commonly 
prescribed, while the examination of other H1 acting psychotropic drugs used in dementia may be 
of interest.  Larger samples will be needed to examine histamine pathway genes as there are very 
few with a minor allele frequency >0.1.  With regard to other genes, of particular interest is 
cytochrome P450 (CYP2D6), responsible for metabolising the majority of antipsychotics.  The 
gene’s metabolic capability is genetically determined and a 5-fold increase in side effects 
(principally sedation and extrapyramidal symptoms) has been associated with poor metabolisers 
(identified through the amount of debrisoquine metabolite excreted after oral administration). 
 
7.3.1 GWAS and emerging technologies in genetic epidemiology: a focus on their impact 
on research into psychotic symptoms in dementia 
 
The candidate gene approach was used in this thesis and, as with any scientific study, 
independent confirmation of these findings is required before the conclusions presented here can 
be fully accepted.  There is evidence that meta-analysis can go some way to address the concern 
of low power in genetic association studies and in order for this to be done in an effective way the 
characteristics of every sample presented here have been described in detail.  It must be 
acknowledged however that there are newer, higher throughput methods for genotyping and 
investigating other types of genetic variation which will, if the field follows the same path as 
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schizophrenia, become part of dementia psychosis research in time.  Such methods can only be 
positive additions to this field, which at present somewhat lags behind other psychiatric genetics 
research. 
 
Perhaps an intermediate step between candidate gene studies, which examine just one 
polymorphism in a gene, and genome wide association (GWA) studies, which cover the whole 
genome, is to examine greater amounts of genetic variation within the gene of interest.  This 
approach is covered in section 7.2.2.2 while the remainder of this section will focus on genome-
wide techniques. 
 
Being able to explain the role of a single gene fully is preferable to basing conclusions concerning 
the genetics of complex symptoms on the effect of a single polymorphism.  The logic here is that 
capturing more genomic variation is a positive attribute to a study.  This leads to the natural 
conclusion that an appropriately powered study with full genome coverage would be among the 
optimum approaches in genetic epidemiology.  GWA studies in the AD and the wider psychiatric 
literature are now commonplace and the recent promising findings and very large cohorts used in 
many ways render the candidate gene approach obsolete in these fields (by way of comparison in 
2011 the Schizophrenia Psychiatric Genome Wide Consortium (Ripke, Sanders et al. 2011) 
carried out a GWAS on 51,695 individuals) . 
 
GWA studies, in which hundreds of thousands of SNPs covering the entire genome are 
genotyped, are now routinely applied to research into schizophrenia and depression.  GWA is a 
hypothesis free approach, an attribute which is particularly attractive in the study of complex 
phenotypes such as psychosis in dementia.  For example, although there is evidence to support 
the role of dopaminergic and serotonergic polymorphisms in the aetiology of these symptoms, 
disease causing pathways are likely to be far more complex and include completely unstudied 
mechanisms about which, by their nature, it is impossible to generate hypotheses.  Looking to 
schizophrenia research, it is clear that the GWAS approach has advanced understanding of this 
disorder, having identified pathways involved in neuronal function and perhaps more 
unexpectedly the immune system (Aberg, Liu et al. 2013).  Such developments are yet to 
translate into clinical practice but one of the most interesting and clinically significant findings to 
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emerge has come from the study of large sections (tens of thousands to millions of base pairs) of 
abnormally deleted or duplicated DNA which are detected by next generation sequencing (NGS). 
 
So-called copy number variation (CNV) associated with schizophrenia has also been identified in 
other disorders which are considered distinct clinical entities and previously thought of as 
biologically separate as well (Schreiber, Dorschner et al. 2013).  This is an excellent example of 
the role newer technologies can play in not just understanding the biology of psychiatric disorders 
but challenging existing clinical distinctions which may lead to new perspectives for subsequent 
research and management.  With regard to the research presented in this thesis, a similar 
application of these newer techniques would be to elucidate whether there are shared pathways 
which underpin psychotic symptoms across the DLB/PDD/AD spectrum.   
 
The use of genome-wide methods in dementia psychosis is limited to one study (Hollingworth, 
Sweet et al. 2012); it included 1,299 patients with psychosis and 735 without but is still relatively 
underpowered for this type of study, a fact acknowledged by the authors.  The phenotype under 
investigation in the Hollingworth et al. (2012) study is another important limitation and one to 
which a good deal of resource should be directed in subsequent research.  A cross sectional 
evaluation of psychosis was employed and given what is known about the course and complexity 
of psychotic symptoms in AD (see section 1.2), it is very likely that this either underestimated 
and/or misclassified psychosis in some individuals.  Moreover, it is still debatable whether 
examining a combined psychosis phenotype (comprising delusions and/or hallucinations) is 
appropriate, a point discussed in full in previous sections of this thesis.  The GWAS and NGS 
approaches have much to offer this field of research but there needs to be a focus on addressing 
methodological issues like those just described.  Thus at present, the most significant impact that 
new and emerging genotyping techniques can have on dementia psychosis research is to 
provided an impetus to iron out concerns like these.  There is limited value in committing 
considerable resource to run experiments in diseases/disorders in which the phenotype under 
investigation is flawed.  There is an urgent need for greater use of longitudinal psychiatric 
evaluations using standardised, validated tools.  The cohorts presented in this thesis go some 
way to addressing this problem and it will be by combining this sort of robust phenoptypic data 




7.4 Concluding remarks 
 
Psychotic symptoms are difficult to study in people with dementia and there is an urgent need for 
research in this area to be carried out in longitudinally assessed and well characterised cohorts.  
The experiments presented in this thesis have addressed this problem in AD and DLB/PDD and 
presented robust results which make a positive contribution to this field.  Consistent with 
neurochemical evidence from in vivo and post mortem studies no evidence was found to support 
a role of the COMT val158met polymorphism in the aetiology of psychotic symptoms in AD or 
DLB/PDD.  The 5HTTLPR LL genotype was found to be a risk factor for persistent delusions in 
DLB/PDD but not in AD, suggesting that there are perhaps different mechanisms which underlie 
these symptoms across different dementias.  New evidence that the COMT val/val genotype is 
associated with more rapid cognitive decline advances current understanding of the complex 
relationship between psychosis, cognitive decline and genetic variation and may help explain the 
discrepancies in previous studies examining psychotic symptoms.  The MAPT H2 haplotype was 
found to modify the disease course of AD, being associated with a worsening of psychotic 
symptoms, complementing previous reports from post mortem studies and extending them by 
indicating there is a direct relationship between tau and psychotic symptoms.   There was also 
preliminary evidence indicating that the H2 haplotype modifies the treatment response to 
memantine: a potentially important finding given the disappointing RCT evidence surrounding this 
drug.  Further evidence into treatments for psychotic symptoms in AD concerned the use of 
antipsychotics.  The findings here provide support for the hypothesis that histamine antagonism is 
an important harmful property of antipsychotic use in AD, with the potential to guide future 
treatment decisions.  
 
Broadly, this thesis underscores the potential of genetic studies to improve clinical practice 
concerning the management of complex traits such as psychotic symptoms in dementia.  Using a 
genetic association approach this thesis identified polymorphisms in genes which may help 
elucidate the complex mechanisms underpinning psychotic symptoms and their treatment and 






1. The development of multiple cognitive deficits manifested by both  
a. memory impairment (impaired ability to learn new information or to recall 
previously learned information)  
b. one (or more) of the following cognitive disturbances: 
o aphasia (language disturbance)  
o apraxia (impaired ability to carry out motor activities despite intact 
motor function)  
o agnosia (failure to recognize or identify objects despite intact sensory 
function)  
o disturbance in executive functioning (i.e., planning, organizing, 
sequencing, abstracting)  
2. The cognitive deficits in 1a and 1b cause significant impairment in social or 
occupational functioning and represent a significant decline from a previous level of 
functioning.  
 
3. The cognitive deficits in Criteria A1 and A2 are not due to any of the following:  
a. other central nervous system conditions that cause progressive deficits in 
memory and cognition (e.g., cerebrovascular disease, Parkinson's disease, 
Huntington's disease, subdural hematoma, normal-pressure hydrocephalus, 
brain tumor)  
b. systemic conditions that are known to cause dementia (e.g., hypothyroidism, 
vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcemia, 
neurosyphilis, HIV infection)  
c. substance-induced conditions 
4. The deficits do not occur exclusively during the course of a delirium.  
5. The disturbance is not better accounted for by another Axis I disorder (e.g., Major 
Depressive Disorder, Schizophrenia).  
 





1. The criteria for the clinical diagnosis of PROBABLE Alzheimer’s disease include: 
 dementia established by clinical examination and documented by the Mini-Mental test, 
Blessed Dementia Scale, or some similar examination, and confirmed by neuropsychological 
tests; 
 deficits in two or more areas of cognition; 
 progressive worsening of memory and other cognitive functions; 
 no disturbance of consciousness and; 
 onset between ages 40 and 90, most often after age65; and absence of systemic disorders 
or other brain diseases. 
2. The diagnosis of PROBABLE Alzheimer’s disease is supported by: 
 progressive deterioration of specific cognitive functions such as language (aphasia), motor 
skills (apraxia) and perception (agnosia); 
 impaired  activities of daily living and altered patterns of behaviour; 
 family history of similar disorders, particularly if confirmed neuropathologically; and 
 laboratory results of: 
 normal lumbar puncture as evaluated by standardised techniques; 
 normal pattern or non-specific changes in EEG; such as increased slow wave 
activity and; 
 evidence of cerebral atrophy on CT with progression documented by serial 
observation. 
3. Other clinical features consistent with the diagnosis of PROBABLE Alzheimer’s disease, after 
exclusion of causes of dementia other than Alzheimer’s disease, include: 
 plateaus in the course of progression of the illness; 
 associated symptoms of depression, insomnia; incontinence, delusions, illusions, 
hallucinations, catastrophic verbal, emotional or physical outbursts, sexual disorders and 
weight loss; 
 other neurological abnormalities in some patients, especially with more advanced disease 
and including motor signs such as increased muscle tone, myoclonus or gait disorder; 
 seizures in advanced age and; 
 CT normal for age. 
4. Features that make the diagnosis of PROBABLE Alzheimer’s disease uncertain or unlikely include: 
 sudden, apoplectic onset; 
 focal neurological findings such as hemiparesis, sensory loss, visual field deficits and 
incoordination early in the course of the illness and; 
 seizures or gait disturbances at the onset or very early in the course of the illness. 
5. Clinical diagnosis of POSSIBLE Alzheimer’s disease: 
 may be made on the basis of the dementia syndrome, in the absence of other neurological 
psychiatric , or systemic disorder sufficient to cause dementia, and in the presence of 
variation at onset, in the presentation, or in the clinical course; 
 may be made in the presence of second systemic or brain disorder sufficient to produce 
dementia, which is not considered to be the cause of the dementia and; 
 should be used in research studies when a single, gradually progressive severe cognitive 
deficit is identified in the absence of other identifiable cause. 
6. Criteria for diagnosis of DEFINITE Alzheimer’s disease are: 
 the clinical criteria for probable Alzheimer’s disease and histopathological evidence obtained 
from a biopsy or autopsy 
7. Classification of Alzheimer’s disease for research purpose should specify features that may 
differentiate subtypes of the disorder, such as: 
 familial occurrence; 
 onset before age 65; 
 presence of trisomy-21 and; 
 coexistence of other relevant conditions such as Parkinson’s disease. 
B. NINCDS-ADRDA criteria for clinical diagnosis of AD 
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1. Central feature (essential for a diagnosis of possible or probable DLB): 
 dementia defined as progressive cognitive decline of sufficient magnitude to 
interfere with normal social or occupational function; 
 prominent or persistent memory impairment may not necessarily occur in the early 
stages but is usually evident with progression; 
 deficits of tests of attention, executive function and visuospatial ability may be 
especially prominent. 
2. Core features (two core features are sufficient for a diagnosis of probable DLB, one for 
possible DLB): 
 fluctuating cognition with pronounced variations in attention and alertness; 
 recurrent visual hallucinations that are typically well formed and detailed; 
 spontaneous features of Parkinsonism. 
3. Suggestive features (if one or more of these is present in the presence of one or more 
core features, a diagnosis of probable DLB can be made.  In the absence of any core 
features, one or more suggestive features is sufficient for possible DLB.  Probable DLB 
should not be diagnosed on the basis of suggestive features alone): 
 REM sleep behaviour disorder; 
 severe neuroleptic sensitivity; 
 low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET 
imaging. 
4. Supportive features (commonly present but not proven to have diagnostic specificity): 
 repeated falls and syncope; 
 transient, unexplained loss of consciousness; 
 severe autonomic dysfunction, e.g. orthostatic hypotension, urinary incontinence; 
 hallucinations in other modalities; 
 systematised delusions; 
 depression; 
 relative preservation of medial temporal lobe structures on CT/MRI scan; 
 generalised low uptake on SPECT/PET perfusion scan with reduced occipital 
activity; 
 abnormal (low uptake) MIBG myocardial scintigraphy; 
 prominent slow wave activity on EEG with temporal lobe transient sharp waves. 
5. A diagnosis of DLB in less likely: 
 in the presence of cerebrovascular disease evident as focal neurologic signs or on 
brain imaging; 
 in the presence of any other physical illness or brain disorder sufficient to account 
in part or in total for the clinical picture; 
 if Parkinsonism only appears for the first time at a stage of severe dementia. 
6. Temporal sequence of symptoms: 
 DLB should be diagnosed when dementia occurs before or concurrently with 
Parkinsonism (it it is present).  The term Parkinson’s disease dementia (PDD) 
should be used to describe dementia that occurs in the context of well established 
Parkinson’s disease.  In a practice setting the term that is most appropriate to the 
clinical situation should be used and generic terms such as Lewy body (LB) 
disease are often helpful.  In research studies in which distinction needs to be 
made between DLB and PDD, the existing one year rule between the onset of 
dementia and Parkinsonism continues to be recommended.  Adoption of other time 
periods will simply confound data pooling or comparison between studies.  In other 
research settings that may include clinicopathologic studies and clinical trials, both 
phenotypes may be considered collectively under categories such as LB disease 
or alpha-synucleinopathy. 
C. Revised consensus criteria for clinical diagnosis of dementia with Lewy bodies 
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Step 1: Diagnosis of Parkinsonian syndrome 
 Bradykinesia (slowness of initiation of voluntary movement with progressive 
reduction in speed and amplitude of repetitive actions); 
 And at least one of the following: 
o muscular rigidity; 
o 4-6 Hz rest tremor; 
o postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction. 
Step 2: Exclusion criteria for Parkinson’s disease 
 History of repeated strokes with stepwise progression of Parkinsonian features; 
 History of repeated head injury; 
 History of definite encephalitis; 
 Oculogyric crises; 
 Neuroleptic treatment at onset of symptoms; 
 More than one affected relative; 
 Sustained remission; 
 Strictly unilateral features after 3 years; 
 Supranuclear gaze palsy; 
 Cerebellar signs; 
 Early severe autonomic involvement; 
 Early severe dementia with disturbances of memory, language, and praxis; 
 Babinski sign; 
 Presence of cerebral tumour or communicating hydrocephalus on CT scan; 
 Negative response to large doses of levodopa (if malabsorption excluded); 
 MPTP exposure. 
Step 3: Supportive prospective criteria for Parkinson’s disease 
(three or more required for a diagnosis of definite Parkinson’s disease) 
 Unilateral onset; 
 Rest tremor present; 
 Progressive disorder; 
 Persistent asymmetry affecting side of onset most; 
 Excellent response to  (70-100%) levodopa; 
 Severe levodopa-induced chorea; 
 Levodopa response for 5 years or more; 
 Clinical course of 10 years or more. 
D. UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria 
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H1 classification Antipsychotic N Deaths Hazard ratio (95% CI) 
H1AP- Risperidone 34 2 (6) Reference 
H1AP+ Thioridazine 34 9 (26) 5 (1.1-22.9) 
H1AP+ Chlorpromazine 14 5 (36) 7.1 (1.4-36.5) 
H1AP+ Promazine 11 3 (30) 4.8 (0.8-28.6) 
H1AP+ Quetiapine 18 2 (11) 2.1 (0.3-14.8) 
H1AP- Haloperidol 12 2 (17) 2.9 (0.4-20.9) 
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